WO2008077554A1 - Cycloalkylamine substituted isoquinoline derivatives - Google Patents

Cycloalkylamine substituted isoquinoline derivatives Download PDF

Info

Publication number
WO2008077554A1
WO2008077554A1 PCT/EP2007/011167 EP2007011167W WO2008077554A1 WO 2008077554 A1 WO2008077554 A1 WO 2008077554A1 EP 2007011167 W EP2007011167 W EP 2007011167W WO 2008077554 A1 WO2008077554 A1 WO 2008077554A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
alkylene
aryl
heterocyclyl
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2007/011167
Other languages
French (fr)
Inventor
Oliver Plettenburg
Armin Hofmeister
Dieter Kadereit
Stefan Peukert
Sven Ruf
Matthias LÖHN
Peter Monecke
Alexander Schiffer
Aimo Kannt
Markus Kohlmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CN200780048527XA priority Critical patent/CN101611012B/en
Priority to HK10106146.8A priority patent/HK1140189B/en
Priority to CA2673920A priority patent/CA2673920C/en
Priority to MX2009005964A priority patent/MX2009005964A/en
Priority to EP07856890A priority patent/EP2125746B1/en
Priority to BRPI0721180-5A priority patent/BRPI0721180A2/en
Priority to AU2007338410A priority patent/AU2007338410B2/en
Priority to JP2009543375A priority patent/JP5405316B2/en
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Priority to AT07856890T priority patent/ATE554072T1/en
Publication of WO2008077554A1 publication Critical patent/WO2008077554A1/en
Priority to US12/487,386 priority patent/US8710228B2/en
Priority to IL199539A priority patent/IL199539A/en
Priority to NO20092432A priority patent/NO20092432L/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Definitions

  • the present invention relates to novel isoquinoline derivatives as described in the claims, their preparation and their use in the treatment and/or prevention of diseases related to the inhibition of Rho-kinase and/or of Rho-kinase mediated phosphorylation of myosin light chain phosphatase.
  • Rho-kinase 2 Activation of a small GTPase RhoA upon agonist stimulation results in conversion of RhoA from the inactive GDP-bound form to the active GTP-bound form with a subsequent binding to and activation of Rho-kinase.
  • Rho-kinase 1 and Rho-kinase 2 Two isoforms, Rho-kinase 1 and Rho-kinase 2, are known.
  • Rho-kinase 2 is expressed in vascular smooth muscle cells and endothelial cells.
  • Rho-kinase 2 Activation of Rho-kinase 2 by the active GTP-bound RhoA leads to calcium sensitization of smooth muscle cells through phosphorylation-mediated inhibition of the myosin light chain phosphatase activity and thereby up-regulation of the activity of myosin regulatory light chain (Uehata et al., Nature 1997, 389, 990-994).
  • Rho-kinase is involved in vasoconstriction, including the development of myogenic tone and smooth muscle hypercontractility (Gokina et al. J. Appl. Physiol. 2005, 98, 1940-8), bronchial smooth muscle contraction (Yoshii et al. Am. J. Resp. Cell MoI. Biol. 20, 1190-1200), asthma (Setoguchi et al. Br J Pharmacol. 2001 , 132, 111 -8; Nakahara, et al.
  • PAOD peripheral arterial occlusive disease
  • sexual dysfunction e.g., penile erectile dysfunction (Chitaley et al. Nature Medicine 2001 , 7, 119-122), retinopathy, inflammation, immune diseases, AIDS, osteoporosis, endocrine dysfunctions, e.g. hyperaldosteronism, central nervous system disorders such as neuronal degeneration and spinal cord injury (Hara, et al. JNeurosurg 2000, 93, 94), cerebral ischemia (Uehata, et al. Nature 1997,389,990; Satoh et al. Life Sci. 2001 , 69, 1441-53; Hitomi, et al.
  • a compound having inhibitory effect on Rho-kinase and/or on Rho-kinase mediated phosphorylation of myosin light chain phosphatase is useful for the treatment and/or prevention of cardiovascular and non-cardiovascular diseases involving Rho- kinase as the primary or secondary disease cause, like hypertension, pulmonary hypertension, ocular hypertension, retinopathy, and glaucoma, peripheral circulatory disorder, peripheral arterial occlusive disease (PAOD), coronary heart disease, angina pectoris, heart hypertrophy, heart failure, ischemic diseases, ischemic organ failure (end organ damage), fibroid lung, fibroid liver, liver failure, nephropathy, including hypertension-induced, non-hypertension-induced, and diabetic nephropathies, renal failure, fibroid kidney, renal glomerulosclerosis, organ hypertrophy, asthma, chronic obstructive pulmonary disease (COPD), adult respiratory distress syndrome, thrombotic disorders, stroke, cerebral
  • neuropathic pain neuronal degeneration, spinal cord injury, Alzheimer's disease, premature birth, erectile dysfunction, endocrine dysfunctions, arteriosclerosis, prostatic hypertrophy, diabetes and complications of diabetes, metabolic syndrome, blood vessel restenosis, atherosclerosis, inflammation, autoimmune diseases, AIDS, osteopathy such as osteoporosis, infection of digestive tracts with bacteria, sepsis, cancer development and progression, e.g. cancers of the breast, colon, prostate, ovaries, brain and lung and their metastases.
  • WO 01/64238 describes isoquinoline-5-sulfonamide derivatives optionally substituted by a -(CH 2 )i-6-0-(CH 2 )o-6-. a -(CH 2 ) ⁇ -6-S-(CH 2 ) ⁇ -6- or a -(CH 2 ) 0 _6-linked heterocyclic group useful as neuroprotective agents.
  • WO 2004/106325 (Schering AG) describes prodrugs of the Rho-kinase inhibitor fasudil carrying an ether or ester group in the 1-position of the isoquinoline ring.
  • JP 10087629 A describes isoquinoline derivatives useful for the treatment of diseases caused by Heliobacter pylori such as for example gastritis cancer or ulcer.
  • the isoquinoline derivatives may be substituted by OH in the 1 -position and are preferably 5-substituted by X-[(C 1 -C 6 )alkylene)]o--
  • I may be among others an optionally substituted isoquinolone and Ar Il may be among others an optionally substituted 03.7 monocyclic saturated heterocyclic system.
  • WO 2005/030791 (Merck & Co.) generically describes as potassium channel inhibitors for the treatment of cardiac arrhythmias, stroke, congestive heart failure etc. isoquinolone derivatives which are optionally substituted in 6-position by a group
  • R 43 is e.g. a (C3-C ⁇
  • WO 2005/030130 (Merck & Co.) generically describes as potassium channel inhibitors for the treatment of cardiac arrhythmias, stroke, congestive heart failure etc. isoquinoline derivatives which may be substituted by hydroxyl in the 1 -position and are optionally substituted in 6-position by a group (CR e Rf)pOR 43 wherein p may be zero, and R 43 is e.g.
  • R 51 and R 52 may be hydrogen, (C 1 -C 6 )alkyl etc.; or R 43 is a group R81 defined as a 4-6 membered unsaturated or saturated monocyclic heterocylic ring with 1 , 2, 3 or 4 heteroatoms; and are substituted by a directly bound optionally substituted aryl or heteroaryl ring in the 4-position.
  • WO 03/053330 (Ube) generically describes isoquinolone derivatives of the formula
  • Rho-kinase inhibitors As Rho-kinase inhibitors.
  • An embodiment of the present invention is a compound of the formula (I)
  • R2 is H, halogen or (C 1 -C 6 )SlRyI;
  • R 3 is H 1 halogen
  • Rg and RQ are independently of each other
  • R8 is H, halogen or (C 1 -C 6 )alkyl
  • n 1 , 2, 3 or 4;
  • n 1 , 2 ,3 ,4 or 5
  • L is O or O- (C 1 -C 6 )alkylene
  • R" is (C 3 -C 8 )cycloalkyl
  • residues R4, R5, RQ, RQ , RJ and Rs alkyl, alkylene or cycloalkyl can optionally be substituted one or more times by OH, OCH3, COOH, COOCH3, NH 2 , NHCH3, N(CH3)2, CONH2, CONHCH3 or CON(CH3)2 ;
  • residues R 1 to Rs alkyl or alkylene can optionally be substituted one or more times by halogen
  • and R3 to R ⁇ (Ce-C 1 rj)aryl and (Cs-C 10 )heterocyclyl are unsubstituted or substituted one or more times by suitable groups independently selected from halogen, OH, NO2, N 3 , CN, C(O)-(C 1 -Ce)alkyl, C(O)-(C ⁇
  • Ce)alkyl-C ⁇ HC-i-Ce)alkyl N(C 1 -C 6 )alkyl-C(O)O-(C 1 -C 6 )alkyl,
  • C 6 )alkyl CONH 2 , (C 1 -C 6 )alkylene-O-fC-i-Ce)alkyl, (C-i-C ⁇ alkylene-O ⁇ Ce-C 10 )aryl, or O ⁇ C-i-C ⁇ alkylene-tCe-C-icOaryl; or wherein (C 6 -C 1 o)aryl is vicinally substituted by a O-(C 1 -C4)alkylene-O group whereby a 5-8-membered ring is formed together with the carbon atoms the oxygen atoms are attached to; and wherein aryl or heterocyclyl substituents of (C 6 -C 1 o)aryl and (Cs-C 10 )heterocyclyl groups may not be further substituted by an aryl or heterocyclyl containing group;
  • R 1 is H, (C-i-C ⁇ alkyl, (C 6 -C 10 )aryl, NH-(C 1 -C 6 )alkyl, NH-(C 6 -C 1 rj)aryl or Nt(C 1 -C 6 )alkyl] 2 . More preferably, R 1 is H, halogen, (C-i-C ⁇ alkyl, NH-(C 1 -C4)alkyl, Nt(C 1 -C 4 )alkyl] 2 or NH-phenyl. Most preferably, R 1 is H, (C-
  • R3 is preferably H, halogen, (C-
  • R4 is H, halogen or (C 1 -C 6 )alkyl. More preferred, R4 is H, halogen or (C-
  • R5 is H, halogen, CN, (C 1 -C 6 )alkyl, (C2-C6)alkenyl, R', NH-(C 6 -Ci rj)aryl or (C 1 -C 6 )alkylene-R'.
  • R5 is H, halogen, (C 1 -C 6 )alkyl, (C2-C6)alkenyl, R', NH-(C 6 -Ci ⁇ jaryl or (C 1 -C 6 )alkylene-R ⁇
  • R5 is H, halogen, (C 1 -C 6 )alkyl, (C2-C6)alkenyl, (C 6 -Ci o)aryl, NH-(C 6 -C 10 )aryl, (C-
  • R5 is H, halogen, phenyl, (C-
  • R5 is H, halogen, methyl, ethyl, vinyl, phenyl, thienyl or pyridyl.
  • R5 are hydrogen, fluoro, chloro, bromo, iodo, methyl, ethyl, vinyl, phenyl, thienyl or pyridyl, nitrile, nitro, (p-methoxy)-phenyl, N-aniline, benzyl, 2-propenyl, s- butenyl, cyclopropyl, tetrazol, amino, 4-methoxy-aniline or N-acetyl, preferably hydrogen, fluoro, chloro, bromo, iodo, methyl, ethyl, vinyl, phenyl, thienyl or pyridyl. More preferred, R5 is H, halogen, methyl, or ethyl, most preferred R5 is H.
  • R 6 and R 6 ' are independently of each other H, (C 1 -C 6 )aIkYl 1
  • R' (C 1 -C4)alkylene-(C3-C8)cycloalkyl
  • RQ and RQ' are independently of each other
  • Rg is H, (C 1 -C 6 )alkyl, (C3-C6)cycloalkyl or (C-] -C4)alkylene-(C3-C6)cycloalkyl, and
  • RQ is H, (C 1 -C 6 )alkyl and RQ' is
  • RQ and Rg' together with the N-atom to which they are attached, form a (C5-C 10 )heterocyclyl group.
  • RQ is H, (C 1 -C 6 )alkyl and RQ' is H, (C 1 -Ce) 3 IkYl;
  • -C4)alkylene-(C5-C 10 )heterocyclyl wherein heterocyclyl is unsubstituted or substituted one or more times, preferably one to three times, more preferabyl one or two times, by a group independently selected from (C-
  • -C 4 )alkyl preferably CH3 or CF3; O-(Ci-C4)alkyl; CN, SO2-NH2; SO2-
  • O-(C 1 -C4)alkyl, or (C6-C 10 )aryl is substituted once by unsubstituted phenyl, unsubstituted O-phenyl or unsubstituted (C5-C6)heterocyclyl; or RQ and RQ', together with the N-atom to which they are attached, form a
  • (C5-C6)heterocyclyl group which is unsubstituted or substituted one to three times, preferably once, by (C-
  • the formed heterocyclyl group is morpholino, piperidino, pyrrolidine or piperazino. More preferably the heterocyclyl group is morpholino or 4- (ethoxycarbonyl)-piperazinyl.
  • R ⁇ is H, (C 1 -C 6 )alkyl and R ⁇ ' is H, (C 1 -C 6 )alky ⁇ , (C3-C8)cycloalkyl.
  • R ⁇ is H and RQ' is H, unsubstituted (C-
  • R ⁇ and R ⁇ ' are H.
  • R6 or R6 ' are, independently from each other, hydrogen, methyl, ethyl, propyl, isopropyl, 3-methyl-butyl, 2-methyl-propyl, butyl, pentyl, 3,3,3-trifuoropropyl, 4,4,4-trifluorobutyl or a substituent selected from the group consisting of
  • R 6 or R 6 ' are, independently from each other,
  • R 6 , R 6 ' forming a (C 5 -C io)heterocyclyl is
  • R7 is H, halogen, CN, (C 1 -C 6 )alkyl, O-(C ⁇
  • R7 is H, fluoro, chloro, bromo, methyl, ethyl, methoxy, phenyl, nitrile, cyclopropyl, thienyl or vinyl, most especially preferred R7 is H, fluoro, chloro, methyl or methoxy. More particular preferred R7 is H.
  • Rg is preferably H, halogen or (C-
  • R2 is H, halogen or (C-
  • R2 is H or (C-
  • R2 may be bound to any carbon atom of the ring including the position where the linker group L is bound.
  • n is 1 , 2 or 3. More preferred, n is 1 or 2. Most preferred n is 1.
  • n is 2, 3 or 4. More preferred m is 3.
  • the linker group L may be bound to the ring in any position via a ring carbon atom.
  • m is 3 and L is attached to the 4-position of the amino cyclohexane ring
  • L is attached to the 4-position of the amino cyclohexane ring.
  • L is O-methylene, O-ethylene or preferably O. More preferably, m is 3 and L is O-methylene, O-ethylene or O attached to the 4- position of the amino cyclohexane ring.
  • an alkyl or alkylene can optionally be substituted one or more times by halogen.
  • alkyl or alkylene is substituted one to three times by halogen selected from chloro or bromo but may be substituted by fluoro once or more, e.g. being perfluorinated.
  • halogen is fluor. More preferred an alkyl or alkylene is not halogenated.
  • alkylene or cycloalkyl can optionally be substituted one or more times by a group selected independently from OH, OCH3, COOH, COOCH 3 , NH 2 , NHCH 3 , N(CH 3 ) 2 , CONH 2 , CONHCH 3 or CON(CH 3 ) 2 .
  • the number of substituents is preferably between 1 , 2, 3 or 4, more preferably 1 or 2 with 1 being even more preferred.
  • R4, R5, R7 and Re are not substituted.
  • an alkylene or cycloalkyl is not substituted. More preferably an alkyl, alkylene or cycloalkyl is not substituted.
  • one or more or all of the groups contained in the compounds of formula (I) can independently of each other have any of the preferred, more preferred or most preferred definitions of the groups specified above or any one or some of the specific denotations which are comprised by the definitions of the groups and specified above, all combinations of preferred definitions, more preferred or most preferred and/or specific denotations being a subject of the present invention.
  • the invention includes the compounds of the formula (I) in all stereoisomeric forms and mixtures of stereoisomeric forms in all ratios, and their pharmaceutically acceptable salts.
  • a preferred embodiment is a compound of the formula (I) wherein
  • R 1 is H, (C-i-C ⁇ alkyl, (C 6 -C 10 )aryl, NH-(C 1 -C 6 )alkyl, NH-(C 6 -C 10 )aryl, or N[(C ⁇ C ⁇ )alkylk;
  • R2 is hydrogen, halogen, or (C 1 -C 6 )alkyl
  • R3 is H, halogen, (C-j-C ⁇ alkylene-R 1 , O-R" or NHR";
  • F*4 is H 1 halogen or (C 1 -C 6 )alkyl;
  • R 5 is H, (C 1 -C 6 ) ⁇ kYl, halogen, CN, (C 2 -C 6 )alkenyl, (C 6 -C 10 )aryl, NH-(C 6 -C 10 )aryl,
  • R 6 and R 6 ' are independently of each other H, R', (C-
  • R7 is H, halogen, CN, (C 1 -C 6 )alkyl, 0-(C ⁇
  • R 8 is H, halogen or (C-
  • n 2, 3 or 4
  • n 1 , 2 or 3
  • L is O, O-methylene or O-ethylene; and their pharmaceutically acceptable salts.
  • a further preferred embodiment is a compound of the formula (I) wherein R 1 is H, (C 1 -C 6 )aIlCyI 1 (C 6 -C 10 )aryl, NH-(C 1 -C 6 )alkyl, NH-(C 6 -C 10 )aryl, or N[(C ⁇ Ce)alkyl ⁇ ;
  • F*2 is H Or (C 1 -C ⁇ aIKyI;
  • R3 is H, halogen or NHR", wherein R" is defined as above;
  • R4 is H, halogen or (C-i-C ⁇ alkyl
  • R5 is H, (C-i-C ⁇ )alkyl, halogen, (C2-C4)alkenyl, (C 6 -C 1 o)aryl, (C 1 -C 6 )alkylene-(C6- C 10 )aryl or (C5-C 10 )heterocyclyl;
  • R 6 and R 6 ' are independently of each other H, (C ⁇ -CsJcycloalkyl, (C-
  • R7 is H, halogen, CN, (C-
  • R ⁇ is H, halogen or (C-
  • n 1 , 2 or 3;
  • L is O; and their pharmaceutically acceptable salts.
  • An especially preferred embodiment is a compound of the formula (I) wherein
  • R 1 is H, (Ci-C4)alkyl, NH-(C 1 -C 4 )alkyl, N[(Ci-C4)alkyl]2 or NH-phenyl;
  • R 2 is H, (C-i-C 4 )alkyl;
  • R3 is H, NH-(C5-C6)heteroaryl or NH-phenyl
  • R4 is H, halogen or (C-
  • R5 is H, (Ci-C4)alkyl, halogen, (C ⁇
  • R6 is H, (C3-C6)cycloalkyl or (Ci-C4)alkyl;
  • R6' is H 1 (C3-C8)cycloalkyl, (Ci-C8)alkyl, (Ci-C3)alkylene-R ⁇ C(O)O-(C 1 -C 6 )alkyl, C(O)(C 1 -C 6 )alkyl, C(O)(C3-C6)cycloalkyl, C(O)(C5-C6)heterocyclyl, C(O)(Ci-C3)alkylene-(C3-C6)cycloalkyl, C(O)(Ci-C3)alkylene-(C5-C6)heterocyclyl, or C(O)(Ci -C3)alkylene-phenyl;
  • R7 is H, halogen, CN, (Ci-C4)alkyl, O(Ci-C4)alkyl, (Ci-C4)alkenyl, phenyl, cyclopropyl, (C5-C6)heteroaryl;
  • R8 is H, halogen or (Ci-C4)alkyl
  • n 1 ;
  • the present invention relates to a compound of formula (I) independently selected from the group of
  • one or more or all of the groups can have any of its preferred, more preferred, most preferred definitions specified above or any one or some of the specific denotations which are comprised by its definitions and are specified above.
  • Isoquinoline substitution pattern is numbered according to IUPAC rules:
  • compositions of the formula (I) mean both their organic and inorganic salts as described in Remington's Pharmaceutical Sciences (17th edition, page 1418 (1985)). Because of the physical and chemical stability and the solubility, preference is given for acidic groups inter alia to sodium, potassium, calcium and ammonium salts; preference is given for basic groups inter alia to salts of maleic acid, fumaric acid, succinic acid, malic acid, tartaric acid, methylsulfonic acid, hydrochloric acid, sulfuric acid, phosphoric acid or of carboxylic acids or sulfonic acids, for example as hydrochlorides, hydrobromides, phosphates, sulfates, methanesulfonates, acetates, lactates, maleates, fumarates, malates, gluconates, and salts of amino acids, of natural bases or carboxylic acids.
  • acidic groups inter alia to sodium, potassium, calcium and ammonium salts
  • basic groups inter alia to salts of maleic acid
  • the compounds of the formula (I) form stable alkali metal, alkaline earth metal or optionally substituted ammonium salts with basic reagents such as hydroxides, carbonates, bicarbonates, alcoholates and ammonia or organic bases, for example trimethyl- or triethylamine, ethanolamine, diethanolamine or triethanolamine, trometamol or else basic amino acids, for example lysine, ornithine or arginine.
  • basic reagents such as hydroxides, carbonates, bicarbonates, alcoholates and ammonia or organic bases, for example trimethyl- or triethylamine, ethanolamine, diethanolamine or triethanolamine, trometamol or else basic amino acids, for example lysine, ornithine or arginine.
  • stable acid addition salts can also be prepared with strong acids.
  • Suitable pharmaceutically acceptable acid addition salts of the compounds of the invention are salts of inorganic acids such as hydrochloric acid, hydrobromic, phosphoric, metaphosphoric, nitric and sulfuric acid, and of organic acids such as, for example, acetic acid, benzenesulfonic, benzoic, citric, ethanesulfonic, fumaric, gluconic, glycolic, isethionic, lactic, lactobionic, maleic, malic, methanesulfonic, succinic, p-toluenesulfonic and tartaric acid.
  • inorganic acids such as hydrochloric acid, hydrobromic, phosphoric, metaphosphoric, nitric and sulfuric acid
  • organic acids such as, for example, acetic acid, benzenesulfonic, benzoic, citric, ethanesulfonic, fumaric, gluconic, glycolic, isethionic, lactic, lactobionic, maleic
  • Salts with a pharmaceutically unacceptable anion such as, for example, trifluoroacetate likewise belong within the framework of the invention as useful intermediates for the preparation or purification of pharmaceutically acceptable salts and/or for use in nontherapeutic, for example in vitro, applications.
  • physiologically functional derivative refers to any physiologically tolerated derivative of a compound of the formula (I) of the invention, for example an N-oxide, which on administration to a mammal such as, for example, a human is able to form (directly or indirectly) a compound of the formula (I) or an active metabolite thereof.
  • Physiologically functional derivatives include prodrugs of the compounds of the invention, as described, for example, in H. Okada et al., Chem. Pharm. Bull. 1994, 42, 57-61. Such prodrugs can be metabolized in vivo to a compound of the invention. These prodrugs may themselves be active or not.
  • the invention relates to compounds of the formula (I) in the form of their stereoisomeric forms, which include racemates, racemic mixtures, pure enantiomers and diastereomers and mixtures thereof.
  • the compounds of the invention may also exist in various polymorphous forms, for example as amorphous and crystalline polymorphous forms. All polymorphous forms of the compounds of the invention belong within the framework of the invention and are a further aspect of the invention.
  • radicals or substituents may occur more than once in the compounds of the formula (I), they may all, independently of one another, have the stated meaning and be identical or different.
  • -C8)alkyl and the corresposponding alkylene substituents are understood as a hydrocarbon residue which can be linear, i.e. straight-chain, or branched and has 1 , 2, 3, 4, 5, 6, 7 or 8 carbon atoms, respectively. This also applies if an alkyl group occurs as a substituent on another group, for example in an alkoxy group (O-alkyl), S-alkyl or a -O(C-
  • alkyl groups are methyl, ethyl, propyl, butyl, pentyl or hexyl, the n-isomers of all these groups, isopropyl, isobutyl, 1-methylbutyl, isopentyl, neopentyl, 2,2-dimethylbutyl, 2- methylpentyl, 3-methylpentyl, isohexyl, sec-butyl, tert-butyl or tert-pentyl.
  • Alkyl or alkylene groups may - if not otherwise stated - be halogenated once or more, e.g. alkyl groups may be fluorinated, e.g. perfluorinated.
  • alkyl groups may be fluorinated, e.g. perfluorinated.
  • halogenated alkyl groups are CF3 and CH2CF3, OCF3, SCF3, or -O-(CF2)2-O-.
  • Halogen means fluoro, chloro, bromo or iodo.
  • (C3-C8)cycloalkyl groups are cyclic alkyl groups containing 3, 4, 5, 6, 7 or 8 ring carbon atoms like cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cyclooctyl, which can also be substituted and/or contain 1 or 2 double bounds (unsaturated cycloalkyl groups) like, for example, cyclopentenyl or cyclohexenyl can be bonded via any carbon atom.
  • a (C ⁇ -C 10 )aryl group means an aromatic ring or a ring system which comprises two aromatic rings which are fused or otherwise linked, for example a phenyl, naphthyl, biphenyl, tetrahydronaphthyl, alpha- or beta-tetralon-, indanyl- or indan-1-on-yl group.
  • a preferred (Ce-C 10 )aryl group is phenyl.
  • a (C5-C 10 )heterocyclyl group means a mono- or bicyclic ring system in which one or more carbon atoms can be replaced by one or more heteroatoms such as, for example, 1 , 2 or 3 nitrogen atoms, 1 or 2 oxygen atoms, 1 or 2 sulfur atoms or combinations of different hetero atoms.
  • the heterocyclyl residues can be bound at any positions, for example on the 1-position, 2-position, 3-position, 4-position, 5-position, 6- position, 7-position or 8-position.
  • Suitable (C5-C 10 )heterocyclyl group include acridinyl, azocinyl, benzimidazolyl, benzofuryl, benzomorpholinyl, benzothienyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, carbazolyl, 4aH-carbazolyl, carbolinyl, furanyl, quinazolinyl, quinolinyl, 4H-quinolizinyl, quinoxalinyl, quinuclidinyl, chromanyl, chromenyl, chromen-2-onyl, cinnolinyl, decahydroquinolinyl, 2H,6H-1 ,5,2-dithiazinyl, dihydrofuro[2,3-b]-tetrahydrofuran, fu
  • Pyridyl stands both for 2-, 3- and 4-pyridyl.
  • Thienyl stands both for 2- and 3-thienyl.
  • Furyl stands both for 2- and 3-furyl.
  • N-oxides of these compounds for example, 1-oxy-2-, 3- or 4-pyridyl.
  • substitutions in (C5-C 10 )heterocyclyl residues can occur on free carbon atoms or on nitrogen atoms.
  • Preferred examples of (C5-C 10 )heterocyclyl residues are pyrazinyl, pyridyl, pyrimidinyl, pyrazolyl, morpholinyl, pyrrolidinyl, piperazinyl, piperidinyl, thienyl, benzofuryl, quinolinyl, tetrazolyl and triazolyl.
  • (C 6 -C 1 rj)aryl anc l (C 5 -C 1 rj)heterocyclyl groups are unsubstituted or, if not stated otherwise, substituted one or more times, preferably one to three times, by suitable groups independently selected from halogen, OH, NO2, N3, CN, C(O)-(C 1 -C 6 )alkyl,
  • Preferred substituents for (C ⁇ -C 10 )aryl groups are (C-
  • -C4)alkyl, O-phenyl, phenyl, C(O)O-(Ci -C ⁇ )alkyl, C(O)OH, C(O)-(Ci-C 4 )alkyl, halogen, NO2, SO2NH2, CN, SO 2 -(Ci -C 4 )alkyl, SO 2 -N CH-N[(C 1 -C 6 )alkyl] 2 , NH-SO 2 -(Ci- C4)alkyl, NH 2 , NH-C(O)-(Ci -C4)alkyl, (C3-C8)cycloalkyl, (Ci-C4)alkyl-OH, C(O)N[(Ci-C 4 )alkyl] 2 , CONH(C 1 -C 6 )alkyl, C(O
  • the substituent can be located in the 2-position, the 3-position or the 4-position, with the 3-position and the 4-position being preferred. If a phenyl group carries two substituents, they can be located in 2, 3-position, 2,4-position, 2,5-position, 2,6-position, 3,4-position or 3,5-position. In phenyl groups carrying three substituents the substituents can be located in 2, 3,4-position, 2, 3,5-position, 2,3,6- position, 2,4,5-position, 2,4,6-position, or 3,4,5-position.
  • phenyl groups correspondingly apply to divalent groups derived from phenyl groups, i.e. phenylene which can be unsubstituted or substituted 1 ,2-phenylene, 1 ,3-phenylene or 1 ,4-phenylene.
  • the above statements also correspondingly apply to the aryl subgroup in arylalkylene groups.
  • arylalkylene groups which can also be unsubstituted or substituted in the aryl subgroup as well as in the alkylene subgroup, are benzyl, 1-phenylethylene, 2-phenylethylene, 3- phenylpropylene, 4-phenylbutylene, 1-methyl-3-phenyl-propylene.
  • Preferred substituents for (C5-Cirj)neterocyclyl groups are (C-
  • substituents for (C5-C 10 )heterocyclyl groups are (C-
  • the present invention therefore also relates to the compounds of the formula (I) and/or their pharmaceutically acceptable salts and/or their prodrugs for use as pharmaceuticals (or medicaments), to the use of the compounds of the formula (I) and/or their pharmaceutically acceptable salts and/or their prodrugs for the production of pharmaceuticals for the treatment and/or prevention of diseases associated with Rho-kinase and/or Rho-kinase mediated phosphorylation of myosin light chain phosphatase, i.e.
  • hypertension for the treatment and/or prevention of hypertension, pulmonary hypertension, ocular hypertension, retinopathy, and glaucoma, peripheral circulatory disorder, peripheral arterial occlusive disease (PAOD), coronary heart disease, angina pectoris, heart hypertrophy, heart failure, ischemic diseases, ischemic organ failure (end organ damage), fibroid lung, fibroid liver, liver failure, nephropathy, including hypertension-induced, non-hypertension-induced, and diabetic nephropathies, renal failure, fibroid kidney, renal glomerulosclerosis, organ hypertrophy, asthma, chronic obstructive pulmonary disease (COPD), adult respiratory distress syndrome, thrombotic disorders, stroke, cerebral vasospasm, cerebral ischemia, pain, e.g.
  • PAOD peripheral arterial occlusive disease
  • COPD chronic obstructive pulmonary disease
  • neuropathic pain neuronal degeneration, spinal cord injury, Alzheimer's disease, premature birth, erectile dysfunction, endocrine dysfunctions, arteriosclerosis, prostatic hypertrophy, diabetes and complications of diabetes, metabolic syndrome, blood vessel restenosis, atherosclerosis, inflammation, autoimmune diseases, AIDS, osteopathy such as osteoporosis, infection of digestive tracts with bacteria, sepsis, cancer development and progression, e.g. cancers of the breast, colon, prostate, ovaries, brain and lung and their metastases.
  • the present invention furthermore relates to pharmaceutical preparations (or pharmaceutical compositions) which contain an effective amount of at least one compound of the formula (I) and/or its pharmaceutically acceptable salts and a pharmaceutically acceptable carrier, i. e. one or more pharmaceutically acceptable carrier substances (or vehicles) and/or additives (or excipients).
  • a pharmaceutically acceptable carrier i. e. one or more pharmaceutically acceptable carrier substances (or vehicles) and/or additives (or excipients).
  • the pharmaceuticals can be administered orally, for example in the form of pills, tablets, lacquered tablets, coated tablets, granules, hard and soft gelatin capsules, solutions, syrups, emulsions, suspensions or aerosol mixtures.
  • Administration can also be carried out rectally, for example in the form of suppositories, or parenterally, for example intravenously, intramuscularly or subcutaneously, in the form of injection solutions or infusion solutions, microcapsules, implants or rods, or percutaneously or topically, for example in the form of ointments, solutions or tinctures, or in other ways, for example in the form of aerosols or nasal sprays.
  • compositions according to the invention are prepared in a manner known per se and familiar to one skilled in the art, pharmaceutically acceptable inert inorganic and/or organic carrier substances and/or additives being used in addition to the compound(s) of the formula (I) and/or its (their) pharmaceutically acceptable salts and/or its (their) prodrugs.
  • pharmaceutically acceptable inert inorganic and/or organic carrier substances and/or additives being used in addition to the compound(s) of the formula (I) and/or its (their) pharmaceutically acceptable salts and/or its (their) prodrugs.
  • pharmaceutically acceptable inert inorganic and/or organic carrier substances and/or additives being used in addition to the compound(s) of the formula (I) and/or its (their) pharmaceutically acceptable salts and/or its (their) prodrugs.
  • for the production of pills, tablets, coated tablets and hard gelatin capsules it is possible to use, for example, lactose, corn starch or derivatives thereof, talc
  • Suitable carrier substances for the production of solutions for example injection solutions, or of emulsions or syrups are, for example, water, saline, alcohols, glycerol, polyols, sucrose, invert sugar, glucose, vegetable oils, etc.
  • Suitable carrier substances for microcapsules, implants or rods are, for example, copolymers of glycolic acid and lactic acid.
  • the pharmaceutical preparations normally contain about 0.5 to about 90 % by weight of the compounds of the formula (I) and/or their pharmaceutically acceptable salts and/or their prodrugs.
  • the amount of the active ingredient of the formula (I) and/or its pharmaceutically acceptable salts and/or its prodrugs in the pharmaceutical preparations normally is from about 0.5 to about 1000 mg, preferably from about 1 to about 500 mg.
  • the pharmaceutical preparations can contain one or more additives such as, for example, fillers, disintegrants, binders, lubricants, wetting agents, stabilizers, emulsifiers, preservatives, sweeteners, colorants, flavorings, aromatizers, thickeners, diluents, buffer substances, solvents, solubilizers, agents for achieving a depot effect, salts for altering the osmotic pressure, coating agents or antioxidants. They can also contain two or more compounds of the formula (I) and/or their pharmaceutically acceptable salts.
  • a pharmaceutical preparation contains two or more compounds of the formula (I) the selection of the individual compounds can aim at a specific overall pharmacological profile of the pharmaceutical preparation. For example, a highly potent compound with a shorter duration of action may be combined with a long-acting compound of lower potency.
  • the flexibility permitted with respect to the choice of substituents in the compounds of the formula (I) allows a great deal of control over the biological and physico-chemical properties of the compounds and thus allows the selection of such desired compounds.
  • the pharmaceutical preparations can also contain one or more other therapeutically or prophylactically active ingredients.
  • the dose can vary within wide limits and, as is customary and is known to the physician, is to be suited to the individual conditions in each individual case. It depends, for example, on the specific compound employed, on the nature and severity of the disease to be treated, on the mode and the schedule of administration, or on whether an acute or chronic condition is treated or whether prophylaxis is carried out.
  • An appropriate dosage can be established using clinical approaches well known in the medical art.
  • the daily dose for achieving the desired results in an adult weighing about 75 kg is from about 0.01 to about 100 mg/kg, preferably from about 0.1 to about 50 mg/kg, in particular from about 0.1 to about 10 mg/kg, (in each case in mg per kg of body weight).
  • the daily dose can be divided, in particular in the case of the administration of relatively large amounts, into several, for example 2, 3 or 4, part administrations. As usual, depending on individual behavior it may be necessary to deviate upwards or downwards from the daily dose indicated.
  • the compounds of the formula (I) can be used as synthesis intermediates for the preparation of other compounds, in particular of other pharmaceutical active ingredients, which are obtainable from the compounds of the formula I, for example by introduction of substituents or modification of functional groups.
  • protective groups that may still be present in the products obtained in the coupling reaction are then removed by standard procedures.
  • tert-butyl protecting groups in particular a tert-butoxycarbonyl group which is a protection form of an amino group
  • tert-butoxycarbonyl group which is a protection form of an amino group
  • functional groups can be generated from suitable precursor groups.
  • a conversion into a pharmaceutically acceptable salt or a prodrug of a compound of the formulae (I) can then be carried out by known processes.
  • a reaction mixture containing a final compound of the formula (I) or (I 1 ) or an intermediate is worked up and, if desired, the product is then purified by customary processes known to those skilled in the art.
  • a synthesized compound can be purified using well known methods such as crystallization, chromatography or reverse phase-high performance liquid chromatography (RP-HPLC) or other methods of separation based, for example, on the size, charge or hydrophobicity of the compound.
  • RP-HPLC reverse phase-high performance liquid chromatography
  • well known methods such as amino acid sequence analysis, NMR, IR and mass spectrometry (MS) can be used for characterizing a compound of the invention.
  • Isoquinolines can by synthesized via a variety of methods.
  • the following general schemes illustrate some of the possible ways to access isoquinolines, but do not limit the present invention.
  • a suitably substituted aldehyde for example substituted by X or Y being independently from each other hydrogen, alkyl, alkoxy or halide attached in a suitable position, can be reacted with a suitable compound such as for example an acetal of aminoacetaldehyde for example in a solvent like THF, chloroform or toluene under acid catalysis by toluene sulfonic acid or another appropriate acid to give imine (ii) wherein Q' can be for instance methyl or ethyl, which in turn can be cyclized by different methods to the isoquinoline (iii).
  • a suitable compound such as for example an acetal of aminoacetaldehyde for example in a solvent like THF, chloroform or toluene under acid catalysis by toluene sulfonic acid or another appropriate acid to give imine (ii) wherein Q' can be for instance methyl or ethyl, which in turn can be cyclized by
  • this can be done by Lewis acid catalysis by suitable Lewis acids like titanium tetrachloride, ferrous halides, aluminium halides etc. at temperatures ranging from ambient to 100 °C or by reducing the imine to the corresponding amine by action of a suitable reducing agent like sodium borohydride, converting the amine into an amide or sulphonamide by reaction with a suitable acid chloride and subsequent cyclization to the isoquinoline by action of an appropriate lewis acid.
  • suitable Lewis acids like titanium tetrachloride, ferrous halides, aluminium halides etc.
  • a suitable reducing agent like sodium borohydride
  • converting the amine into an amide or sulphonamide by reaction with a suitable acid chloride and subsequent cyclization to the isoquinoline by action of an appropriate lewis acid.
  • the products like (iv) obtained via this method can then either be liberated or, if a suitable amino functionality is present, be reacted with suitable aldehydes or ketones in the presence of a reducing agent like sodium triacetoxy borohydride, sodium borohydride or sodium cyanoborohydride in a suitable solvent and in the presence of a water withdrawing agent like molecular sieves or a suitable ortho ester.
  • a reducing agent like sodium triacetoxy borohydride, sodium borohydride or sodium cyanoborohydride in a suitable solvent and in the presence of a water withdrawing agent like molecular sieves or a suitable ortho ester.
  • This amino group may have to be liberated in an initial step like for example acidic removal of Boc-groups.
  • Isoquinoline derivatives like (iv) can be obtained as free bases or as various salts like for example hydrochlorides, hydrobromides, phosphates, trifluoroacetates, sulfates or fumarates.
  • the salts obtained can be converted into the corresponding free base by either subjecting them to ion exchange chromatography or for example by alkaline aqueous treatment and subsequent extraction with suitable organic solvents like for example methyl tert. butyl ether, chloroform, ethyl acetate or isopropanol / dichloromethane mixtures and subsequent evaporation to dryness.
  • the starting material was dissolved in 2M hydrochloric acid and stirred overnight.
  • methanol or dioxane was added until a homogenous solution was obtained.
  • 4M hydrochloric acid in isopropanol was used to deprotect the compound.
  • the reaction mixture was lyophilised and the deprotected product was obtained as the corresponding hydrochloride of the free amine.
  • the examples 16 and 17 were also synthesized using a similar method as described for the synthesis of 12 and 13.
  • the respective starting materials are 6-fluoro isoquinoline (5) and either cis or trans 4-amino-cyclohexanol hydrochloride.
  • the crude material (2.2 g) was dissolved in 200 mL acetone and 10 mL water. 1.5 g (7.9 mmol) of para-toluene sulfonic acid were added and the reaction was heated to reflux temperature for 6 h. Then the solvents were distilled off. The remainder was dissolved in dichloromethane and was extracted with aqueous Na 2 CO 3 solution. After drying over Na 2 SO 4 , filtration and removal of the solvents the crude product was purified by flash chromatography to yield 1.19 g of 27 as a white solid.
  • the Boc group was removed by dissolving the intermediate in isopropanol and addition of 5-6 N HCI in isopropanol. The precipitate was isolated by filtration.
  • the Boc group was removed by dissolving the intermediate in isopropanol and addition of 5-6 N HCI in isopropanol. The precipitate was isolated by filtration.
  • amine building block 0.25 mmol of the amine building block (hydrochloride) was weighted into the reaction tube. 3 ml trimethyl orthoformiate was added, then 0.25 mmol of the carbonyl compound (in 0.2 ml THF or solid), followed by 1.5 mmol (2.5 mmol in case of dihydrochlorides) Et 3 N. The mixture was stirred for 1h at room temperature, then cooled to -10 0 C. 1.5 ml of a freshly prepared solution of NaHB(OAc) 3 (1.25 mmol) in DMF was added, followed by 1.225 mmol acetic acid. The mixture was stirred for 30 min in the cold, then allowed to reach room temperature. Stirring was continued over night at room temperature.
  • Step i
  • the solution was allowed to stir for an additional 3 hours to reach room temperature, then the solvent was removed partially and the precipitated product was collected by filtration.
  • Step 4 16.5 g of (cis-4-hydroxy-cyclohexyl)-carbamic acid tert-butyl ester were dissolved in 210 ml of diglyme and treated with 4.1g 50% NaH under nitrogen. The resulting mixture was stirred for 1 h at room temperature, then 14.8 g of the product from Step 3 were added. The mixture was allowed to stir for 1 day at room temperature, then 100 ml of toluene were added and the resulting mixture was washed with water 3 times. The organic phases were collected and the solvent was removed in vacuo.
  • Step 6 The products of Step 5 are dissolved in 5 ml of ethanol saturated with gaseous HCI. After stirring for 5h the desired product is isolated as its hydrochloride by removal of the solvent in vacuo.
  • the following examples were synthesized as hydrochlorides following this general procedure (Table 9):
  • the aqueous layer was lyophilized and purified by HPLC, the resulting product was converted into its HCI salt by taking it up in 0.1 M HCI and subsequent lyophilisation.
  • IC50 values were determined according to the following protocol:
  • Buffer 25mM Tris pH7,5; 0,02% BSA; 5% Glycerol; 0,008% Triton X100; 2% DMSO,
  • Biotinylated substrate diluted to 0.25 ⁇ M with buffer described above (without ATP)
  • PIC50 negative decadal logarithm of the IC50

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)

Abstract

The invention relates to 6-substituted isoquinoline derivatives of the Formula (I) useful for the treatment and/or prevention of diseases associated with Rho-kinase and/or Rho-kinase mediated phosphorylation of myosin light chain phosphatase, and compositions containing such compounds.

Description

Cycloalkylamine substituted isoquinoline derivatives
The present invention relates to novel isoquinoline derivatives as described in the claims, their preparation and their use in the treatment and/or prevention of diseases related to the inhibition of Rho-kinase and/or of Rho-kinase mediated phosphorylation of myosin light chain phosphatase.
Activation of a small GTPase RhoA upon agonist stimulation results in conversion of RhoA from the inactive GDP-bound form to the active GTP-bound form with a subsequent binding to and activation of Rho-kinase. Two isoforms, Rho-kinase 1 and Rho-kinase 2, are known. Rho-kinase 2 is expressed in vascular smooth muscle cells and endothelial cells. Activation of Rho-kinase 2 by the active GTP-bound RhoA leads to calcium sensitization of smooth muscle cells through phosphorylation-mediated inhibition of the myosin light chain phosphatase activity and thereby up-regulation of the activity of myosin regulatory light chain (Uehata et al., Nature 1997, 389, 990-994).
It is known that Rho-kinase is involved in vasoconstriction, including the development of myogenic tone and smooth muscle hypercontractility (Gokina et al. J. Appl. Physiol. 2005, 98, 1940-8), bronchial smooth muscle contraction (Yoshii et al. Am. J. Resp. Cell MoI. Biol. 20, 1190-1200), asthma (Setoguchi et al. Br J Pharmacol. 2001 , 132, 111 -8; Nakahara, et al. Eur J 2000,389,103) and chronic obstructive pulmonary disease (COPD, Maruoka, Nippon Rinsho, 1999 , 57, 1982-7), hypertension, pulmonary hypertension (Fukumoto et al. Heart, 91 , 391-2, 2005, Mukai et al. Nature 1997,389, 990-4 ) and ocular hypertension and regulation of intraoccular pressure (Honjo et al. Invest. Ophthalmol. Visual Sci. 2001 , 42, 137-144), endothelial dysfunction (Steioff et al. Eur. J. Pharmacol. 2005, 512, 247-249), angina (Masumoto et al. Circ 2002, 105, 1545-47, Shimokawa et al. JCP, 2002, 40, 751-761), nephropathy, including hypertension-induced, non-hypertension-induced, and diabetic nephropathies, renal failure and peripheral arterial occlusive disease (PAOD) (Wakino et al. Drug News Perspect. 2005, 18, 639-43), myocardial infarction (Demiryurek et al. Eur J Pharmacol. 2005, 527, 129-40, Hattori et al. Circulation, 2004, 109,2234-9), cardiac hypertrophy and failure (Yamakawa, et al. Hypertension 2000, 35, 313-318, Liao et al. Am J Physiol Cell Physiol. 2006, 290, C661-8, Kishi et al. Circ 2005, 111 , 2741-2747), coronary heart disease, artherosclerosis, restenosis (Pacaud et al. Arch. MaI. Coeur 2005, 98, 249-254, Retzer, et al. FEBS Lett 2000,466,70, Negoro, et al. Biochem Biophys Res Commun 1999,262, 211), diabetes, diabetic complications, glucose utilization and metabolic syndrome (Sandu, et al. Diabetes 2000,49,2178, Maeda et al. Cell Metab. 2005, 2, 119-29), sexual dysfunction, e.g., penile erectile dysfunction (Chitaley et al. Nature Medicine 2001 , 7, 119-122), retinopathy, inflammation, immune diseases, AIDS, osteoporosis, endocrine dysfunctions, e.g. hyperaldosteronism, central nervous system disorders such as neuronal degeneration and spinal cord injury (Hara, et al. JNeurosurg 2000, 93, 94), cerebral ischemia (Uehata, et al. Nature 1997,389,990; Satoh et al. Life Sci. 2001 , 69, 1441-53; Hitomi, et al. Life Sci 2000,67,1929; Yamamoto, et al. J Cardiovasc Pharmacol. 2000, 35, 203-11), cerebral vasospasm (Sato, et al. Circ Res 2000,87,195; Kim, et al. Neurosurgery 2000,46,440), pain, e.g. neuropathic pain (Tatsumi, et al. Neuroscience 2005, 131 ,491 , Inoue, et al. Nature medicine 2004, 10, 712), infection of digestive tracts with bacteria (WO 98/06433), cancer development and progression, neoplasia where inhibition of Rho kinase has been shown to inhibit tumor cell growth and metastasis (Itoh, et al. Nature Medicine 1999,5,221 ; Somlyo, et al. Res Commun 2000,269,652), angiogenesis (Uchida, et al. Biochem Biophys Res 2000, 269,633-40 ; Gingras, et al. Biochem J 2000, 348,273), vascular smooth muscle cell proliferation and motility (Tammy et al. Circ. Res. 1999, 84, 1186-1193; Tangkijvanich et al. Atherosclerosis 2001 , 155, 321-327), endothelial cell proliferation, endothelial cell retraction and motility (Oikawa et al. Biochem. Biophys. Res. Commun. 2000, 269, 633-640), stress fiber formation (Kimura et al. Science 1997, 275, 1308-1311 ; Yamashiro et al. J. Cell Biol. 2000, 150, 797-806), thrombotic disorders (Kikkawa, et al. FEBS Lett. 2000, 466, 70-74; Bauer et al. Blood 1999, 94, 1665-1672, Klages, et al. J Cell Biol 1999,144, 745; Retzer, et al. Cell Signal 2000,12,645) and leukocyte aggregation (Kawaguchi, et al. Eur J Pharmacol. 2000, 403:203-8; Sanchez-Madrid, et al. J Immunol. 2003, 171 :1023-34, Sanchez-Madrid, et al. J Immunol. 2002, 168:400-10), and bone resorption (Chellaiah, et al. J Biol Chem. 2003, 278:29086-97). Na/H exchange transport system activation (Kawaguchi, et al. Eur J Pharmacol. 2000, 403:203-8), Alzheimer's disease (Zhou et al. Science 2003, 302, 1215-1217), adducin activation (Fukata et al. J. Biol. Chem., 1998, 273, 5542- 5548), and in SREB (Sterol response binding element) signalling and its effects on lipid metabolism (Lin et al. Circ. Res., 92, 1296-304, 2003).
Therefore, a compound having inhibitory effect on Rho-kinase and/or on Rho-kinase mediated phosphorylation of myosin light chain phosphatase is useful for the treatment and/or prevention of cardiovascular and non-cardiovascular diseases involving Rho- kinase as the primary or secondary disease cause, like hypertension, pulmonary hypertension, ocular hypertension, retinopathy, and glaucoma, peripheral circulatory disorder, peripheral arterial occlusive disease (PAOD), coronary heart disease, angina pectoris, heart hypertrophy, heart failure, ischemic diseases, ischemic organ failure (end organ damage), fibroid lung, fibroid liver, liver failure, nephropathy, including hypertension-induced, non-hypertension-induced, and diabetic nephropathies, renal failure, fibroid kidney, renal glomerulosclerosis, organ hypertrophy, asthma, chronic obstructive pulmonary disease (COPD), adult respiratory distress syndrome, thrombotic disorders, stroke, cerebral vasospasm, cerebral ischemia, pain, e.g. neuropathic pain, neuronal degeneration, spinal cord injury, Alzheimer's disease, premature birth, erectile dysfunction, endocrine dysfunctions, arteriosclerosis, prostatic hypertrophy, diabetes and complications of diabetes, metabolic syndrome, blood vessel restenosis, atherosclerosis, inflammation, autoimmune diseases, AIDS, osteopathy such as osteoporosis, infection of digestive tracts with bacteria, sepsis, cancer development and progression, e.g. cancers of the breast, colon, prostate, ovaries, brain and lung and their metastases.
WO 01/64238 describes isoquinoline-5-sulfonamide derivatives optionally substituted by a -(CH2)i-6-0-(CH2)o-6-. a -(CH2)θ-6-S-(CH2)θ-6- or a -(CH2)0_6-linked heterocyclic group useful as neuroprotective agents.
WO 2004/106325 (Schering AG) describes prodrugs of the Rho-kinase inhibitor fasudil carrying an ether or ester group in the 1-position of the isoquinoline ring.
WO 2001/039726 generically describes -O-(Crj-C10)alkyl-heteroaryl substituted cyclohexyl derivatives useful for the treatment of microbial infections. JP 10087629 A describes isoquinoline derivatives useful for the treatment of diseases caused by Heliobacter pylori such as for example gastritis cancer or ulcer. The isoquinoline derivatives may be substituted by OH in the 1 -position and are preferably 5-substituted by X-[(C1-C6)alkylene)]o--|-Y wherein X may be oxygen and Y may be an aryl or a heterocyclic group.
Hagihara et al. (Bioorg. Med. Chem. 1999, 7, 2647-2666) disclose 6-benzyloxy- isoquinoline for the treatment of infections caused by Heliobacter pylori.
US 5,480,883 generically discloses as EGF and/or PDGF receptor inhibitors useful for inhibiting cell proliferation compounds of the formula "Ar I - X - Ar II" wherein X may be (CHR-i )m-Z-(CHR-|)n, e.g. Z-CH2, wherein Z may be O, R-| is hydrogen or alkyl, Ar
I may be among others an optionally substituted isoquinolone and Ar Il may be among others an optionally substituted 03.7 monocyclic saturated heterocyclic system.
WO 2005/030791 (Merck & Co.) generically describes as potassium channel inhibitors for the treatment of cardiac arrhythmias, stroke, congestive heart failure etc. isoquinolone derivatives which are optionally substituted in 6-position by a group
(CReRf)pOR43 wherein p may be zero, and R43 is e.g. a (C3-C<|rj)cycloalkyl residue optionally substituted by NR5I R52 wherein R51and R52 may be hydrogen, (C-j-Cβ)alkyl etc.; or R43 js a group R^1 defined as a 4-6 membered unsaturated or saturated monocyclic heterocylic ring with 1 , 2, 3 or 4 heteroatoms; and are substituted by a directly bound optionally substituted aryl or heteroaryl ring in the 4-position.
WO 2005/030130 (Merck & Co.) generically describes as potassium channel inhibitors for the treatment of cardiac arrhythmias, stroke, congestive heart failure etc. isoquinoline derivatives which may be substituted by hydroxyl in the 1 -position and are optionally substituted in 6-position by a group (CReRf)pOR43 wherein p may be zero, and R43 is e.g. a (C3-C10)cycloalkyl residue optionally substituted by NR51 R52, wherein R51and R52 may be hydrogen, (C1-C6)alkyl etc.; or R43 is a group R81 defined as a 4-6 membered unsaturated or saturated monocyclic heterocylic ring with 1 , 2, 3 or 4 heteroatoms; and are substituted by a directly bound optionally substituted aryl or heteroaryl ring in the 4-position.
WO 03/053330 (Ube) generically describes isoquinolone derivatives of the formula
{aromatic ring} - C(R)(R)(NH2)
Figure imgf000006_0001
as Rho-kinase inhibitors.
An embodiment of the present invention is a compound of the formula (I)
Figure imgf000006_0002
wherein
R1 is
H,
(C1-C6)SlRyI,
R', NH-(C1-C6)SlRyI1
NHR', or N[(Ci-CβJa'kylfe;
R2 is H, halogen or (C1-C6)SlRyI;
R3 is H1 halogen,
(C-i-Cβ)alkyl,
(C1-C6)alkylene-R',
OH,
O-R",
NH2,
NHR",
NR"R" or
NH-C(O)-R",
R4 is
H, halogen, hydroxy,
CN,
(C-i-Cβ)alkyl,
R',
(C1-C6)alkylene-R';
R5 is
H, halogen,
CN,
NO2,
(C-i-Cβ)alkyl,
(C2-C6)alkenyl,
R',
(C1-C6)alkylene-(C6-C10)aryl,
(C1-C6)alkenylene-(C6-C10)aryl, (C1-C6)alkylene-(C5-C10)heterocyc|yl, CH(OH)-(C1-C6)alkyl,
NH2,
NH-R',
NH-SO2H,
NH-SO2-(C1-C6)alkyl, NH-SO2-R', NH-C(O)-(C1-C6)alkyl,
NH-C(O)-R', C(O)N[ (C1-C6)alkyl]2,
C(O)OH, or C(O)O- (C1-C6)alkyl;
Rg and RQ are independently of each other
H, R', (C1-C8)alkyl,
(C1-C6)alkylene-R',
(C1-C6)alkylene-O-(C1-C6)alkyl,
(C1-C6)alkylene-O-R1,
(C1-C6)alkylene-CHtR'k,
(C1-C6)alkylene-C(O)-R',
(C1-C6)alkylene-C(O)NH2,
(C1-C6)alkylene-C^NH-R1,
(C1-C6)alkylene-C^NH-(C1-C6)alkyl,
(C1-C6)alkylene-C^N[(C1-C6)alkylk,
(C1-C6)alkylene-C^NtR1^;
(C1-C6)alkylene-C(O)O-(C1-C6)alkyl,
C(O)O-(C1-C6)alkyl, C(O)OR' C(O)(C1-C6)alkyl,
C(O)R', C(O)NH-(C1-Ce)BlKyI,
C(O)NHR', C(O)Nt(C1 -C6)alkyl]R'
C(O)N[(C1 -C6)alkyl]2,
C(O)-(C1 -C6)alkylene-R',
C(O)O(C1-C6)alkylene-R', or Re and RQ , together with the N-atom to which they are attached, form a (Cs-C1 O) heterocyclyl group;
R7 is
H, halogen,
CN,
NO2,
(C-i-C^alkyl,
O-tC-i-Ce)alkyl,
(C2-C6)alkenyl,
R',
(C1-C6)alkenylene-(C6-C10)aryl,
(C1-C6)alkylene-R1,
CH^HHC-i-Ce)alkyl,
NH2,
NH-R', NH-SO2H,
NH-SO2-(C1-C6)alkyl, NH-SO2-R', SO2-NH2,
SO2-NHR',
NH-C(O)- (C1-C6)alkyI,
NH-C(O)-R',
CCON[ (C1-C6)alkylfe.
C(O)OH, or
C(O)O-(C-i-Ce)alkyl;
R8 is H, halogen or (C1-C6)alkyl;
n is 1 , 2, 3 or 4;
m is 1 , 2 ,3 ,4 or 5, and
L is O or O- (C1-C6)alkylene;
wherein
R' is
(C3-C8)cycloalkyl,
(C5-C10)heterocyclyl, (C6-C10)aryl; and
R" is (C3-C8)cycloalkyl,
(C5-C10)heterocyclyl,
(C6-C10)aryl,
(C-i-C^alkyl,
(C1-C6)alkylene-R'I
(C1-C6)alkylene-O^CvCe)alkyl,
(C1-C6)alkylene-O-R1, or (C1-C6)alkylene-NRxRy; and wherein Rx and Ry are independently of each other
(C1-C6)alkyl,
(C5-C10)heterocyclyl,
(C6-C10)aryl,
(C-|-C4)alky!ene-(C5-C10)heterocyclyl,
(C i -C4)alkylene-(C6-C <| 0)ary I ,
(C-i-C^alkylene-NI-KC-i-Ce)alkyl,
(Ci-C4)alkylene-N[(C1-C6)alkyl]2,
(Ci-C4)alkylene-N[(C6-C10)aryl]2, or
(Ci-C4)alkylene-N[(C5-C10)heterocyclyl]2;
wherein in residues R4, R5, RQ, RQ , RJ and Rs alkyl, alkylene or cycloalkyl can optionally be substituted one or more times by OH, OCH3, COOH, COOCH3, NH2, NHCH3, N(CH3)2, CONH2, CONHCH3 or CON(CH3)2 ;
wherein in residues R1 to Rs alkyl or alkylene can optionally be substituted one or more times by halogen;
wherein in residues R-| and R3 to Rø (Ce-C1 rj)aryl and (Cs-C10)heterocyclyl are unsubstituted or substituted one or more times by suitable groups independently selected from halogen, OH, NO2, N3, CN, C(O)-(C1 -Ce)alkyl, C(O)-(C<|-C6)aryl,
COOH, COO(C1-C6)alkyl, CONH2, CONH^-C^alkyl, CONf(C1 -C6)alkyl]2, (C3-C8)cycloalkyl, (C1-C6)alkyl, (C-|-C6)alkylene-OH, (C1-C6)alkylene-NH2,
(C1-C6)alkylene-NH^-i-Ce)alkyl, (C1-C6)alkylene-N^C-i-Ce)alkyl^, (C2-C6)alkenyl, (C2-C6)alkynyl, O^C^Ce)alkyl, 0-C(O)-(C1-C6)alkyl, PO3H2, SO3H, SO2-NH2, SO2NH(C1 -C6)alkyl, SO2NI(C1 -C6)alkyl]2 , S-(C1 -C6)alkyl, SO-(C1-C6)alkyl, SO2- (C-i-C^alkyl, SO2-N=CH-N[(C1-C6)alkyl]2, C(NH)(NH2), NH2, NH-fC-i-Cβ)alkyl, Nt(C1 -C6)alkyl]2, NH-C(O)-(C1 -C6)alkyl,
NH-C(O)O-(C1 -C6)alkyl,
NH-SO2-(C1 -C6)alkyl, NH-SO2-(Ce-C1 o)aryl, NH-SO2-(Cs-C1 o)heterocyclyl, N(C1-
Ce)alkyl-C^HC-i-Ce)alkyl, N(C1-C6)alkyl-C(O)O-(C1-C6)alkyl,
N^-i-C^alkyl-C^-NH^C-i-Ce)alkyl],
(C6-C10)aryl, (C1-C6)alkylene-tCe-C-irjJaryl, 0-(C6-C1 o)aryl,
O-(C -J -C6)alkylene-(C6-C <| o)aryl, (C5-C \ o)heterocyclyl ,
(C1-C6)alkylene^Cs-C10)heterocyclyl, or O-(C1-C6)alkylene-(C5-C10)heterocyclyl, wherein the (C6-C1 rj)aryl or (Cs-C10)heterocyclyl may be substituted one to three times by a group independently selected from halogen, OH, NO2, CN, O^C-i-C^alky!,
(C1-C6)alkyl, NH2, NH^-C^alkyl, Nt(C1 -C6)alkyl]2, SO2CH3, COOH, C(O)O-(C1-
C6)alkyl, CONH2, (C1-C6)alkylene-O-fC-i-Ce)alkyl, (C-i-C^alkylene-O^Ce-C10)aryl, or O^C-i-C^alkylene-tCe-C-icOaryl; or wherein (C6-C1 o)aryl is vicinally substituted by a O-(C1-C4)alkylene-O group whereby a 5-8-membered ring is formed together with the carbon atoms the oxygen atoms are attached to; and wherein aryl or heterocyclyl substituents of (C6-C1 o)aryl and (Cs-C10)heterocyclyl groups may not be further substituted by an aryl or heterocyclyl containing group;
and their pharmaceutically acceptable salts.
Preferably, R1 is H, (C-i-C^alkyl, (C6-C10)aryl, NH-(C1 -C6)alkyl, NH-(C6-C1 rj)aryl or Nt(C1 -C6)alkyl]2. More preferably, R1 is H, halogen, (C-i-C^alkyl, NH-(C1 -C4)alkyl, Nt(C1 -C4)alkyl]2 or NH-phenyl. Most preferably, R1 is H, (C-|-C2)alkyl or NH-(C1- C2)alkyl, especially preferred R1 is H.
R3 is preferably H, halogen, (C-|-C4)alkylene-R', O-R" or NHR". More preferred, R3 is H or NHR". Most preferred, R3 is H, NH-(C5-C6)heterocyclyl or NH-phenyl, especially preferred are H, NH-(C5-C6)heteroary! containing one or more N atoms or NH-phenyl. Most especially preferred, R3 is H. Examples of R3 substituents are
Figure imgf000013_0001
Preferably, R4 is H, halogen or (C1-C6)alkyl. More preferred, R4 is H, halogen or (C-|- C4)alkyl. Most preferred, R4 is H.
Preferably, R5 is H, halogen, CN, (C1-C6)alkyl, (C2-C6)alkenyl, R', NH-(C6-Ci rj)aryl or (C1-C6)alkylene-R'. More preferably, R5 is H, halogen, (C1-C6)alkyl, (C2-C6)alkenyl, R', NH-(C6-Ci øjaryl or (C1-C6)alkylene-R\ Most preferably, R5 is H, halogen, (C1-C6)alkyl, (C2-C6)alkenyl, (C6-Ci o)aryl, NH-(C6-C10)aryl, (C-|-C2)alkyl-(C6-C10)ary' or (C5-C10)heteroaryl. Especially preferred, R5 is H, halogen, phenyl, (C-|-C6)alkyl, (C2-C6)alkenyl, (C6-C10)aryl or (C5-C6)heteroaryl. Most especially preferred R5 is H, halogen, methyl, ethyl, vinyl, phenyl, thienyl or pyridyl.
Examples of R5 are hydrogen, fluoro, chloro, bromo, iodo, methyl, ethyl, vinyl, phenyl, thienyl or pyridyl, nitrile, nitro, (p-methoxy)-phenyl, N-aniline, benzyl, 2-propenyl, s- butenyl, cyclopropyl, tetrazol, amino, 4-methoxy-aniline or N-acetyl, preferably hydrogen, fluoro, chloro, bromo, iodo, methyl, ethyl, vinyl, phenyl, thienyl or pyridyl. More preferred, R5 is H, halogen, methyl, or ethyl, most preferred R5 is H.
Preferably, R6 and R6' are independently of each other H, (C1-C6)aIkYl1
R', (C1-C4)alkylene-(C3-C8)cycloalkyl,
(C-i-C^alkylene-fCs-C10)heterocyclyl, (C ! -C4)alkylene-(C6-C 1 o)aryl,
(C1-C6)alkylene-O-(C1-C6)alkyl, (Ci-C4)alkylene-C(O)-(C5-C10)heterocyclyl, (C-|-C4)alkylene-C(O)-(C6-C10)aryl,
(C1-C6)a\ky\ene-C(O)N[(C^CQ)a\kγ\]2,
(C1-C6)alkylene-C(O)N H- (C1-C6)alkyl,
(C1-C6)alkylene-C(O)O- (C1-C6)alkyl,
C(O)R'
C(O)(C1 -C6)alkyl,
CfCOCHC-i-Ce)alkyl, C(O)NH-(C1 -C6)alkyl,
C{0)N[{C<\-CQ)a\ky\\2> or
C(O)(C1 -C6)alkylene-R', or
R6 and RQ , together with the N-atom to which they are attached, form a
(Cs-C1 o)heterocyclyl group.
In a further preferred embodiment, RQ and RQ' are independently of each other
H,
(C1-C6)alkyl,
(C5-C10)heterocyclyl,
(C3-Cδ)cycloalkyl,
(C6-C10)aryl ,
(C1-C4)alkylene-(C3-C8)cycloalkyl,
(C1-C4)alkylene-(C5-C10)heterocyclyl,
(C-i-C^alkylene^Ce-CioJaryl, (C1-C6)alkylene-O- (C1-C6)a\ky\,
(C1-C6)alkylene-C(O)N[ (C1-C6)alkyl]2,
(C1-C6)alkylene-CCOJNH^C-i-Ce)alkyl,
(C1-C6)alkylene-C(O)O-(C1-C6)alkyl,
C{O)O- (C1-C6)a\ky\,
C(O) (C1-C6)a\ky\,
C(O)(C3-C8)cycloalkyl,
C(O)NH-(C1-C6)alkyl,
C^N[(^-C^alkylfc,
C(O) (C1-C6)alkylene-(C3-C8)cycloalkyl,
C(O) (C1-C6)alkylene- (C5-C<ιo)heterocyclyl,
C(O) (C1-C6)alkylene--(C6-Ci o)aryl, or
RQ and RQ', together with the N-atom to which they are attached form a
(C5-C10)heterocyclyl group.
In a more preferred embodiment, Rg is H, (C1-C6)alkyl, (C3-C6)cycloalkyl or (C-] -C4)alkylene-(C3-C6)cycloalkyl, and
R61 'S H,
(C1-C6)alkyl,
(C3-C8)cycloalkyl,
(C5-C<io)heterocyclyl,
(C5-C10)aryl,
(Ci-C4)alkylene-(C3-C8)cycloalkyl,
(Ci-C4)alkylene-(C5-C10)heterocyclyl,
(C 1 -C4)alkylene-(C6-C i o)aryl,
(C1-C6)alkylene-O-(C1-C6)alkyl,
(C1-C6)alkylene-C(O)NH-(C1-C6)alkyl,
(C1-C6)a\ky\ene-C(O)U[(CvC6)a\ky\]2, (C1-C6)alkylene-C(O)O-(C<|-C6)alkyl,
CfOJCKC-i-Ce)alkyl,
C(O)(C^-CQ)a\ky\,
C(O)(C3-C8)cycloalkyl,
C(O)NH-(C1 -C6)alkyl,
C(O)NI(C1 -C6)alkyl]2,
C(O) (C1-C6)aikylene-(C3-C8)cycloalkyl,
C(O) (C1-C6)alkylene-(C5-C10)heterocyclyl,
C(O) (C1-C6)alkylene^Ce-C10)aryl, or
R6 and RQ', together with the N-atom to which they are attached, form a
(C5-C1rj)heterocyclyl group.
In a further more preferred embodiment, RQ is H, (C1-C6)alkyl and RQ' is
H,
(C1-C6)alkyl,
(C3-C8)cycloalkyl, (C6-C1 o)aryl, (C5-C-1 o)heterocyclyl, (C1-C4)alkylene-(C3-C8)cycloalkyl, (C1-C4)alkylene-(C5-C10)heterocyclyl,
(C1-C6)alkylene^Ce-C10)aryl, (C -i -C4)alkylene-O-(C -| -C4)alkyl, CtOX^-Ce)alkyl,
(Ci-C4)alkylene-C(O)N[(Ci-C4)alkyl]2,
(C1-C6)alkylene-C(O)NH-(C1-C6)alkyl, or
RQ and Rg', together with the N-atom to which they are attached, form a (C5-C10)heterocyclyl group.
In a further even more preferred embodiment, RQ is H, (C1-C6)alkyl and RQ' is H, (C1-Ce)3IkYl;
(C3-C8)cycloalkyl;
(C-|-C4)alkylene-(C3-C8)cycloalkyl;
(C-|-C4)alkylene-O-(Ci-C4)alkyl;
C^CC-i-C^alkyl;
(Ci-C^alkylene-CCOJN[(C-i^alkylk;
(C-|-C4)alkylene-(C5-C10)heterocyclyl wherein heterocyclyl is unsubstituted or substituted one or more times, preferably one to three times, more preferabyl one or two times, by a group independently selected from (C-|-C4)alkyl, O(C-|-C4)alkyl, halogen or phenyl, or is substituted once by (Cs-Cøjheterocyclyl; wherein phenyl or (C5-C6)heterocyclyl are unsubstituted or substituted one to three times by halogen, (C-|-C4)alkyl or O(C-|-C4)alkyl; or
(Ci-C4)alkylene-(C6-C10)aryl wherein aryl is unsubstituted or substituted one or more times, preferably one to three times, by a group independently selected from halogen;
(C<|-C4)alkyl, preferably CH3 or CF3; O-(Ci-C4)alkyl; CN, SO2-NH2; SO2-
(C1-C4)alkyl preferably SO2-CH3 or SO2-CF3; 802-N=CH-Nt(C1 -C4)alkyl]2, preferably SO2-N=N-N(CH3)2; NH-CO-(C1 -C4)alkyl, preferably NH-CO-CH3; or CO-
O-(C1-C4)alkyl, or (C6-C10)aryl is substituted once by unsubstituted phenyl, unsubstituted O-phenyl or unsubstituted (C5-C6)heterocyclyl; or RQ and RQ', together with the N-atom to which they are attached, form a
(C5-C6)heterocyclyl group, which is unsubstituted or substituted one to three times, preferably once, by (C-|-C4)alkyl or C(O)O(C1 -C4)alkyl; wherein a (C1-C4)alkyl or (C1-C6)alkyl residue is unsubstituted or substituted one to three times by halogen, preferably by fluoro.
Preferably the formed heterocyclyl group is morpholino, piperidino, pyrrolidine or piperazino. More preferably the heterocyclyl group is morpholino or 4- (ethoxycarbonyl)-piperazinyl. In a most preferred embodiment, Rβ is H, (C1-C6)alkyl and Rβ' is H, (C1-C6)alkyϊ, (C3-C8)cycloalkyl.
In a further most preferred embodiment, Rβ is H and RQ' is H, unsubstituted (C-|- Cβ)alkyl, or unsubstituted (Cβ-Cgjcycloalkyl. Especially preferred, Rβ and Rβ' are H.
As examples for these embodiments, R6 or R6' are, independently from each other, hydrogen, methyl, ethyl, propyl, isopropyl, 3-methyl-butyl, 2-methyl-propyl, butyl, pentyl, 3,3,3-trifuoropropyl, 4,4,4-trifluorobutyl or a substituent selected from the group consisting of
Figure imgf000018_0001
Figure imgf000019_0001
Figure imgf000020_0001
Other examples for these embodiments of R6 or R6 ' are, independently from each other,
Figure imgf000020_0002
An example for R6, R6 ' forming a (C5-C io)heterocyclyl is
Figure imgf000020_0003
The * denotes where the bond is connected to the N atom of the amine. Preferably, R7 is H, halogen, CN, (C1-C6)alkyl, O-(C<|-C6)alkyl, (C2-C6)alkenyl, R' or (C-|-C6)alkylene-(C3-C8)cycloalkyl. More preferred, R7 is H1 halogen, CN, (C-|-C4)alkyl, O-(C-|-C4)alkyl, (Ci-C4)alkenyl, phenyl, cyclopropyl or (C5-C6)heteroaryl. Most preferably, R7 is H, fluoro, chloro, bromo, methyl, ethyl, methoxy, phenyl, nitrile, cyclopropyl, thienyl or vinyl, most especially preferred R7 is H, fluoro, chloro, methyl or methoxy. More particular preferred R7 is H.
Rg is preferably H, halogen or (C-|-C4)alkyl. More preferred, Rg is H, Cl, F, methyl or ethyl. Most preferred Rg is H.
Preferably, R2 is H, halogen or (C-|-C4)alkyl. Preferably, R2 is H or (C-|-C2)alkyl. More preferred, R2 is H, methyl or ethyl. Most preferred R2 is H. R2 may be bound to any carbon atom of the ring including the position where the linker group L is bound.
Preferably, n is 1 , 2 or 3. More preferred, n is 1 or 2. Most preferred n is 1.
Preferably m is 2, 3 or 4. More preferred m is 3.
The linker group L may be bound to the ring in any position via a ring carbon atom. In a preferred embodiment, m is 3 and L is attached to the 4-position of the amino cyclohexane ring
Figure imgf000021_0001
or L is attached to the 3-position of the amino cyclohexane ring
Figure imgf000022_0001
In an especially preferred embodiment, L is attached to the 4-position of the amino cyclohexane ring.
In a further preferred embodiment, L is O-methylene, O-ethylene or preferably O. More preferably, m is 3 and L is O-methylene, O-ethylene or O attached to the 4- position of the amino cyclohexane ring.
In residues R-| to Rg an alkyl or alkylene can optionally be substituted one or more times by halogen. Preferably alkyl or alkylene is substituted one to three times by halogen selected from chloro or bromo but may be substituted by fluoro once or more, e.g. being perfluorinated. Preferably halogen is fluor. More preferred an alkyl or alkylene is not halogenated.
In residues R4, R5, RQ ,RQ', RJ and Rg alkyl, alkylene or cycloalkyl can optionally be substituted one or more times by a group selected independently from OH, OCH3, COOH, COOCH3, NH2, NHCH3, N(CH3)2, CONH2, CONHCH3 or CON(CH3)2. If substituted, the number of substituents is preferably between 1 , 2, 3 or 4, more preferably 1 or 2 with 1 being even more preferred.. Preferably R4, R5, R7 and Re are not substituted. Preferably an alkylene or cycloalkyl is not substituted. More preferably an alkyl, alkylene or cycloalkyl is not substituted.
In preferred embodiments of the present invention one or more or all of the groups contained in the compounds of formula (I) can independently of each other have any of the preferred, more preferred or most preferred definitions of the groups specified above or any one or some of the specific denotations which are comprised by the definitions of the groups and specified above, all combinations of preferred definitions, more preferred or most preferred and/or specific denotations being a subject of the present invention. Also with respect to all preferred embodiments the invention includes the compounds of the formula (I) in all stereoisomeric forms and mixtures of stereoisomeric forms in all ratios, and their pharmaceutically acceptable salts.
The term "*-" in the exemplified substituents vide supra marks the point where the substituent is attached, which means, for example, for a R3 substituent
Figure imgf000023_0001
and m is 3 a compound of the formula
Figure imgf000023_0002
A preferred embodiment is a compound of the formula (I) wherein
R1 is H, (C-i-C^alkyl, (C6-C10)aryl, NH-(C1 -C6)alkyl, NH-(C6-C10)aryl, or N[(C^Cβ)alkylk;
R2 is hydrogen, halogen, or (C1-C6)alkyl;
R3 is H, halogen, (C-j-C^alkylene-R1, O-R" or NHR"; F*4 is H1 halogen or (C1-C6)alkyl;
R5 is H, (C1-C6)^kYl, halogen, CN, (C2-C6)alkenyl, (C6-C10)aryl, NH-(C6-C10)aryl,
(C1-C6)alkylene^Ce-C10)aryl, (C5-C10)heterocyclyl or
(C1-C6)alkylene-(C5-C10)heterocyclyl;
R6 and R6' are independently of each other H, R', (C-|-C8)alkyl, (C-i-C^alkylene-R1,
(C1-C6)alkylene-O-(C1-C6)alkyl, (C-j-C^alkylene-O-R1, (C-i-C^alkylene-CHtR'tø,
(C1-C6)alkylene-C(O)NH2, (C1-C6)alkylene-C^NH-R', (C<|-C6)alkylene-C(O)N[(Ci- C4)alkyl]2, (C1-C6)alkylene-C(O)N[R']2, C(O)O-(C1 -C6)alkyl, C(O)(C1 -C6)alkyl, C(O)(C3-C8)cycloalkyl, C(O)(C5-C1 o)heterocyclyl, C(O)NH-(C1-C6)alkyl, C(O)Nf(C1- C6)alkyl]2, C(O)-(C1-C6)alkylene-(C3-C8)cycloalkyl, C(O) (C-i-C^alkylene^Cs-C10)heterocyclyl, C(O)(C1 -C^alkylene-^e-C10)aryl, or R6 and R6', together with the N-atom to which they are attached, form a (C5-C6)heterocyclyl group.
R7 is H, halogen, CN, (C1-C6)alkyl, 0-(C<|-C6)alkyl, (C2-C6)alkenyl or R';
R8 is H, halogen or (C-|-C6)alkyl;
m is 2, 3 or 4
n is 1 , 2 or 3, and
L is O, O-methylene or O-ethylene; and their pharmaceutically acceptable salts.
A further preferred embodiment is a compound of the formula (I) wherein R1 is H, (C1-C6)aIlCyI1 (C6-C10)aryl, NH-(C1 -C6)alkyl, NH-(C6-C10)aryl, or N[(C^Ce)alkyl^;
F*2 is H Or (C1-C^aIKyI;
R3 is H, halogen or NHR", wherein R" is defined as above;
R4 is H, halogen or (C-i-C^alkyl;
R5 is H, (C-i-Cβ)alkyl, halogen, (C2-C4)alkenyl, (C6-C1 o)aryl, (C1-C6)alkylene-(C6- C10)aryl or (C5-C10)heterocyclyl;
R6 and R6' are independently of each other H, (Cβ-CsJcycloalkyl, (C-|-C8)alkyl, (C1- C6)alkylene-O-(C1-C6)aHcyl, (C-i-Ca)alkylene-R1; C(O)(C1 -C6)alkyl, C(O)(C3- C8)cycloalkyl, C(O)(Cs-C1 o)heterocyclyl, C(O)(C1 -C6)alkylene-(C3-C8)cycloalkyl, C(O)(C1 -C^alkylene^Cs-C-injheterocyclyl or C(O)(C1 -C6)alkylene-(C6-C10)aryl;
R7 is H, halogen, CN, (C-|-C6)alkyl, 0(C<|-C6)alkyl, (C2-C6)alkenyl or R';
Rβ is H, halogen or (C-|-C6)alkyl;
m is 2, 3 or 4 n is 1 , 2 or 3; and
L is O; and their pharmaceutically acceptable salts.
An especially preferred embodiment is a compound of the formula (I) wherein
R1 is H, (Ci-C4)alkyl, NH-(C1 -C4)alkyl, N[(Ci-C4)alkyl]2 or NH-phenyl; R2 is H, (C-i-C4)alkyl;
R3 is H, NH-(C5-C6)heteroaryl or NH-phenyl;
R4 is H, halogen or (C-|-C4)alkyl;
R5 is H, (Ci-C4)alkyl, halogen, (C<|-C4)alkenyl, (Ce-Ci rj)aryl, (C-|-C2)alkyl- (Ce-C-i o)aryl or (C5-C6)heteroaryl;
R6 is H, (C3-C6)cycloalkyl or (Ci-C4)alkyl;
R6' is H1 (C3-C8)cycloalkyl, (Ci-C8)alkyl, (Ci-C3)alkylene-R\ C(O)O-(C1-C6)alkyl, C(O)(C1-C6)alkyl, C(O)(C3-C6)cycloalkyl, C(O)(C5-C6)heterocyclyl, C(O)(Ci-C3)alkylene-(C3-C6)cycloalkyl, C(O)(Ci-C3)alkylene-(C5-C6)heterocyclyl, or C(O)(Ci -C3)alkylene-phenyl;
R7 is H, halogen, CN, (Ci-C4)alkyl, O(Ci-C4)alkyl, (Ci-C4)alkenyl, phenyl, cyclopropyl, (C5-C6)heteroaryl;
R8 is H, halogen or (Ci-C4)alkyl;
m is 3
n is 1 ; and
L is O;
and their pharmaceutically acceptable salts. In an embodiment the present invention relates to a compound of formula (I) independently selected from the group of
10 trans-[4-(7-Chloro-isoquinolin-6-yloxy)-cyclohexyl]-carbamic acid tert-butyl ester,
11 trans-4-(7-Chloro-isoquinolin-6-yloxy)-cyclohexylamine,
12 [cis-4-(5-Chloro-isoquinolin-6-yloxy)-cyclohexyl]-carbamic acid tert-butyl ester,
13 cis-4-(5-Chloro-isoquinolin-6-yloxy)-cyclohexylamine,
14 cis-4-(4-Chloro-isoquinolin-6-yloxy)-cyclohexylamine,
15 cis^-^-Methoxy-isoquinolin-β-yloxyJ-cyclohexylamine,
16 cis^-^soquinolin-δ-yloxyj-cyclohexylamine,
17 trans-4-(lsoquinolin-6-yloxy)-cyclohexylamine,
18 trans-4-(5-Bromo-isoquinolin-6-yloxy)-cyclohexylamine,
19 cis-4-(5-Bromo-isoquinolin-6-yloxy)-cyclohexylamine,
20 (3-Fluoro-benzyl)-[cis-4-(isoquinolin-6-yloxy)-cyclohexyl]-amine,
21 [cis-4-(lsoquinolin-6-yloxy)-cyclohexyl]-propyl-amine,
22 [cis-4-(lsoquinolin-6-yloxy)-cyclohexyl]-(3,3,3-trifluoro-propyl)-amine,
23 [cis-4-(lsoquinolin-6-yloxy)-cyclohexyl]-pyhdin-3-ylmethyl-amine,
24 Cyclopropyl-methyl-cis-[4-(isoquinolin-6-yloxy)-cyclo-hexyl]-amine,
25 lsobutyl-cis-[4-(isoquinolin-6-yloxy)-cyclohexyl]-amine,
26 lsopropyl-cis-[4-(isoquinolin-6-yloxy)-cyclohexyl]-amine,
28 Cyclopropyl-[4-(isoquinolin-6-yloxy)-cyclohexyl]-amine,
29 [4-(lsoquinolin-6-yloxy)-cyclohexyl]-dimethyl-amine,
30 Ethyl-[4-(isoquinolin-6-yloxy)-cyclohexyl]-pyridin-4-ylmethyl-amine,
31 Benzyl-[4-(isoquinolin-6-yloxy)-cyclohexyl]-methyl-amine,
32 [4-(lsoquinolin-6-yloxy)-cyclohexyl]-(4-phenoxy-benzyl)-amine,
33 [4-(lsoquinolin-6-yloxy)-cyclohexyl]-[5-(4-methoxy-phenyl)-isoxazol-3-ylmethyl]- amine,
34 N-(4-{[4-(lsoquinolin-6-yloxy)-cyclohexylamino]-methyl}-phenyl)-acetamide,
35 [4-(lsoquinolin-6-yloxy)-cyclohexyl]-(4-methoxy-benzyl)-amine,
36 (4-Chloro-benzyl)-[4-(isoquinolin-6-yloxy)-cyclohexyl]-amine,
37 (2,3-Dimethoxy-benzyl)-[4-(isoquinolin-6-yloxy)-cyclohexyl]-amine,
38 5-(4-{[4-(lsoquinolin-6-yloxy)-cyclohexylamino]-methyl}-phenyl)-5-methyl- imidazolidine-2,4-dione, (3,5-Dimethoxy-benzyl)-[4-(isoquinolin-6-yloxy)-cyclohexyl]-amine, 3-{[4-(lsoquinolin-6-yloxy)-cyclohexylamino]-methyl}-benzonitrile, ^-(Isoquinolin-e-yloxyJ-cyclohexyll^-methanesulfonyl-benzyO-amine, [2-(1 H-lndol-3-yl)-ethyl]-[4-(isoquinolin-6-yloxy)-cyclohexyl]-methyl-amin, 2-{[4-(lsoquinolin-6-yloxy)-cyclohexyl]-methyl-amino}-N,N-dimethyl-acetamide, 4-[4-(lsoquinolin-6-yloxy)-cyclohexyl]-piperazine-1-carboxylic acid ethyl ester, lsobutyl-[4-(isoquinolin-6-yloxy)-cyclohexyl]-methyl-amine, ^-(Isoquinolin-β-yloxyJ-cyclohexyll-methyl-pyridin^-ylmethyl-amine, Ethyl-[4-(isoquinolin-6-yloxy)-cyclohexyl]-(2-methoxy-ethyl)-amine, 4-{[4-(lsoquinolin-6-yloxy)-cyclohexylamino]-methyl}-benzonitrile, 6-(4-Morpholin-4-yl-cyclohexyloxy)-isoquinoline, 4-{[4-(lsoquinolin-6-yloxy)-cyclohexylamino]-methyl}-benzoic acid methyl ester, (4-tert-Butyl-benzyl)-[4-(isoquinolin-6-yloxy)-cyclohexyl]-amine, [1 -(4-Fluoro-phenyl)-1 H-pyrazol-4-ylmethyl]-[4-(isoquinolin-6-yloxy)-cyclohexyl]- methyl-amine, [4-(lsoquinolin-6-yloxy)-cydohexyl]-(5-methyl-3-phenyl-isoxazol-4-ylmethyl)- amine, [4-(lsoquinolin-6-yloxy)-cyclohexyl]-naphthalen-1-ylmethyl-amine, [4-(lsoquinolin-6-yloxy)-cyclohexyl]-(2-phenyl-oxazol-4-ylmethyl)-amine, (2,3-Dihydro-benzofuran-5-ylmethyl)-[4-(isoquinolin-6-yloxy)-cyclohexyl]-amine, [4-(lsoquinolin-6-yloxy)-cyclohexyl]-(5-methyl-isoxazol-3-ylmethyl)-amine, [4-(lsoquinolin-6-yloxy)-cyclohexyl]-(2-thiophen-2-yl-thiazol-4-ylmethyl)-amine, (3,5-Dimethyl-benzyl)-[4-(isoquinolin-6-yloxy)-cyclohexyl]-amine, Biphenyl-2-ylmethyl-[4-(isoquinolin-6-yloxy)-cyclohexyl]-amine, [4-(lsoquinolin-6-yloxy)-cyclohexyl]-(4-pyrazol-1-yl-benzyl)-amine, [4-(lsoquinolin-6-yloxy)-cyclohexyl]-(4-methoxy-phenyl)-amine, Cyclopropyl-[trans-4-(isoquinolin-6-yloxy)-cyclohexyl]-amine, Cyclopropyl-[cis-4-(isoquinolin-6-yloxy)-cyclohexyl]-amine, [trans-4-(lsoquinolin-6-yloxy)-cyclohexyl]-(4-phenoxy-benzyl)-amine, [cis-4-(lsoquinolin-6-yloxy)-cyclohexyl]-(4-phenoxy-benzyl)-amine, Benzyl-[trans-4-(isoquinolin-6-yloxy)-cyclohexyl]-methyl-amine, Benzyl-[cis-4-(isoquinolin-6-yloxy)-cyclohexyl]-methyl-amine, [trans-4-(lsoquinolin-6-yloxy)-cyclohexyl]-dimethyl-amine, [cis^^lsoquinolin-β-yloxyj-cyclohexyll-dimethyl-amine, N-(4-{[trans-4-(lsoquinolin-6-yloxy)-cyclohexylamino]-methyl}-phenyl)- acetamide, N-(4-{[cis-4-(lsoquinolin-6-yloxy)-cyclohexylamino]-methyl}-phenyl)-acetamide, 2-Chloro-5-{cis-[4-(5-chloro-isoquinolin-6-yloxy)-cyclohexylamino]-methyl}-N- dimethylaminomethylene-benzenesulfonamide, 2-Chloro-5-{[4-(5-chloro-isoquinolin-6-yloxy)-cyclohexylamino]-methyl}- benzenesulfonamide, Cyclopropylmethyl-[trans-4-(isoquinolin-6-yloxy)-cyclohexyl]-amine, Bis-cyclopropylmethyl-[trans-4-(isoquinolin-6-yloxy)-cyclohexyl]-amine, [4-(5-Chloro-isoquinolin-6-yloxy)-cyclohexyl]-cyclohexyl-amine, [4-(5-Chloro-isoquinolin-6-yloxy)-cyclohexyl]-cyclopropyl-amine, [4-(5-Chloro-isoquinolin-6-yloxy)-cyclohexyl]-cyclobutyl-amine, [4-(5-Chloro-isoquinolin-6-yloxy)-cyclohexyl]-cyclopentyl-amine, ^-(S-Chloro-isoquinolin-δ-yloxyJ-cyclohexyll-isopropyl-amine, [cis-4-(5-Bromo-isoquinolin-6-yloxy)-cyclohexyl]-carbamic acid tert-butyl ester, cis^-^-Ethyl-isoquinolin-δ-yloxyJ-cyclohexylamine, cis^^δ-Thiophen-S-yl-isoquinolin-e-yloxyJ-cyclohexylamine, cis^^δ-Methyl-isoquinolin-e-yloxyJ-cyclohexylamine, cis-4-(5-Pyridin-3-yl-isoquinolin-6-yloxy)-cyclohexylamine, cis-4-(5-Vinyl-isoquinolin-6-yloxy)-cyclohexylamine, cis^^S-Thiophen^-yl-isoquinolin-β-yloxyJ-cyclohexylamine, cis-4-(5-Phenyl-isoquinolin-6-yloxy)-cyclohexylamine, cis-4-(5-Pyridin-2-yl-isoquinolin-6-yloxy)-cyclohexylamine, cis-4-(5-Pyridin-4-yl-isoquinolin-6-yloxy)-cyclohexylamine, trans-4-(5,7-Dichloro-isoquinolin-6-yloxy)-cyclohexylamine, [cis-4-(7-Chloro-isoquinolin-6-yloxy)-cyclohexyl]-carbamic acid tert-butyl ester, cis-4-(7-Chloro-isoquinolin-6-yloxy)-cyclohexylamine, cis-4-(5,7-Difluoro-isoquinolin-6-yloxy)-cyclohexylamine, [cis-4-(7-Chloro-isoquinolin-6-yloxy)-cyclohexyl]-propyl-amine, Butyl-[cis-4-(7-chloro-isoquinolin-6-yloxy)-cyclohexyl]-amine, 105 [cis-4-(7-Chloro-isoquinolin-6-yloxy)-cyclohexyl]-isopropyl-amine,
106 [cis-4-(7-Chloro-isoquinolin-6-yloxy)-cyclohexyl]-(1 -ethyl-propyl)-amine,
107 [cis-4-(7-Chloro-isoquinolin-6-yloxy)-cyclohexyl]-isobutyl-amine,
108 [cis-4-(7-Chloro-isoquinolin-6-yloxy)-cyclohexyl]-cyclopropylmethyl-amine,
109 [cis-4-(7-Chloro-isoquinolin-6-yloxy)-cyclohexyl]-(3-methyl-butyl)-amine,
110 [cis-4-(7-Chloro-isoquinolin-6-yloxy)-cyclohexyl]-cyclohexylmethyl-amine,
111 [cis-4-(7-Chloro-isoquinolin-6-yloxy)-cyclohexyl]-cyclohexyl-amine,
112 (4-Chloro-benzyl)-[cis-4-(7-chloro-isoquinolin-6-yloxy)-cyclohexyl]-amine,
113 (3-Chloro-benzyl)-[cis-4-(7-chloro-isoquinolin-6-yloxy)-cyclohexyl]-amine,
114 [cis-4-(7-Chloro-isoquinolin-6-yloxy)-cyclohexyl]-(2,4-dichloro-benzyl)-amine,
115 [cis-4-(7-Chloro-isoquinolin-6-yloxy)-cyclohexy]-4-(4-trifluoromethyl-benzyl)- amine,
116 [cis-4-(7-Chloro-isoquinolin-6-yloxy)-cyclohexyl]-pyridin-4-ylmethyl-amine,
117 [cis-4-(7-Chloro-isoquinolin-6-yloxy)-cyclohexyl]-ethyl-amine,
118 [trans-4-(7-Chloro-isoquinolin-6-yloxy)-cyclohexyl]-propyl-amine,
119 Butyl-[trans-4-(7-chloro-isoquinolin-6-yloxy)-cyclohexyl]-amine,
120 [trans-4-(7-Chloro-isoquinolin-6-yloxy)-cyclohexyl]-isopropyl-amine,
121 [trans-4-(7-Chloro-isoquinolin-6-yloxy)-cyclohexyl]-(3-methyl-butyl)-amine,
122 [trans-4-(7-Chloro-isoquinolin-6-yloxy)-cyclohexyl]-cyclohexylmethyl-amine,
123 Benzyl-[trans-4-(7-chloro-isoquinolin-6-yloxy)-cyclohexyl]-amine,
124 [trans-4-(7-Chloro-isoquinolin-6-yloxy)-cyclohexyl]-(4-methyl-benzyl)-amine,
125 [trans-4-(7-Chloro-isoquinolin-6-yloxy)-cyclohexyl]-pyridin-3-ylmethyl-amine,
126 [trans-4-(7-Chloro-isoquinolin-6-yloxy)-cyclohexyl]-(4-methanesuIfonyl-benzyl)- amine,
127 [trans^^-Chloro-isoquinolin-e-yloxyJ-cyclohexyll-naphthalen-i -ylmethyl- amine,
128 [trans-4-(7-Chloro-isoquinolin-6-yloxy)-cyclohexyl]-(tetrahydro-furan-3-ylmethyl)- amine,
129 [trans-4-(7-Chloro-isoquinolin-6-yloxy)-cyclohexyl]-cyclohexyl-amine,
130 [trans-4-(7-Chloro-isoquinolin-6-yloxy)-cyclohexyl]-cyclopropylmethyl-amine,
131 [trans-4-(7-Chloro-isoquinolin-6-yloxy)-cyclohexyl]-isobutyl-amine,
132 (4-Chloro-benzyl)-[trans-4-(7-chloro-isoquinolin-6-yloxy)-cyclohexyl]-amine, 133 (3-Chloro-benzyl)-[trans-4-(7-chloro-isoquinolin-6-yloxy)-cyclohexyl]-amine,
134 [trans-4-(7-Chloro-isoquinolin-6-yloxy)-cyclohexyl]-(2,4-dichloro-benzyl)-amine,
135 [trans-4-(7-Chloro-isoquinolin-6-yloxy)-cyclohexyl]-(3,5-dichloro-benzyl)-amine,
136 (2-Chloro-benzyl)-[trans-4-(7-chloro-isoquinolin-6-yloxy)-cyclohexyl]-amine,
137 3-{[trans-4-(7-Chloro-isoquinolin-6-yloxy)-cyclohexylamino]-methyl}-N-[1 - dimethylamino-meth-(E)-ylidene]-4-methoxy-benzenesulfonamide,
138 [trans-4-(7-Chloro-isoquinolin-6-yloxy)-cyclohexyl]-4-(4-trifluoromethanesulfonyl- benzyl)-amine,
139 [trans-4-(7-Chloro-isoquinolin-6-yloxy)-cyclohexyl]-4-(4-trifluoromethyl-benzyl)- amine,
145 [6-(cis-4-Amino-cyclohexyloxy)-isoquinolin-3-yl]-(3-methoxy-phenyl)-amine,
146 [6-(cis-4-Amino-cyclohexyloxy)-isoquinolin-3-yl]-(4-methoxy-phenyl)-amine,
147 [6-(cis-4-Amino-cyclohexyloxy)-isoquinolin-3-yl]-(3-chloro-phenyl)-amine,
148 [6-(cis-4-Amino-cyclohexyloxy)-isoquinolin-3-yl]-(4-chloro-phenyl)-amine,
149 [6-(cis-4-Amino-cyclohexyloxy)-isoquinolin-3-yl]-(3,4,5-trimethoxy-phenyl)- amine,
150 ^-(cis^-Amino-cyclohexyloxyJ-isoquinolin-S-yll-pyrazin^-yl-amine, or 156 cis-4-(4-Ethyl-isoquinolin-6-yloxy)-cyclohexylamine, and their pharmaceutically acceptable salts. (Example No. given)
As in any embodiment of the invention, in the preceding embodiments which contain preferred, more preferred, most preferred or exemplary definitions of compounds according to the invention, one or more or all of the groups can have any of its preferred, more preferred, most preferred definitions specified above or any one or some of the specific denotations which are comprised by its definitions and are specified above.
Isoquinoline substitution pattern is numbered according to IUPAC rules:
Figure imgf000031_0001
All references to "compound(s) of formula (I)" hereinafter refer to compound(s) of the formula (I) as described above, and their pharmaceutically acceptable salts, and/or to their stereoisomeric forms, polymorphs and solvates. Physiologically functional derivatives as described herein are also included.
Pharmaceutically acceptable salts of compounds of the formula (I) mean both their organic and inorganic salts as described in Remington's Pharmaceutical Sciences (17th edition, page 1418 (1985)). Because of the physical and chemical stability and the solubility, preference is given for acidic groups inter alia to sodium, potassium, calcium and ammonium salts; preference is given for basic groups inter alia to salts of maleic acid, fumaric acid, succinic acid, malic acid, tartaric acid, methylsulfonic acid, hydrochloric acid, sulfuric acid, phosphoric acid or of carboxylic acids or sulfonic acids, for example as hydrochlorides, hydrobromides, phosphates, sulfates, methanesulfonates, acetates, lactates, maleates, fumarates, malates, gluconates, and salts of amino acids, of natural bases or carboxylic acids. The preparation of pharmaceutically acceptable salts from compounds of the formula (I) which are capable of salt formation, including their stereoisomeric forms, takes place in a manner known per se. The compounds of the formula (I) form stable alkali metal, alkaline earth metal or optionally substituted ammonium salts with basic reagents such as hydroxides, carbonates, bicarbonates, alcoholates and ammonia or organic bases, for example trimethyl- or triethylamine, ethanolamine, diethanolamine or triethanolamine, trometamol or else basic amino acids, for example lysine, ornithine or arginine. Where the compounds of the formula (I) have basic groups, stable acid addition salts can also be prepared with strong acids. Suitable pharmaceutically acceptable acid addition salts of the compounds of the invention are salts of inorganic acids such as hydrochloric acid, hydrobromic, phosphoric, metaphosphoric, nitric and sulfuric acid, and of organic acids such as, for example, acetic acid, benzenesulfonic, benzoic, citric, ethanesulfonic, fumaric, gluconic, glycolic, isethionic, lactic, lactobionic, maleic, malic, methanesulfonic, succinic, p-toluenesulfonic and tartaric acid. Salts with a pharmaceutically unacceptable anion such as, for example, trifluoroacetate likewise belong within the framework of the invention as useful intermediates for the preparation or purification of pharmaceutically acceptable salts and/or for use in nontherapeutic, for example in vitro, applications.
The term "physiologically functional derivative" used herein refers to any physiologically tolerated derivative of a compound of the formula (I) of the invention, for example an N-oxide, which on administration to a mammal such as, for example, a human is able to form (directly or indirectly) a compound of the formula (I) or an active metabolite thereof.
Physiologically functional derivatives include prodrugs of the compounds of the invention, as described, for example, in H. Okada et al., Chem. Pharm. Bull. 1994, 42, 57-61. Such prodrugs can be metabolized in vivo to a compound of the invention. These prodrugs may themselves be active or not.
The invention relates to compounds of the formula (I) in the form of their stereoisomeric forms, which include racemates, racemic mixtures, pure enantiomers and diastereomers and mixtures thereof.
The compounds of the invention may also exist in various polymorphous forms, for example as amorphous and crystalline polymorphous forms. All polymorphous forms of the compounds of the invention belong within the framework of the invention and are a further aspect of the invention.
If radicals or substituents may occur more than once in the compounds of the formula (I), they may all, independently of one another, have the stated meaning and be identical or different.
The terms (C-|-C2)alkyl, (C-|-C4)alkyl, (C1-C6)alkyl, (C-|-C8)alkyl and the corresposponding alkylene substituents are understood as a hydrocarbon residue which can be linear, i.e. straight-chain, or branched and has 1 , 2, 3, 4, 5, 6, 7 or 8 carbon atoms, respectively. This also applies if an alkyl group occurs as a substituent on another group, for example in an alkoxy group (O-alkyl), S-alkyl or a -O(C-|-
Cøjalkylene-O-, an alkoxycarbonyl group or an arylalkyl group. Examples of alkyl groups are methyl, ethyl, propyl, butyl, pentyl or hexyl, the n-isomers of all these groups, isopropyl, isobutyl, 1-methylbutyl, isopentyl, neopentyl, 2,2-dimethylbutyl, 2- methylpentyl, 3-methylpentyl, isohexyl, sec-butyl, tert-butyl or tert-pentyl. Alkyl or alkylene groups may - if not otherwise stated - be halogenated once or more, e.g. alkyl groups may be fluorinated, e.g. perfluorinated. Examples of halogenated alkyl groups are CF3 and CH2CF3, OCF3, SCF3, or -O-(CF2)2-O-.
Alkenyl are, for example, vinyl, 1-propenyl, 2-propenyl (= allyl), 2-butenyl, 3-butenyl, 2- methyl-2-butenyl, 3-methyl-2-butenyl, 5-hexenyl or 1 ,3-pentadienyl.
Alkynyl are, for example, ethynyl, 1-propynyl, 2-propynyl (= propargyl) or 2-butynyl.
Halogen means fluoro, chloro, bromo or iodo.
(C3-C8)cycloalkyl groups are cyclic alkyl groups containing 3, 4, 5, 6, 7 or 8 ring carbon atoms like cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cyclooctyl, which can also be substituted and/or contain 1 or 2 double bounds (unsaturated cycloalkyl groups) like, for example, cyclopentenyl or cyclohexenyl can be bonded via any carbon atom.
A (Cβ-C10)aryl group means an aromatic ring or a ring system which comprises two aromatic rings which are fused or otherwise linked, for example a phenyl, naphthyl, biphenyl, tetrahydronaphthyl, alpha- or beta-tetralon-, indanyl- or indan-1-on-yl group. A preferred (Ce-C10)aryl group is phenyl.
A (C5-C10)heterocyclyl group means a mono- or bicyclic ring system in which one or more carbon atoms can be replaced by one or more heteroatoms such as, for example, 1 , 2 or 3 nitrogen atoms, 1 or 2 oxygen atoms, 1 or 2 sulfur atoms or combinations of different hetero atoms. The heterocyclyl residues can be bound at any positions, for example on the 1-position, 2-position, 3-position, 4-position, 5-position, 6- position, 7-position or 8-position. (C5-C10)neterocyclyl groups may be (1) aromatic [= heteroaryl groups] or (2) saturated or (3) mixed aromatic/saturated.
Suitable (C5-C10)heterocyclyl group include acridinyl, azocinyl, benzimidazolyl, benzofuryl, benzomorpholinyl, benzothienyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, carbazolyl, 4aH-carbazolyl, carbolinyl, furanyl, quinazolinyl, quinolinyl, 4H-quinolizinyl, quinoxalinyl, quinuclidinyl, chromanyl, chromenyl, chromen-2-onyl, cinnolinyl, decahydroquinolinyl, 2H,6H-1 ,5,2-dithiazinyl, dihydrofuro[2,3-b]-tetrahydrofuran, furyl, furazanyl, homomorpholinyl, homopiperazinyl, imidazolidinyl, imidazolinyl, imidazolyl, 1 H-indazolyl, indolinyl, indolizinyl, indolyl, 3H-indolyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl, benzimidazolyl, isothiazolyl, isoxazolyl, morpholinyl, naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl, 1 ,2,3- oxadiazolyl, 1 ,2,4-oxadiazolyl, 1 ,2,5-oxadiazolyl, 1 ,3,4-oxadiazolyl, oxazolidinyl, oxazolyl, oxazolidinyl, pyrimidinyl, phenanthridinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, prolinyl, pteridinyl, purynyl, pyranyl, pyrazinyl, pyroazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridonyl, pyridooxazoles, pyridoimidazoles, pyridothiazoles, pyridinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, 6H-1 ,2,5-thiadazinyl, thiazolyl, 1 ,2,3- thiadiazolyl, 1 ,2,4-thiadiazolyl, 1 ,2,5-thiadiazolyl, 1 ,3,4-thiadiazolyl, thienyl, triazolyl, tetrazolyl and xanthenyl. Pyridyl stands both for 2-, 3- and 4-pyridyl. Thienyl stands both for 2- and 3-thienyl. Furyl stands both for 2- and 3-furyl. Also included are the corresponding N-oxides of these compounds, for example, 1-oxy-2-, 3- or 4-pyridyl.
Substitutions in (C5-C10)heterocyclyl residues can occur on free carbon atoms or on nitrogen atoms. Preferred examples of (C5-C10)heterocyclyl residues are pyrazinyl, pyridyl, pyrimidinyl, pyrazolyl, morpholinyl, pyrrolidinyl, piperazinyl, piperidinyl, thienyl, benzofuryl, quinolinyl, tetrazolyl and triazolyl.
(C6-C1 rj)aryl ancl (C5-C1 rj)heterocyclyl groups are unsubstituted or, if not stated otherwise, substituted one or more times, preferably one to three times, by suitable groups independently selected from halogen, OH, NO2, N3, CN, C(O)-(C1-C6)alkyl,
C(O)-(Ci -CβJaryl, COOH, COO(C1 -C6)alkyl, CONH2, CONH(C1 -C6)alkyl, CONt(C1- C6)alkyl]2, (C3-C8)cycloalkyl, (C-i-C^alkyl, (C1-C6)alkylene-OH, (C-i-C^alkylene- NH2, (C1-C6)alkylene-NH^i-Ce)alkyl, (C1-C6)alkylene-N[(C1-C6)alkyl]2, (C2-C6)alkenyl, (C2-C6)alkynyl, O^-C^alky!, 0-C(O)-(C1-C6)alkyl, PO3H2, SO3H, SO2-NH2, SO2NH(C1 -C6)alkyl, SO2Nf(C1 -C6)alkyl]2, S-(C1 -C6)alkyl; SO-(C1- C6)alkyl, SO2-(C1 -C6)alkyl, SO2-N=CH-NI(C1 -C6)alkyl]2, C(NH)(NH2), NH2, NH-tC-i-Ce)alkyl, Nt(C1 -C6)alkyl]2, NH-C(O)-(C1 -C6)alkyl, NH-C(O)O-(C1 -C6)alkyl,
NH-SO2-(C1 -C6)alkyl, NH-SO2-(Ce-C10)aryl, NH-SO2-(C5-C10)heterocyclyl, N(C1- Ce)alkyl-C^HC^Ce)alkyl, N(C1-C6)alkyl-C(O)O-(C1-C6)alkyl, N^-i-Ce)alkyl-C^-NH^C-i-Ce)alkyl], (C6-C1 o)aryl, (C-i-C^alkylene-fCe-C10)aryl, 0-(C6-C1 o)aryl, O^C-i-Ce)alkylene^Ce-C10)aryl, (C5-C1 o)heterocyclyl,
(C1-C6)alkylene-(C5-C10)heterocyclyl, O-(C1-C6)alkylene-(C5-C10)heterocyclyl, wherein the (C6-C -|o)aryl or (C5-C1 øjheterocyclyl may be substituted one to 3 times by a group independently selected from halogen, OH, NO2, CN, O-(C-|-C6)alkyl, (C1- C6)alkyl, NH2, NH(C1 -C6)alkyl, Nt(C1 -C6)alkyl]2, SO2CH3, COOH, C(O)O-(C1- C6)alkyl, CONH2, (C-i-C^alkylene-O^C-i-C^alkyl, (C1-C6)alkylene-O^Ce-C10)aryl, O-(C1-C6)alkylene-(C6-C10)aryl; or wherein (C6-C10)aryl is vicinally substituted by a O-(C1-C4)alkylene-O group whereby a 5-8-membered ring is formed together with the carbon atoms the oxygen atoms are attached to. Aryl or heterocyclyl substituents of (Cβ-Ciøjaryl and (C5-Ciø.)heterocyclyl groups may not be further substituted by an aryl or heterocyclyl containing group.
Preferred substituents for (Cρ-C10)aryl groups are (C-|-C4)alkyl, O-(C-|-C4)alkyl, O-phenyl, phenyl, C(O)O-(Ci -Cβ)alkyl, C(O)OH, C(O)-(Ci-C4)alkyl, halogen, NO2, SO2NH2, CN, SO2-(Ci -C4)alkyl, SO2-N=CH-N[(C1-C6)alkyl]2, NH-SO2-(Ci- C4)alkyl, NH2, NH-C(O)-(Ci -C4)alkyl, (C3-C8)cycloalkyl, (Ci-C4)alkyl-OH, C(O)N[(Ci-C4)alkyl]2, CONH(C1-C6)alkyl, C(O)NH2, N[(Ci-C4)alkyl]2, (Ci- C4)alkylene-(C6-C10)aryl, wherein the (Cρ-CiQjaryl may be further substituted one to three times, preferabyl once, by (Ci-C4)alkyl, (Ci-C4)alkylene-O-(C1-C6)alkyl, (C6-C10)aryl, O-(C1-C6)alkyl-(Cg-C10)aryl, or may be vicinally substituted by a O-(Ci-C4)alkylene-O group whereby a 5-8-membered ring is formed together with the carbon atoms the oxygen atoms are attached to. More preferred substituents for (CQ- C10)aryl are halogen, CN, phenyl, O-phenyl, NH-C(O)-(Ci-C4)alkyl especially NH-C(O)-CH3, C(O)-(C1 -C4)alkyl especially C(O)-CH3, C(O)-O(C i-C4)alkyl especially C(O)-OCH3, (Ci-C4)alkyl especially CH3 or CF3, O-(Ci-C4)alkyl especially 0-CH3 SO2-NH2, SO2-(C i-C4)alkyl especially SO2-CH3 or SO2-CF3; or SO2-N=CH- N[(Ci-C4)alkyl]2 especially SO2-N=CH-N[(CH3)2.
In monosubstituted phenyl groups the substituent can be located in the 2-position, the 3-position or the 4-position, with the 3-position and the 4-position being preferred. If a phenyl group carries two substituents, they can be located in 2, 3-position, 2,4-position, 2,5-position, 2,6-position, 3,4-position or 3,5-position. In phenyl groups carrying three substituents the substituents can be located in 2, 3,4-position, 2, 3,5-position, 2,3,6- position, 2,4,5-position, 2,4,6-position, or 3,4,5-position.
The above statements relating to phenyl groups correspondingly apply to divalent groups derived from phenyl groups, i.e. phenylene which can be unsubstituted or substituted 1 ,2-phenylene, 1 ,3-phenylene or 1 ,4-phenylene. The above statements also correspondingly apply to the aryl subgroup in arylalkylene groups. Examples of arylalkylene groups which can also be unsubstituted or substituted in the aryl subgroup as well as in the alkylene subgroup, are benzyl, 1-phenylethylene, 2-phenylethylene, 3- phenylpropylene, 4-phenylbutylene, 1-methyl-3-phenyl-propylene.
Preferred substituents for (C5-Cirj)neterocyclyl groups are (C-|-C4)alkyl, O-(Ci-C4)alkyl, (C-i-C^alkylene-phenyl, halogen, (C-|-C4)alkylene-O-(Ci-C4)alkyl, (C5-C10)heterocyclyl, (C-|-C4)alkylene-N[(C-|-C4)alkyl]2, or (Cβ-CioJaryl, wherein the (C6-C10)aryl may be further substituted by halogen, (C-|-C4)alkyl, O(C-|-C4)alkyl, (C-|-C4)alkylene-O-(C1-C6)alkyl, O-(C1-C6)alkyl-(C6-C10)aryl, or may be vicinally substituted by a O-(Ci-C4)alkylene-O group whereby a 5-8-membered ring is formed together with the carbon atoms the oxygen atoms are attached to. More preferred substituents for (C5-C10)heterocyclyl groups are (C-|-C4)alkyl, O(C-|-C4)alkyl, halogen or phenyl, wherein the phenyl may be further substituted one to three times, preferably once, by halogen, (Ci-C4)alkyl or O-(C-|-C4)alkyl.
The general and preferred substituents of (C6-C-| o)aryl and (C5-C10)heterocyclyl groups may be combined with the general and preferred definitions of R-j , R2, R3, R4, R5. Rβ- R6'. R7. Rβ> n> m and L as described above.
The present invention therefore also relates to the compounds of the formula (I) and/or their pharmaceutically acceptable salts and/or their prodrugs for use as pharmaceuticals (or medicaments), to the use of the compounds of the formula (I) and/or their pharmaceutically acceptable salts and/or their prodrugs for the production of pharmaceuticals for the treatment and/or prevention of diseases associated with Rho-kinase and/or Rho-kinase mediated phosphorylation of myosin light chain phosphatase, i.e. for the treatment and/or prevention of hypertension, pulmonary hypertension, ocular hypertension, retinopathy, and glaucoma, peripheral circulatory disorder, peripheral arterial occlusive disease (PAOD), coronary heart disease, angina pectoris, heart hypertrophy, heart failure, ischemic diseases, ischemic organ failure (end organ damage), fibroid lung, fibroid liver, liver failure, nephropathy, including hypertension-induced, non-hypertension-induced, and diabetic nephropathies, renal failure, fibroid kidney, renal glomerulosclerosis, organ hypertrophy, asthma, chronic obstructive pulmonary disease (COPD), adult respiratory distress syndrome, thrombotic disorders, stroke, cerebral vasospasm, cerebral ischemia, pain, e.g. neuropathic pain, neuronal degeneration, spinal cord injury, Alzheimer's disease, premature birth, erectile dysfunction, endocrine dysfunctions, arteriosclerosis, prostatic hypertrophy, diabetes and complications of diabetes, metabolic syndrome, blood vessel restenosis, atherosclerosis, inflammation, autoimmune diseases, AIDS, osteopathy such as osteoporosis, infection of digestive tracts with bacteria, sepsis, cancer development and progression, e.g. cancers of the breast, colon, prostate, ovaries, brain and lung and their metastases.
The present invention furthermore relates to pharmaceutical preparations (or pharmaceutical compositions) which contain an effective amount of at least one compound of the formula (I) and/or its pharmaceutically acceptable salts and a pharmaceutically acceptable carrier, i. e. one or more pharmaceutically acceptable carrier substances (or vehicles) and/or additives (or excipients). The pharmaceuticals can be administered orally, for example in the form of pills, tablets, lacquered tablets, coated tablets, granules, hard and soft gelatin capsules, solutions, syrups, emulsions, suspensions or aerosol mixtures. Administration, however, can also be carried out rectally, for example in the form of suppositories, or parenterally, for example intravenously, intramuscularly or subcutaneously, in the form of injection solutions or infusion solutions, microcapsules, implants or rods, or percutaneously or topically, for example in the form of ointments, solutions or tinctures, or in other ways, for example in the form of aerosols or nasal sprays.
The pharmaceutical preparations according to the invention are prepared in a manner known per se and familiar to one skilled in the art, pharmaceutically acceptable inert inorganic and/or organic carrier substances and/or additives being used in addition to the compound(s) of the formula (I) and/or its (their) pharmaceutically acceptable salts and/or its (their) prodrugs. For the production of pills, tablets, coated tablets and hard gelatin capsules it is possible to use, for example, lactose, corn starch or derivatives thereof, talc, stearic acid or its salts, etc. Carrier substances for soft gelatin capsules and suppositories are, for example, fats, waxes, semisolid and liquid polyols, natural or hardened oils, etc. Suitable carrier substances for the production of solutions, for example injection solutions, or of emulsions or syrups are, for example, water, saline, alcohols, glycerol, polyols, sucrose, invert sugar, glucose, vegetable oils, etc. Suitable carrier substances for microcapsules, implants or rods are, for example, copolymers of glycolic acid and lactic acid. The pharmaceutical preparations normally contain about 0.5 to about 90 % by weight of the compounds of the formula (I) and/or their pharmaceutically acceptable salts and/or their prodrugs. The amount of the active ingredient of the formula (I) and/or its pharmaceutically acceptable salts and/or its prodrugs in the pharmaceutical preparations normally is from about 0.5 to about 1000 mg, preferably from about 1 to about 500 mg.
In addition to the active ingredients of the formula (I) and/or their pharmaceutically acceptable salts and to carrier substances, the pharmaceutical preparations can contain one or more additives such as, for example, fillers, disintegrants, binders, lubricants, wetting agents, stabilizers, emulsifiers, preservatives, sweeteners, colorants, flavorings, aromatizers, thickeners, diluents, buffer substances, solvents, solubilizers, agents for achieving a depot effect, salts for altering the osmotic pressure, coating agents or antioxidants. They can also contain two or more compounds of the formula (I) and/or their pharmaceutically acceptable salts. In case a pharmaceutical preparation contains two or more compounds of the formula (I) the selection of the individual compounds can aim at a specific overall pharmacological profile of the pharmaceutical preparation. For example, a highly potent compound with a shorter duration of action may be combined with a long-acting compound of lower potency. The flexibility permitted with respect to the choice of substituents in the compounds of the formula (I) allows a great deal of control over the biological and physico-chemical properties of the compounds and thus allows the selection of such desired compounds. Furthermore, in addition to at least one compound of the formula (I) and/or its pharmaceutically acceptable salts, the pharmaceutical preparations can also contain one or more other therapeutically or prophylactically active ingredients. When using the compounds of the formula (I) the dose can vary within wide limits and, as is customary and is known to the physician, is to be suited to the individual conditions in each individual case. It depends, for example, on the specific compound employed, on the nature and severity of the disease to be treated, on the mode and the schedule of administration, or on whether an acute or chronic condition is treated or whether prophylaxis is carried out. An appropriate dosage can be established using clinical approaches well known in the medical art. In general, the daily dose for achieving the desired results in an adult weighing about 75 kg is from about 0.01 to about 100 mg/kg, preferably from about 0.1 to about 50 mg/kg, in particular from about 0.1 to about 10 mg/kg, (in each case in mg per kg of body weight). The daily dose can be divided, in particular in the case of the administration of relatively large amounts, into several, for example 2, 3 or 4, part administrations. As usual, depending on individual behavior it may be necessary to deviate upwards or downwards from the daily dose indicated.
Furthermore, the compounds of the formula (I) can be used as synthesis intermediates for the preparation of other compounds, in particular of other pharmaceutical active ingredients, which are obtainable from the compounds of the formula I, for example by introduction of substituents or modification of functional groups.
In general, protective groups that may still be present in the products obtained in the coupling reaction are then removed by standard procedures. For example, tert-butyl protecting groups, in particular a tert-butoxycarbonyl group which is a protection form of an amino group, can be deprotected, i. e. converted into the amino group, by treatment with trifluoroacetic acid. As already explained, after the coupling reaction also functional groups can be generated from suitable precursor groups. In addition, a conversion into a pharmaceutically acceptable salt or a prodrug of a compound of the formulae (I) can then be carried out by known processes.
In general, a reaction mixture containing a final compound of the formula (I) or (I1) or an intermediate is worked up and, if desired, the product is then purified by customary processes known to those skilled in the art. For example, a synthesized compound can be purified using well known methods such as crystallization, chromatography or reverse phase-high performance liquid chromatography (RP-HPLC) or other methods of separation based, for example, on the size, charge or hydrophobicity of the compound. Similarly, well known methods such as amino acid sequence analysis, NMR, IR and mass spectrometry (MS) can be used for characterizing a compound of the invention.
Isoquinolines can by synthesized via a variety of methods. The following general schemes illustrate some of the possible ways to access isoquinolines, but do not limit the present invention.
Figure imgf000042_0001
Scheme 1 :
A suitably substituted aldehyde, for example substituted by X or Y being independently from each other hydrogen, alkyl, alkoxy or halide attached in a suitable position, can be reacted with a suitable compound such as for example an acetal of aminoacetaldehyde for example in a solvent like THF, chloroform or toluene under acid catalysis by toluene sulfonic acid or another appropriate acid to give imine (ii) wherein Q' can be for instance methyl or ethyl, which in turn can be cyclized by different methods to the isoquinoline (iii). For example this can be done by Lewis acid catalysis by suitable Lewis acids like titanium tetrachloride, ferrous halides, aluminium halides etc. at temperatures ranging from ambient to 100 °C or by reducing the imine to the corresponding amine by action of a suitable reducing agent like sodium borohydride, converting the amine into an amide or sulphonamide by reaction with a suitable acid chloride and subsequent cyclization to the isoquinoline by action of an appropriate lewis acid.
Figure imgf000043_0001
Scheme 2:
The above obtained 6-fluoro-isoquinolines (iii) can be reacted with suitable Pi / P2 substituted amino alcohols wherein P1 / P2 are independently from each other for example hydrogen, alkyl or a protecting group like for example Boc or phthaloyl in the presence of base such as DBU, cesium carbonate or sodium hydride to give the corresponding alkoxy substituted derivatives (iv). The products like (iv) obtained via this method can then either be liberated or, if a suitable amino functionality is present, be reacted with suitable aldehydes or ketones in the presence of a reducing agent like sodium triacetoxy borohydride, sodium borohydride or sodium cyanoborohydride in a suitable solvent and in the presence of a water withdrawing agent like molecular sieves or a suitable ortho ester. This amino group may have to be liberated in an initial step like for example acidic removal of Boc-groups.
Isoquinoline derivatives like (iv) can be obtained as free bases or as various salts like for example hydrochlorides, hydrobromides, phosphates, trifluoroacetates, sulfates or fumarates. The salts obtained can be converted into the corresponding free base by either subjecting them to ion exchange chromatography or for example by alkaline aqueous treatment and subsequent extraction with suitable organic solvents like for example methyl tert. butyl ether, chloroform, ethyl acetate or isopropanol / dichloromethane mixtures and subsequent evaporation to dryness.
The general methods for the preparation of isoquinoline derivatives as described above can be readily adapted to the preparation of the compounds of the formula (I). In the following examples the preparation of the compounds of the present invention is outlined in more detail. Accordingly, the following examples are part of and intended to illustrate but not to limit the present invention.
It is understood that modifications that do not substantially affect the activity of the various embodiments of this invention are included within the invention disclosed herein.
LCMS methods
Method #1
Column: YMC J'sphere 33x2 4μm
Gradient: (ACN+0.05% TFA) : (H2O+0.05% TFA)
5:95 (Omin) to 95:5 (2.5 min) to 95:5 (3.0 min) Flow: 1ml/min
Method #2
Column: YMC J'sphere 33x2 4μm
Gradient: (ACN+0.05% TFA) : (H2O+0.05% TFA)
5:95 (Omin) to 95:5 (3.4min) to 95:5 (4.4min) Flow: 1ml/min
Method #3
Column: YMC J'sphere 33x2 4μm
Gradient: ( ACN+0.08%FA : H2O+0.1 %FA)
5:95 (Omin) to 95:5 (2.5min) to 95:5 (3min) Flow: 1ml/min
Method #4:
Column: YMC Jsphere ODS H80 20 x 2 4 μM
Gradient: ACN : H2O+0.05% TFA 4:96 (0 min) to 95:5 (2.0 min) to 95:5 (2.4 min)
Flow: 1 ml/min
5-Chloroisoquinoline-6-ol (1)
Figure imgf000045_0001
0.61 mL (1.02 g, 7.6 mmol) of sulfuryl chloride were added to a solution of 1.0 g (6,9 mmol) of 6-hydroxy-isoquinoline in 30 mL of dichloromethane. Three drops diethyl ether were added and the reaction was stirred at room temperature for 5 h. The solvents were removed by distillation and the remainder was treated with aqueous NaHCO3 solution. The precipitate was filtered, washed with water and dried to give 1.1 g (89%) of 1 as a green-yellow solid.
1H-NMR (d6-DMSO): δ = 11.37 (1 H, s), 9.18 (1 H, s), 8.50 (1 H, d, J = 6 Hz), 8.00 (1 H, d, J= 8.8 Hz), 7.83 (1 H1 J = 6 Hz), 7.44 (1 H, d, J = 8.7 Hz). MS: m/z = 180 (MH+). 5-Bromoisoquinoline-6-ol (2)
Figure imgf000045_0002
7.9 mL (19.18 g, 120 mmol) of bromine were added dropwise to a suspension of 17.42 g (120 mmol) of 6-hydroxy isoquinoline in 250 mL of chloroform at room temperature. After stirring for 2 h, ethyl acetate was added. The precipitate was filtered, washed with ethyl acetate and dried. Aqueous NaHCO3 solution was added carefully. The precipitate was filtered and washed with NaHCO3 solution until the filtrate had a pH of 8. Drying gave 23.78 g (88%) of 2 as an off-white solid.
1H-NMR (de-DMSO): δ = 11.30 (1 H, s), 9.13 (1 H, s), 8.48 (1 H, d, J = 5.9 Hz), 8.02 (1 H, d, J= 8.8 Hz), 7.78 (1 H, J = 5.9 Hz), 7.40 (1 H, d, J = 8.8 Hz). MS: m/z = 224 (MH+). (2,2-Dimethoxy-ethyl)-(4-fluoro-benzyl)-amine (3)
Figure imgf000046_0001
12.4 g of 4-Fluorobenzaldehyde were dissolved in 100 ml of toluene and reacted with
10.5 g 2-aminoacetaldehyde dimethylacetal and 1.90 g (10 mmol) p-toluenesulfonic acid monohydrate for two hours at a Dean Stark apparatus. The solution was allowed to cool down, extracted with saturated sodium bicarbonate, water and brine, dried over magnesium sulfate and evaporated to dryness. The crude product was dissolved in 100 ml of ethanol. 1.89 g of sodium borohydride were added portionwise. Stirring was continued overnight. For workup, acetic acid was added until no gas evolution could be observed. Then the solution was evaporated to dryness, taken up in dichloromethane and washed twice with water. The organic layer was extracted with brine, dried over magnesium sulfate and evaporated to dryness. The obtained crude product (20 g) was used without purification. Rt = 0.86 min (Method #1). Detected mass: 182.1 (M-OMe"), 214.2 (M+H+). N-(2,2-Dimethoxy-ethyl)-N-(4-fluoro-benzyl)-4-methyl-benzene-sulfonamide (4)
Figure imgf000046_0002
20 g (2,2-Dimethoxy-ethyl)-(4-fluoro-benzyl)-amine (3) were dissolved in 120 ml of dichloromethane. 20 ml of pyridine were added. At 0 0C a solution of 23.8 g p-toluene sulfonic acid chloride in dichloromethane was added dropwise. The reaction was allowed to warm to room temperature and stirring was continued until conversion was completed. For workup, the reaction mixture was extracted twice with 2M hydrochloric acid, twice with sodium bicarbonate and once with brine. The organic layer was dried over magnesium sulfate, evaporated to dryness and the obtained crude product was purified by silica gel chromatography to yield 22.95 g of 4 as an orange oil. Rt = 1.71 min (Method #4). Detected mass: 336.1 (M-OMe ). 6-Fluoro-isoquinoline (5)
Figure imgf000047_0001
41.6 g AICI3 were suspended in 400 ml of dichloroethane. At room temperature, a solution of 22.95 g of N-(2,2-dimethoxy-ethyl)-N-(4-fluoro-benzyl)-4-methyl- benzenesulfonamide (4) in 150 ml of dichloroethane was added. Stirring was continued at room temperature overnight, the solution was poured on ice, the organic layer was separated, the aqueous phase was extracted twice with dichloromethane and the combined organic layers were then extracted twice with sodium bicarbonate solution. The organic layer was dried over magnesium sulfate, evaporated to dryness and the obtained crude product (8.75g) was purified by silica gel chromatography to yield 2.74 g of 5. R1 = 0.30 min (Method #4). Detected mass: 148.1 (M+H+).
7-Chloro-6-fluoro-isoquinoline (6)
Figure imgf000047_0002
Starting from 3-chloro-4-fluoro-benzaldehyde, the title compound was prepared by the same reaction sequence as 6-fluoro-isoquinoline (5). Rt = 0.77 min (Method #2). Detected mass: 182.1/184.1 (M+H+).
7-Methoxy-6-fluoro-isoquinoline (7)
Figure imgf000047_0003
Starting from 3-methoxy-4-fluoro-benzaldehyde, the title compound was prepared by the same reaction sequence as 6-fluoro-isoquinoline (5). Rt = 0.70 min (Method #4). Detected mass: 178.1 (M+H+). 5-Chloro-6-fluoro-isoquinoline (8)
Figure imgf000048_0001
7.0 g (38.1 mmol) 6-Fluoroisoquinoline (5) were dissolved in 60 ml concentrated sulfuric acid. At 00C 10.18 g N-chlorosuccinimide were added. After 1 h another 5.2 g of N-chlorosucciminide were added and the solution was warmed to 500C. Two more portions of 5.2 g N-chlorosuccinimide were added successively and stirring was continued at 50 °C until the reaction was complete. The reaction mixture was cooled to room temperature, poured on ice and adjusted to pH 10 by addition of sodium hydroxide. The precipitate was filtered off, taken up in dichloromethane and washed with aqueous sodium hydroxide. The organic layer was dried over magnesium sulfate, evaporated and the crude product was purified by preparative HPLC to yield 4.04 g of the desired product as trifluoroacetate. Rt = 0.97 min (Method #2). Detected mass: 182.0/184.0 (M+H+).
4-Chloro-6-fluoro-isoquinoline (9)
Figure imgf000048_0002
A solution of 1.5 g 6-fluoro-isoquinoline (5) in 4.5 ml sulfuryl chloride was heated to 60 °C in a microwave reactor (CEM Discovery) for 8 h. After cooling to room temperature the mixture was poured on ice and extracted three times with CHCI3. After drying over Na2SO4 the solvent was distilled off and the crude product was purified by flash chromatography to yield 930 mg of 9. Rt = 1.37 min (Method #1). Detected mass: 182.0 (M+H+).
trans-[4-(7-Chloro-isoquinolin-6-yloxy)-cyclohexyl]-carbamic acid tert-butyl ester (10)
Figure imgf000049_0001
450 mg (0.21 mmol) trans-(4-Hydroxy-cyclohexyl)-carbamic acid tert-butyl ester were dissolved in 25 ml N,N-dimethyl acetamide. Under an argon atmosphere, 101 mg (4.2 mmol) sodium hydride were added and the mixture was stirred at room temperature. After 30 minutes, 250 mg (0.14 mmol) 7-chloro-6-fluoro-isoquinoline (6) were added and the solution was heated to 80 0C. After 4 h, the solvent was removed under reduced pressure. The residue was taken up in H2O and extracted three times with ethyl acetate. The combined organic layers were dried over MgSO4 and evaporated. The crude product was purified by preparative HPLC, which delivered 18 mg of the title compound. R1 = 1.38 min (Method #1). Detected mass: 377.2/379.3 (M+H+).
trans-4-(7-Chloro-isoquinolin-6-yloxy)-cyclohexylamine (11)
Figure imgf000049_0002
18 mg (0.05 mmol) trans-[4-(5-Chloro-isoquinolin-6-yloxy)-cyclohexyl]-carbamic acid tert-butyl ester (10) were stirred in 2 M HCI at room temperature. After 2 days, the solvent was removed i. vac. and the residue was purified by preparative HPLC. 8 mg of the title compound could be obtained as trifluoro acetate. Rt = 0.69 min (Method #1). Detected mass: 277.2/279.2 (M+H+).
cis-[4-(5-Chloro-isoquinolin-6-yloxy)-cyclohexyl]-carbamic acid tert-butyl ester (12)
Figure imgf000049_0003
Starting from 5-chloro-6-fluoro-isoquinoline (8) and cis-(4-hydroxy-cyclohexyl)- carbamic acid tert-butyl ester the title compound was prepared by the method described for trans-[4-(5-chloro-isoquinolin-6-yloxy)-cyclohexyl]-carbamic acid tert- butyl ester (10), whereas DMF was used as solvent. Rt = 1.14 min (Method #4). Detected mass: 377.2/379.2 (M+H+). cis-4-(5-Chloro-isoquinolin-6-yloxy)-cyclohexylamine (13)
Figure imgf000050_0001
50 mg (0.13 mmol) cis-[4-(5-Chloro-isoquinolin-6-yloxy)-cyclohexyl]-carbamic acid tert- butyl ester (12) were dissolved in ethanol/2N HCI (1 :1) and stirred at room temperature until complete conversion could be detected (LCMS). Evaporation of the solvent furnished 36 mg of the title compound as hydrochloride. Rt = 0.71 min (Method #1). Detected mass: 277.2/279.2 (M+H+).
cis-4-(4-Chloro-isoquinolin-6-yloxy)-cyclohexylamine (14)
Figure imgf000050_0002
Starting from 4-chloro-6-fluoro-isoquinoline (9) and cis-(4-hydroxy-cyclohexyl)- carbamic acid tert-butyl ester the title compound was prepared as hydrochloride by the method described for trans-[4-(5-chloro-isoquinolin-6-yloxy)-cyclohexyl]-carbamic acid tert-butyl ester (10) followed by deprotection using 4M hydrochloric acid in isopropanol. Rt = 0.79 min (Method #1). Detected mass: 277.1/279.1 (M+H+).
cis-4-(7-methoxy-isoquinolin-6-yloxy)-cyclohexylamine (15)
Figure imgf000050_0003
Starting from 7-methoxy-6-fluoro-isoquinoline (7) and cis-(4-hydroxy-cyclohexyl)- carbamic acid tert-butyl ester the title compound was prepared as trifluoroacetate by the method described for trans-[4-(5-chloro-isoquinolin-6-yloxy)-cyclohexyl]-carbamic acid tert-butyl ester (10) followed by deprotection using 4M hydrochloric acid in isopropanol and purification via preparative HPLC. Rt = 0.62 min (Method #2). Detected mass: 273.19 (M+H+). General procedure for the reaction of N-boc-protected aminoalcohols with 6-hydroxy isoquinolines (Mitsunobu-reaction):
To 500 mg (1.5 mmol) of triphenylphosphine (bound to polystyrene, 3mmol/g) and 10 ml of dichloromethane were added 0.195 ml_ (1.2 mmol) of diethylazodicarboxylate (or alternatively diisopropylazodicarboxylate). The reaction mixture was allowed to shake for 10 min. and then 0.14 ml_ of triethylamine, 145 mg of the 6-hydroxyisoquinoline derivative (reagent 1) and 1 mmol of the desired, boc-protected aminoalcohol (reagent 2) was added. The reaction was shaken at room temperature until no further conversion could be observed by LCMS. For workup, the solution was filtered, the residue was washed with dichloromethane and the organic layer was washed twice with 1 N sodium hydroxide, twice with water and once with brine, dried over magnesium sulfate and evaporated. The crude product was purified by preparative HPLC to yield the boc protected coupled product.
General procedure for removal of the boc-group:
The starting material was dissolved in 2M hydrochloric acid and stirred overnight. To compounds with poor aqueous solubility, methanol or dioxane was added until a homogenous solution was obtained. Alternatively, 4M hydrochloric acid in isopropanol was used to deprotect the compound. The reaction mixture was lyophilised and the deprotected product was obtained as the corresponding hydrochloride of the free amine.
The following examples were prepared according to this protocol (Table 1):
Figure imgf000052_0001
Figure imgf000053_0001
The examples 16 and 17 were also synthesized using a similar method as described for the synthesis of 12 and 13. The respective starting materials are 6-fluoro isoquinoline (5) and either cis or trans 4-amino-cyclohexanol hydrochloride.
(3-Fluoro-benzyl)-[cis-4-(isoquinolin-6-yloxy)-cyclohexyl]-amine (20)
Figure imgf000054_0001
100 mg (0.36 mmol) cis-4-(lsoquinolin-6-yloxy)-cyclohexylamine (16) were dissolved in 15 ml dichloromethane. At room temperature 53.6 mg (0.43 mmol) 3-fluoro benzaldehyde, 29.5 mg (0.36 mmol) sodium acetate, 10.8 mg (0.18 mmol) acetic acid and freshly dried molecular sieves were added and the reaction mixture was stirred at room temperature. After 1 h 91.2 mg (0.43 mmol) sodium triacetoxy borohydride were added and stirring was continued. After 3 h additional 2 equivalents of sodium triacetoxy borohydride were added and the reaction was stirred until complete conversion could be detected. For working up, acetic acid was added to destroy excess boron hydride reagent and the mixture was filtered. The filtrate was dissolved in dichloromethane and washed twice with saturated sodium bicarbonate solution. The organic layer was separated, dried over MgSO4 and evaporated. Final purification by preparative HPLC delivered the title compound as trifluoro acetate, which was dissolved in 1 N HCI. Lyphilization furnished the corresponding HCI-salt. After a second lyophilization from H2O, 28.6 mg of the desired compound could be obtained as hydrochloride. Rt = 0.96 min (Method #1). Detected mass: 351.3 (M+H+).
Figure imgf000055_0001
Figure imgf000056_0001
56
4-(lsoquinolin-6-yloxy)-cyc!ohexanone (27)
Figure imgf000057_0001
A suspension of 9 g triphenylphosphine (bound to polystyrene, Argonaut, 1.6 mmol/g, 14.4 mmol) and 1.57 ml_ (1.74 g, 10 mmol) diethyl azocarboxylate in 100 mL dichloromethane was stirred for 10 min under argon atmosphere. Then 1.45 g (10 mmol) 6-hydroxy-isoquinoline and 1.58 g (10 mmol) 1 ,4-dioxa-spiro[4.5]decan-8-ol were added. After 40 min 1.39 mL (1 g, 10 mmol) triethyl amine was added and the reaction was allowed to shake for 16 h at room temperature. After filtration the organic layer was extracted with 1 N NaOH, dried over Na2SO4, filtered and concentrated in vacuo.
The crude material (2.2 g) was dissolved in 200 mL acetone and 10 mL water. 1.5 g (7.9 mmol) of para-toluene sulfonic acid were added and the reaction was heated to reflux temperature for 6 h. Then the solvents were distilled off. The remainder was dissolved in dichloromethane and was extracted with aqueous Na2CO3 solution. After drying over Na2SO4, filtration and removal of the solvents the crude product was purified by flash chromatography to yield 1.19 g of 27 as a white solid. 1H-NMR (de-DMSO): δ = 9.16 (1 H, s), 8.41 (1 H, d, J = 5.8 Hz), 8.05 (1 H, d, J = 8.9 Hz), 7.70 (1 H, d, J = 5.8 Hz), 7.51 (1 H, d, J = 2.5 Hz), 7.36 (1 H, dd, J = 8.9 und 2.5 Hz), 5.04 (1 H, m), 2.44 (4H, m), 2.22 (2H, m), 2.11 (2H, m). MS: m/z = 242 (MH+).
General procedure for preparation of 4-(isoquinolin-6-yloxy)-cyclohexylamines
Figure imgf000057_0002
1.2 eq amine and 2.5 eq MP-triacetoxyborohydride (Argonaut, 2 mmol/g) were added to a solution of 60 mg (0.25 mmol, 1 eq.) 4-(isoquinolin-6-yloxy)-cyclohexanone (27) in 2 mL dry THF and allowed to shake for 16 h at room temperature. Upon completion the polymer was removed by filtration and washed with THF. Removal of the solvent gave the crude product which was purified by preparative HPLC if neccessary. The title compounds were obtained as a mixture of cis and trans isomers.
Figure imgf000059_0001
Figure imgf000060_0001
Figure imgf000061_0001
Figure imgf000062_0001
Figure imgf000063_0001
Figure imgf000064_0001
Figure imgf000065_0001
Ul
Figure imgf000066_0001
Figure imgf000067_0001
Figure imgf000068_0001
Figure imgf000069_0001
Figure imgf000070_0001
Figure imgf000071_0001
Figure imgf000072_0001
Figure imgf000073_0001
Figure imgf000074_0001
Figure imgf000075_0001
Figure imgf000076_0001
Figure imgf000077_0001
Figure imgf000078_0001
Figure imgf000079_0001
Figure imgf000080_0001
The relative stereochemistry of 70 was confirmed by this alternative synthesis: [4-(lsoquinolin-6-yloxy)-cyclohexyl]-dimethyl-amine (70)
Figure imgf000081_0001
435 mg para-formaldehyde (5.2 mmol, 2.2 eq.) were added to a solution of 660 mg 16 (2.4 mmol) in 5.4 g (50 eq.) formic acid. The mixture was heated to reflux for two hours. Another 0.25 equivalents of para formaldehyde were added and the mixture was heated again for 2 hours to reflux temperature. After cooling the solvent was removed in vacuo. 5 ml 2 N aqueous NaOH and CH3CI/i-Propanol 3:1 were added. The mixture was filtered through a PTS-cartridge. After washing the combined fractions were evaporated and the crude product was purified by preparative HPLC chromatography.
The product was dissolved in 10 ml_ isopropanol. 5-6 N HCI in isopropanol was added and the solvents were removed in vacuo to yield 200 mg of the title compound as a hydrochloride.
2-Chloro-N-dimethylaminomethylene-5-formyl-benzenesulfonamide (73)
Figure imgf000081_0002
5.0 g (22.8 mmol) 2-Chloro-5-formyl-benzenesulfonamide were dissolved in 50 ml dichloromethane. 4.08 g (34.3 mmol) dimethylformamide dimethylacetal were added and the mixture was refluxed for 2 h. After cooling to room temperature, the solution was washed twice with H2O1 dried over magnesium sulfate and evaporated. 5.16 g of the crude product were obtained and used in the next step without further purification. Rt = 1.14 min (Method #1). Detected mass: 275.1/277.1 (M+H+).
2-Chloro-5-{cis-[4-(5-chloro-isoquinolin-6-yloxy)-cyclohexylamino]-methyl}-N- dimethylaminomethylene-benzenesulfonamide (74)
Figure imgf000082_0001
34 mg (0.11 mmol) cis-4-(5-Chloro-isoquinolin-6-yloxy)-cyclohexylamine (13) were dissolved in 5 ml MeOH and 22 mg (0.22 mmol) thethylamine were added. After the reaction was stirred 30 min, 65 mg (1.1 mmol) acetic acid, 60 mg (0.22 mmol) 2- chloro-N-dimethylaminomethylene-5-formyl-benzenesulfonamide (73) and freshly dried molecular sieves were added and the mixture was stirred for 30 minutes at room temperature. A solution of 20.5 mg (0.33 mmol) sodium cyanoborohydride in 1 ml methanol was added and the mixture was allowed to stand at room temperature overnight. The solvent was removed i. vac. The residue was dissolved in dichloromethane, washed with 1 N NaOH and brine, dried over MgSO4 and evaporated. 53 mg of the title compound were isolated as crude product and used without further purification. Rt = 0.87 min (Method #4). Detected mass: 535.2/537.1 (M+H+).
2-Chloro-5-{[4-(5-chloro-isoquinolin-6-yloxy)-cyclohexylamino]-methyl}- benzenesulfonamide (75)
Figure imgf000082_0002
53 mg 2-Chloro-5-{cis-[4-(5-chloro-isoquinolin-6-yloxy)-cyclohexylamino]-methyl}-N- dimethylaminomethylene-benzenesulfonamide (74) were dissolved in 5 ml ethanol. 2 ml 2N NaOH were added and the mixture was heated to 65 0C. After 5 h, the solvent was remoived i. vac, the residue was dissolved in H2O and neutralized by adding 1 N HCI. The precipitate was filtered and dried, to yield 23 mg of the title compound as hydrochloride. Rt = 0.89 min (Method #1). Detected mass: 480.2/484.2 (M+H+).
Cyclopropylmethyl-[trans-4-(isoquinolin-6-yloxy)-cyclohexyl]-amine (76)
Figure imgf000083_0001
A suspension of 69.7 mg (0.25 mmol) trans-4-(isoquinolin-6-yloxy)-cyclohexylamine (17), 52.7 μl_ triethyl amine (1.25 mmol, 5 eq.) and 21 mg cyclopropanecarbaldehyde (0.3 mmol, 1.2 eq.) in 3 ml_ trimethylorthoformate was stirred at room temperature for 1 h. Then a solution of 321.6 mg sodium triacetoxy borohydride (1.25 mmol, 5 eq) and 72 μl_ acetic acid (75.1 mg, 1.25 eq) in 2 ml_ DMF was added. The reduction was complete after 10 min. Then the solvents were removed in vacuo and the product was isolated via preparative HPLC to yield 41 mg of the title compound as trifluoroacetate. R1 = 0.89 min (Method #1). Detected mass: 297.3 (M+H+).
Bis-cyclopropylmethyl-[trans-4-(isoquinolin-6-yloxy)-cyclohexyl]-amine (77)
Figure imgf000083_0002
The title compound as trifluoroacetate was isolated as side product in the reaction described for cyclopropylmethyl-[trans-4-(isoquinolin-6-yloxy)-cyclohexyl]-amine (76). Rt = 0.97 min (Method #1). Detected mass: 351.2 (M+H+).
5-Chloro-6-(1 ,4-dioxa-spiro[4.5]dec-8-yloxy)-isoquinoline (78)
Figure imgf000083_0003
887 mg (5.61 mmol) 1 ,4-Dioxa-spiro[4.5]decan-8-ol were dissolved in 50 ml DMF and 224 mg (5.61 mmol) sodium hydride (60%) werde added. After stirring for 30 minutes at room temperature, a solution of 815 mg (4.49 mmol) 5-chloro-6-fluoro-isoquinoline (8) in 10 ml DMF was added and the mixture was heated to 100 0C. After 4 h one additional equivalent of 1 ,4-dioxa-spiro[4.5]decan-8-ol and sodium hydride were added and stirring was continued at 100 0C. After 1.5 h complete conversion could be detected. For working up, the solvent was removed under reduced pressure, the residue was taken up in H2O and extracted three times with ethyl acetate. The combined organic layers were dried over MgSO4 and evaporated. The obtained orange oil (2.17 g) was stirred in diisopropyl ether and the insoluble white precipitate was filtered off. After drying of the precipitate, 549 mg of the title compound could be isolated. Rt = 1.15 min (Method #1). Detected mass: 320.1/322.1 (M+H+).
4-(5-Chloro-isoquinolin-6-yloxy)-cyclohexanone (79)
Figure imgf000084_0001
549 mg (1.72 mmol) 5-Chloro-6-(1 ,4-dioxa-spiro[4.5]dec-8-yloxy)-isoquinoline (78) were dissolved in 20 ml THF/H2O (3:1). 1 ml TFA was added and the mixture was stirred at room temperature. After 1 h, 2 ml TFA were added and the temperature was increased to 50 0C. After 5 d at 50 0C, 2 ml TFA were added. After one additional day, 2 ml TFA were added and the temperature was increased to 100 0C. After 5 h, the reaction was allowed to cool down to room temperature and the mixture was diluted with dichloromethane and H2O. Solid NaHCOβ was added for neutralization. The phases were separated and the aqueous phase was extracted with dichloromethane. The combined organic layers were dried over MgSO4 and evaporated. After final purification by preparative HPLC, 533 mg of the title compound as trifluoroacetate were obtained. Rt = 0.88 min (Method #4). Detected mass: 276.2/278.2 (M+H+).
[4-(5-Chloro-isoquinolin-6-yloxy)-cyclohexyl]-cyclohexyl-amine (80)
Figure imgf000084_0002
100 mg (0.36 mmol) 4-(5-Chloro-isoquinolin-6-yloxy)-cyclohexanone (79) were dissolved in 10 ml methanol. After adding 73 mg (0.73 mmol) triethyl amine, 108 mg (1.09 mmol) cyclohexylamine, 218 mg (3.63 mmol) acetic acid and freshly dried molecular sieves, the reaction was stirred at room temperature. After 30 minutes, a solution of 68 mg (1.09 mmol) sodium cyanoborohydride in 2 ml methanol was added and the reaction was kept at room temperature until complete conversion was achieved. For working up, the reaction mixture was filtered and the filtrate was brought to alkaline pH by adding solid NaHCO3. After evaporation of the solvent, the residue was taken up in H2O and extracted three times with dichloromethane. The combined organic layers were dried over MgSO4 and evaporated. Final purification by preparative HPLC gave 69 mg of the desired product as trifluoroacetate, which was dissolved in 2 N HCI and lyophilized, to yield 45 mg of the corresponding HCI-salt. Rt = 1.08/1.15 min (Method #1). Detected mass: 359.3/361.3 (M+H+).
Figure imgf000086_0001
Figure imgf000087_0001
cis-[4-(5-Bromo-isoquinolin-6-yloxy)-cyclohexyl]-carbamic acid tert-butyl ester (85)
Figure imgf000088_0001
4.33 mL (5.75 g, 33 mmol) of diethyl azo dicarboxylate were added to 18 g (68.75 mmol) of triphenylphosphine in 500 mL of dichloromethane at 00C and stirred for 15 min. 6.16 g (27.5 mmol) 5-bromo-isoquinolin-6-ol (2), 5.92 g (27.5 mmol) (trans-4- hydroxy-cyclohexyO-carbamic acid tert-butyl ester and 3.81 mL (33 mmol) triethyl amine were added. The mixture was stirred for 4 days. The precipitate was removed by filtration, washed with dichloromethane and the solvents were distilled off. The crude product was purified by flash chromatography using ethyl acetate/n-heptane as eluent to give 2.77 g (24%) of 85. Rt = 1.37 min (Method #1). Detected mass: 421.1/423.1 (M+H+).
General procedure for Suzuki-coupling with cis-[4-(5-bromo-isoquinolin-6-yloxy)- cyclohexyl]-carbamic acid tert-butyl ester (85)
2M Aqueous Na2Cθ3 solution (0.2 ml, 0.4 mmol, 2 eq.) was added to a solution of 81 mg (0.2 mmol, 1 eq.) of cis-[4-(5-bromo-isoquinolin-6-yloxy)-cyclohexyl]-carbamic acid tert-butyl ester (85) and 1.5 eq. (0.3 mmol) of the corresponding boronic acid in 3 mL of DME. Argon was bubbled through the reaction mixture for 10 min. Then, 23 mg (0.1 eq.) Pd(PPh3)4 were added and the reaction was stirred at 95 0C overnight under argon atmosphere. After cooling 2 mL of water and 10 mL of ethyl acetate were added.
The organic layer was separated, dried and the solvent was distilled off. The remainder was subjected to preparative HPLC.
The Boc group was removed by dissolving the intermediate in isopropanol and addition of 5-6 N HCI in isopropanol. The precipitate was isolated by filtration.
In some reactions no hydrochloride precipitated or the purity of the precipitate was unsatisfactory. In these cases the solvent was distilled off and the remainder was purified by preparative HPLC.
The following examples were synthesized using this method (Table 6):
Figure imgf000089_0001
Figure imgf000090_0001
General procedure for Coupling with cis-^δ-bromo-isoquinolin-θ-yloxyj-cyclohexyl]- carbamic acid tert-butyl ester (85)
Under argon atmosphere 1.2 eq. of the stannane and 0.1 eq. of Pd(PPh3)4 were added to a solution of of with cis-[4-(5-bromo-isoquinolin-6-yloxy)-cyclohexyl]-carbamic acid tert-butyl ester (85) in 4 ml of toluene. The reaction was heated to 1000C in a microwave reactor (CEM Discovery) for 1 h.
After cooling to room temperature water and ethyl acetate were added. The mixture was filtered through a Celite cartridge, washed with ethyl acetate and concentrated. The crude Boc protected product was purified by preparative HPLC.
The Boc group was removed by dissolving the intermediate in isopropanol and addition of 5-6 N HCI in isopropanol. The precipitate was isolated by filtration.
The following examples were synthesized using this method (Table 7):
Figure imgf000092_0001
Figure imgf000093_0001
Figure imgf000094_0001
5,7-Dichloro-6-fluoro-isoquinoline (95)
Figure imgf000095_0001
5 g (23.1 mmol) 7-Chloro-6-fluoro-isoquinoline (6) were dissolved in 90 ml cone, sulfuric acid. At room temperature 7.34 g (55 mmol) N-chlorosuccinimide were added. The solution was heated to 50 0C and another 3.67 g (27.5 mmol) N-chlorosuccinimide were added. After standing overnight at room temperature, the reaction was again heated to 50 0C and another 18.35 g (137.5 mmol) N-chlorosuccinimide were added during the next 8 h. For working up, the reaction mixture was poured on ice. The aqueous solution was adjustedt to alkaline pH with sodium hydroxide. The precipitate was filtered off and extracted three times with dichloromethane. The dichloromethane phases were dried with magnesium sulfate and evaporated to yield 1.09 g of the title compound, which was used without further purification.
trans-4-(5,7-Dichloro-isoquinolin-6-yloxy)-cyclohexylamine (96)
Figure imgf000095_0002
Starting with 5,7-dichloro-6-fluoro-isoquinoline (95) and trans-(4-hydroxy-cyclohexyl)- carbamic acid tert-butyl ester, the title compound was synthesized following the protocol described for trans-[4-(5-chloro-isoquinolin-6-yloxy)-cyclohexyl]-carbamic acid tert-butyl ester (10). Purification of the obtained Boc-protected crude product by preparative HPLC, followed by treatment with thfluoroacetic acid gave the title compound as trifluoroacetate, which was dissolved in 2 M HCI. Evaporation of the solvent gave the desired product as HCI-salt. Rt = 0.94 min (Method #1). Detected mass: 311.2/313.2 (M+H+).
cis-[4-(7-Chloro-isoquinolin-6-yloxy)-cyclohexyl]-carbamic acid tert-butyl ester (97)
Figure imgf000096_0001
Starting with 7-chloro-6-fluoro-isoquinoline (6) and cis-(4-hydroxy-cyclohexyl)-carbamic acid tert-butyl ester, the title compound was prepared by the protocol described for trans-[4-(5-chloro-isoquinolin-6-yloxy)-cyclohexyl]-carbamic acid tert-butyl ester (10). Rt = 1.07 min (Method #4). Detected mass: 377.2/379.2 (M+H+).
cis-4-(7-Chloro-isoquinolin-6-yloxy)-cyclohexylamine (98)
Figure imgf000096_0002
cis-[4-(7-Chloro-isoquinolin-6-yloxy)-cyclohexyl]-carbamic acid tert-butyl ester (97) was deprotected following the method described for trans-4-(7-chloro-isoquinolin-6-yloxy)- cyclohexylamine (11) in methanol / 2N HCI (1 :1). After complete conversion, the solution was brought to alkaline pH by adding sodium hydroxide. The aqueous solution was extracted three times with dichloromethane. The combined organic layers were dried over MgSO4 and evaporated. The crude product was purified by silicagel chromatography (CH2CI2/MeOH 1 :1 → MeOH, 1% NH3) followed by preparative HPLC, after which the desired product was isolated as trifluoroacetate. Rt = 0.69 min (Method #1). Detected mass: 277.1 (M+H+).
(2,2-Dimethoxy-ethyl)-(3,4,5-trifluoro-benzyl)-amine (99)
Figure imgf000096_0003
Starting from 3,4,5-trifluorobenzaldehyde, the title compound was prepared following the method described for 2,2-dimethoxy-ethyl)-(4-fluoro-benzyl)-amine (3). Rt = 0.79 min (Method #4). Detected mass: 250.1 (M+H+).
N-(2,2-Dimethoxy-ethyl)-4-methyl-N-(3,4,5-trifluoro-benzyl)-benzene-sulfonamide (100)
Figure imgf000097_0001
Starting from (2,2-Dimethoxy-ethyl)-(3,4,5-trifluoro-benzyl)-amine (99), the title compound was prepared following the method described for N-(2,2-dimethoxy-ethyl)- N-(4-fluoro-benzyl)-4-methyl-benzene-sulfonamide (4). Rt = 1.76 min (Method #4). Detected mass: 372.1 (M+H+).
5,6,7-Trifluoro-isoquinoline (101 )
Figure imgf000097_0002
Cyclisation of N-(2,2-dimethoxy-ethyl)-4-methyl-N-(3,4,5-trifluoro-benzyl)-benzene- sulfonamide (100) by the methode described for 6-fluoro-isoquinoline (5) gave the desired isoquinoline, which was isolated as trifluoro acetate after final purification by prep. HPLC. R4 = 1.15 min (Method #1). Detected mass: 184.0 (M+H+).
cis-4-(5,7-Difluoro-isoquinolin-6-yloxy)-cyclohexylamine (102)
Figure imgf000097_0003
Starting from 5,6,7-trifluoro-isoquinoline (101) and cis-(4-hydroxy-cyclohexyl)-carbamic acid tert-butyl ester, the Boc-protected intermediate was prepared by the methode described for trans-[4-(5-chloro-isoquinolin-6-yloxy)-cyclohexyl]-carbamic acid tert- butyl ester (10). Deprotection using standard procedures (see 11 or 13) gave the title compound, which was isolated as trifluoro acetate after prep. HPLC. Subsequent treatment of the obtained trifluoro acetate with 2N HCI, followed by lyophilisation gave the corresponding HCI-salt. Rt = 0.86 min (Method #1). Detected mass: 279.1 (M+H+). General procedure for the reductive amination reaction:
0.25 mmol of the amine building block (hydrochloride) was weighted into the reaction tube. 3 ml trimethyl orthoformiate was added, then 0.25 mmol of the carbonyl compound (in 0.2 ml THF or solid), followed by 1.5 mmol (2.5 mmol in case of dihydrochlorides) Et3N. The mixture was stirred for 1h at room temperature, then cooled to -10 0C. 1.5 ml of a freshly prepared solution of NaHB(OAc)3 (1.25 mmol) in DMF was added, followed by 1.225 mmol acetic acid. The mixture was stirred for 30 min in the cold, then allowed to reach room temperature. Stirring was continued over night at room temperature. 0.5 ml water was added and the solvents were evaporated. The residue was dissolved in DMF, filtered over syringe filters, and purified by prep. HPLC. The purified products were dissolved in 1 ml HCI in isopropanol (5-6M), left at room temperature overnight, diluted with 2 ml water and freeze-dried to yield the hydrochlorides. In some cases, the obtained products had to be purified a second time by prep. HPLC. In these cases, the final products were isolated as trifluoroacetates (Table 8).
Figure imgf000099_0001
Figure imgf000100_0001
Figure imgf000101_0001
Figure imgf000102_0001
Figure imgf000103_0001
Figure imgf000104_0001
Figure imgf000105_0001
Figure imgf000106_0001
Figure imgf000107_0001
Figure imgf000108_0001
Figure imgf000109_0001
Figure imgf000110_0001
Synthesis of intermediate 144
Figure imgf000111_0001
Step i :
188 g of 5-Fluoro-indanone-1 (140) were dissolved in 1.8 I of diethyl ether, 50 ml of
EtOH saturated with HCI were added at 00C and 1.1 I of a 15% ethyl nitrite solution in ether was added over 1 hour.
The solution was allowed to stir for an additional 3 hours to reach room temperature, then the solvent was removed partially and the precipitated product was collected by filtration.
Step 2
129 g of the product from Step 1 was added to a mixture of 170 g of PCI5 in 2 I of POCI3. Then gaseous HCI was added at 00C until saturation of the solution was reached. The remaining mixture was heated to 600C for 6h, the solvent partially removed in vacuo and the residue was hydrolyzed on a crushed ice/water mixture. The precipitated product was isolated by filtration.
Step 3 155 g of crude product from Step 2 were added to a mixture of 740 ml HOAc and 330 ml HI (57%) containing 53 g of red phosphorous. After heating to reflux for 4 hours, the solution was treated with concentrated NaOH (until pH = 8) and the precipitated product was isolated by filtration.
Step 4: 16.5 g of (cis-4-hydroxy-cyclohexyl)-carbamic acid tert-butyl ester were dissolved in 210 ml of diglyme and treated with 4.1g 50% NaH under nitrogen. The resulting mixture was stirred for 1 h at room temperature, then 14.8 g of the product from Step 3 were added. The mixture was allowed to stir for 1 day at room temperature, then 100 ml of toluene were added and the resulting mixture was washed with water 3 times. The organic phases were collected and the solvent was removed in vacuo.
General procedure for derivatization of the 3-position of 144
Figure imgf000112_0001
Step 5:
100 mg of compound 144 and 1.1 equivalents of the corresponding aniline were dissolved in 5 ml of dioxane, 350 mg of CS2CO3, 20mg of Pd(OAc)2 and 60 mg of XANTHPHOS are added and the resulting mixture was heated to reflux under nitrogen until the starting material was consumed, (reaction was monitored by LCMS) The solvent was removed in vacuo and the residue was subjected to chromatography on a HPLC system.
Step 6: The products of Step 5 are dissolved in 5 ml of ethanol saturated with gaseous HCI. After stirring for 5h the desired product is isolated as its hydrochloride by removal of the solvent in vacuo. The following examples were synthesized as hydrochlorides following this general procedure (Table 9):
Figure imgf000113_0001
Figure imgf000114_0003
trans-2-(4-Hydroxy-cyclohexyl)-isoindole-1 ,3-dione (151)
Figure imgf000114_0001
5g of trans-4-cyclohexanolamine hydrochloride, 4.88 g of phthalic anhydride and 7.8 ml_ of tributyl amine were mixed and heated to 150 0C for 10h. The mixture was cooled to room temperature, the solid was dissolved in dichloromethane and extracted with 1 N HCI, evaporated to dryness and filtered over silica to yield 7.9g of 151 as a colorless solid. R1 = 1.28 min (Method #1). Detected mass: 228.0 (M- H2O+H+).
6-Methoxy-isoquinoline (152)
Figure imgf000114_0002
6-methoxy-isoquinoline (152) could be prepared by a similar reaction sequence as described for the synthesis of 6-fluoro-isoquinoline (5), starting from 4-methoxy benzaldehyde. Rt = 0.65 min (Method #2). Detected mass: 160.1 (M+H+). 4-Ethyl-6-methoxy-isoquinoline (153)
Figure imgf000115_0001
6 g of 6-Methoxy-isoquinoline (152) were dissolved in dry THF. Under argon a 1 M solution of potassium triethylborane (37.7 ml_) was added dropwise. The solution was stirred for five hours, then iodoethane (3.3 ml_) was added dropwise. The solution was stirred overnight, cooled to 0 0C and 96 ml_ of 1 N NaOH and 36 ml_ of 35% sodium peroxide were added. After gas evolution stopped, water and dicholoromethane were added, the aqueous layer was extracted three times with dichloromethane ,the organic layer was dried over sodium sulfate and the solvent was removed in vacuo. The residue was purified by silica gel chromatography to yield 1.96 g of product 153. Rt = 0.95 min (Method #1). Detected mass: 188.1 (M+H+)
4-Ethyl-isoquinolin-6-ol (154)
Figure imgf000115_0002
1.69 g of 4-Ethyl-6-methoxy-isoquinoline (153) were dissolved in dichloroethane and stirred with 1.7 ml_ of boron tribromide at room temperature for 3 hours and one additional hour at 40 0C. The solution was poured on ice water, pH was adjusted to 9 by addition of sodium hydroxide and the solution was extracted with dichloromethane: isopropanol 3:1. The organic layer was evaporated to dryness and the product was purified by silica gel chromatography to yield 980 mg of 154. Detected Mess: 173.9 (M+H+) (ESI) 2-[cis-4-(4-Ethyl-isoquinolin-6-yloxy)-cyclohexyl]-isoindole-1 ,3-dione (155)
Figure imgf000116_0001
157 mg of 4-Ethyl-isoquinolin-6-ol (154), 319 mg of trans-2-(4-Hydroxy-cyclohexyl)- isoindole-1 ,3-dione (151) and 923 mg of diphenyl-[4-[1 H,1 H,2H,2H- perfuorodecyl]phenyl]phosphine were suspended in 1mL of THF. The solution was cooled to 00C and 1.1g of Bis-(1 H, 2H, 2H, 3H, 3H-perflourononyl)- azodicarboxylate, dissolved in 1mL of THF was added dropwise. The solution was warmed to room temperature and stirred overnight, filtered over a fluoroflash cartridge and the residue was purified by HPLC. Upon evaporation of the solvent, the product was isolated as the TFA salt. 180 mg with R4 = 1.51 min (Method #1). Detected mass: 401.3 (M+H+).
cis-4-(4-Ethyl-isoquinolin-6-yloxy)-cyclohexylamine (156)
Figure imgf000116_0002
170 mg of 2-[cis-4-(4-Ethyl-isoquinolin-6-yloxy)-cyclohexyl]-isoindole-1 ,3-dione (155) were dissolved in 1 mL of methanol. 3.6 mL of 2M methylamine in methanol were added and the solution was stirred overnight. Another 0.5 mL of the methylamine solution was added and stirring was continued for another night.
The solution was evaporated, taken up in 1 M HCI and extracted with ethyl acetate.
The aqueous layer was lyophilized and purified by HPLC, the resulting product was converted into its HCI salt by taking it up in 0.1 M HCI and subsequent lyophilisation.
The reaction yielded 71 mg of cis-4-(4-Ethyl-isoquinolin-6-yloxy)-cyclohexylamine as its hydrochloride (156). R1 = 0.79 min (Method #1). Detected mass: 271.2 (M+H+). Determination of Rho kinase inhibition
To measure Rho-kinase inhibition, IC50 values were determined according to the following protocol:
Buffer: 25mM Tris pH7,5; 0,02% BSA; 5% Glycerol; 0,008% Triton X100; 2% DMSO,
1mM DTT; 1mM MgCI2; 0,5μCi/wel.l γ33P ATP
Enzyme: ROCKII or ROKα) (Upstate, Catalog # 14-451 Lot # 24880U) 0.1 ng/μl
Final concentration of ATP in reaction mixture 40μM
Biotinylated substrate, diluted to 0.25μM with buffer described above (without ATP)
1. 10μl Tris buffer (± Inhibitor)
2. Add 30 μl_ of enzyme solution
3. Start the reaction with 30μL of mix substrate/ATP/ATP33 4. Incubate for 20 min at room temperature
5. Stop reaction with 30 μ L of 50 m M EDTA
6. Transfer 50 μl_ of stopped solution to Streptavidin Flash Plate plus, Perkin Elmer,
SMP 103A
7. Incubate for 30 min at RT 8. Wash 4 times with 300 μl of PBS/0.1 % Tween 20 9. Radioactivity in the well was determined
Figure imgf000117_0001
Figure imgf000118_0001
The given activity is denoted as the negative decadal logarithm of the IC50 (PIC50) as follows:
+: plC50 <3.0
++: 3.0<plC50<4.0
+++ 4.0<plC5Q< 5.0
++++: 5.0<plC50<6.0
+++++ 6.0 < PlC50

Claims

Claims
1. A compound of the formula (I)
Figure imgf000119_0001
wherein
R-I is
H,
(C1-C6)aIKyI.
R', NH-(C1-C6)alkyl,
NHR', or N[(C1-Ce)8IlCyIk;
R2 is H, halogen or (Ci-Cρjalkyl;
R3 is
H, halogen,
(C1-C6)alkyl,
(C1-C6)alkylene-R\
OH, O-R", NH2, NHR", NR"R" or NH-C(O)-R";
R4 is H, halogen, hydroxy, CN,
(C1-C6)aIlCyI, R',
(C1-C6)alkylene-R';
R5 is
H, halogen, CN, NO2,
(C1-C6)aIlCyI1 (C2-C6)alkenyl, R1,
(C-i-C^alkylene-fCe-C10)aryl,
(C -| -C6)alkenylene-(C6-C -| o)aryl,
(C1-C6)alkylene-(C5-C10)heterocyclyl, CH(OH)-(C1 -C6)alkyl, NH2, NH-R', NH-SO2H,
NH-SO2-(C1 -C6)alkyl, NH-SO2-R', NH-C(O)-(C1 -C6)alkyl, NH-C(O)-R', CtOJN[ (C1-C6)alkyl]2, C(O)OH, or C(O)O- (C1-C6)alkyl;
RQ and RQ are independently of each other
H,
R1, (CH-Cβ)alkyl,
(C1-C6)alkylene-R\
(C1-C6)alkylene-O- (C1-C6)alkyl,
(C1-C6)alkylene-O-R',
(C1-C6)alkylene-CH[R']2,
(C-|-C6)alkylene-C(O)-R',
(C1-C6)alkylene-C(O)NH2,
(C1-C6)alkylene-C(O)NH-R',
(C1-C6)alkylene-C(O)NH-(C1-C6)alkyl,
(C1-C6)alkylene-C(O)N[(C1-C6)alkyl]2,
(C1-C6)alkylene-C(O)N[R']2;
(C1-C6)alkylene-C(O)O-(C1-C6)alkyl,
C^O^C-i-C^alkyl,
C(O)OR' C(O)(CvCQ)a\ky\,
C(O)R', C(O)NH-(C1-C6)alkyl, C(O)NHR', C(0)N[(C1-C6)alkyl]R'
C^N^Ci-C^alkyl^, C(O)- (C1-C6)alkylene-R', C(O)O(C1-C6)alkylene-R', or
RQ and Rβ\ together with the N-atom to which they are attached, form a (C5-C10) heterocyclyl group;
R7 is
H, halogen, CN, NO2,
(C1-C6)alkyl, CHC-i-C^alkyl, (C2-C6)alkenyl,
R',
(C1-C6)alkenylene-(C6-C10)aryl, (C-i-C6)alkylene-R', CH(OH)-(C1-C6)alkyl, NH2, NH-R', NH-SO2H, NH-SO2-(C1 -C6)alkyl,
NH-SO2-R',
SO2-NH2,
SO2-NHR',
NH-C(O)-(C-I -C6)alkyl, NH-C(O)-R',
CfOJN[(C1-C6)alkylb,
C(O)OH, or
C^O^C-i-C^alkyl; Rg is H, halogen or (C-j-Cβ)alkyl;
n is 1 , 2, 3 or 4; m is 1 , 2, 3, 4 or 5; and
L is O or O-(C1-C6)alkylene;
wherein R' is (C3-C8)cycloalkyl,
(C5-C1 o)neterocyclyl, (C6-C10)aryl; and
R" is (C3-C8)cycloalkyl,
(C5-C1 o)heterocyclyl,
(C6-C1 o)aryl,
(C1-C6)aIKyI,
(C1-C6)alkylene-R1,
(C1-C6)alkylene-O-(C1-C6)alkyl,
(C1-C6)alkylene-O-R1, or
(C1-C6)alkylene-N RxRy; and wherein Rx and Ry are independently of each other
(C-i-Cβ)alkyl, (Cs-C1 rjjheterocyclyl,
(C6-C1 oJaryl,
(C-i-C^alkylene^Cs-C10)heterocyclyl,
(C-i-C^alkylene-tCβ-C10)aryl,
(C1-C4)alkylene-NH(C1-C6)alkyl, (Ci-C4)alkylene-N[(C1-C6)alkyl]2,
(C-|-C4)alkylene-N[(C6-C10)aryl]2- or (Ci-C4)alkylene-N[(C5-C10)heterocyclyl]2;
wherein in residues R4, R5, RQ, Rg' , R7 and Re alkyl, alkylene or cycloalkyl can optionally be substituted one or more times by OH, OCH3, COOH, COOCH3, NH2, NHCH3, N(CH3)2, CONH2, CONHCH3 or CON(CH3)2 ;
wherein in residues R-| to Re alkyl or alkylene can optionally be substituted one or more times by halogen;
wherein in residues R-| , R3 to Rg (Cβ-CioJaryl and (C5-C10)heterocyclyl are unsubstituted or substituted one or more times by suitable groups independently selected from halogen, OH, NO2, N3, CN, C(O)-(Ci -Cβ)alkyl, C(O)-(Ci -CβJaryl, COOH, COO(Ci -C6)alkyl, CONH2, CONH(C1-C6)alkyl, CON[(C1-C6)alkyl]2, (C3-C8)cycloalkyl, (C1-C6)alkyl, (Ci-Cø)alkylene-OH, (C1-C6)alkylene-NH2,
(C1-C6)alkylene-NH(C1-C6)alkyl, (C1-C6)alkylene-N[(C1-C6)alkyl]2, (C2-C6)alkenyl, (C2-C6)alkynyl, O-(C1-C6)alkyl, O-C(O)-(C1-C6)alkyl, PO3H2, SO3H, SO2-NH2, SO2NH(C1-C6)alkyl, SO2N[(C1-C6)alkyl]2, S-(C1-C6)alkyl; SO-(C1-C6)alkyl, SO2-
(C1-C6)alkyl, SO2-N=CH-N[(C1-C6)alkyl]2,
C(NH)(NH2), NH2, NH-(C1-C6)alkyl, N[(C1-C6)alkyl]2, NH-C(O)-(C1-C6)alkyl, NH-C(O)O-(C1-C6)alkyl,
NH-SO2-(C1-C6)alkyl, NH-SO2-(C6-C10)aryl, NH-SO2-(C5-Ci 0)heterocyclyl, N(Ci- C6)alkyl-C(O)-(C1-C6)alkyl, N(C1-C6)alkyl-C(O)O-(C1-C6)alkyl, N(C1-C6)alkyl-C(O)-NH-(C1-C6)alkyl],
(C6-C10)aryl, (C1-C6)alkylene-(C6-Ci0)aryl, 0-(C6-Ci O)aryl, O-(C1-C6)alkylene-(C6-C10)aryl, (C5-C10)heterocyclyl,
(C1-C6)alkylene-(C5-C10)heterocyclyl, O-(C1-C6)alkylene-(C5-C10)heterocyclyl, wherein the (C6-C10)aryl or (C5-C10)heterocyclyl may be substituted one to three times by a group independently selected from halogen, OH, NO2, CN, O-(C1-C6)alkyl, (C-i-Cβ)alkyl, NH2, NH^-C^alkyl, N^-C^alky!]^ SO2CH3, COOH, C(O)O-(C1- C6)alkyl, CONH2, (C-i-C^alkylene-O-fC-i-Ce)alkyl, (C -|-C6)alkylene-O-(C6-C io)aryl, or O-(C1-C6)alkylene-(C6-C10)aryl; or wherein (C6-C1 rj)aryl is vicinally substituted by a O-(C-|-C4)alkylene-O group whereby a 5-8-membered ring is formed together with the carbon atoms the oxygen atoms are attached to; and wherein aryl or heterocyclyl substituents of (C6-C1 rj)aryl and (C5-C10)heterocyclyl groups may not be further substituted by an aryl or heterocyclyl containing group;
and their pharmaceutically acceptable salts.
2. A compound according to claim 1 , wherein R1 is H, (^-C^alky!, (C6-C1 o)aryl, NH-(C1 -C6)alkyl, NH-(C6-C10)aryl or N[(C1-C6)alkyl]2.
3. A compound according to one of claims 1 or 2, wherein R1 is H, (C-i-C^alkyl,
NH-(C1 -C4)alkyl, N[(C-|-C4)alkyl]2 or NH-phenyl.
4. A compound according to one of claims 1 to 3, wherein R1 is H, (C-|-C2)alkyl or NH-(C1 -C2)alkyl.
5. A compound according to one of claims 1 to 4, wherein R1 is H.
6. A compound according to one of claims 1 to 5, wherein R3 is H, halogen, (C-|-C4)alkylene-R', O-R" or NHR".
7. A compound according to one of claims 1 to 6, wherein R3 is H or NHR".
8. A compound according to one of claims 1 to 7, wherein R3 is H; NH-(C5-C6)heterocyclyl, or NH-phenyl.
9. A compound according to one of claims 1 to 8, wherein R3 is H.
10. A compound according to one of claims 1 to 9, wherein Rg is H1 halogen or (C1- C4)alkyl.
11. A compound according to one of claims 1 to 10, wherein Rs is H, Cl, F, methyl or ethyl.
12. A compound according to one of claims 1 to 11 , wherein Rg is H.
13. A compound according to one of claims 1 to 12, wherein R4 is H, halogen or (C-i-Cβ)alkyl.
14. A compound according to one of claims 1 to 13, wherein R4 is H, halogen or
(C<|-C4)alkyl.
15. A compound according to one of claims 1 to 14, wherein R4 is H.
16. A compound according to one of claims 1 to 15, wherein R5 is H, halogen, CN, (C-i-C6)alkyl, (C2-C6)alkenyl, R', NH-(Ce-C1 o)aryl or (C1-C6)alkylene-R1.
17. A compound according to one of claims 1 to 16, wherein R5 is H, halogen, (C-|-C6)alkyl, (C2-C6)alkenyl, R1, NH-(Ce-C10)aryl or (C1-C6)alkylene-R1.
18. A compound according to one of claims 1 to 17, wherein R5 is H, halogen, (C-i-C^alkyl, (C2-C6)alkenyl, (C6-C10)aryl, NH-(C6-C1 0)aryl, (C1-C2)alkyl-(C6- C10)aryl or (Cs-C1 o)heteroaryl.
19. A compound according to one of claims 1 to 18, wherein R5 is H1 halogen, (C-|-C6)alkyl, (C^-C^alkenyl, (Ce-C10)aryl, or (C5-C -|rj)heteroaryl.
20. A compound according to one of claims 1 to 19, wherein R5 is H, halogen, methyl, ethyl, vinyl, phenyl, thienyl, or pyridyl.
21. A compound according to one of claims 1 to 20, wherein R5 is H, halogen, methyl, or ethyl.
22. A compound according to one of claims 1 to 21 , wherein R5 is H.
23. A compound according to one of claims 1 to 22, wherein R7 is H, halogen, CN, (C<|-C6)alkyl, O-(C<|-C6)alkyl, (C2-C6)alkenyl, R' or
(C1-C6)alkylene-(C3-C8)cycloalkyl.
24. A compound according to one of claims 1 to 23, wherein R7 is H, halogen, CN,
(Ci-C4)alkyl, O-(C-|-C4)alkyl, (C-|-C4)alkenyl, phenyl, cyclopropyl or (C5-C6)heteroaryl.
25. A compound according to one of claims 1 to 24, wherein R7 is H, fluoro, chloro, bromo, methyl, ethyl, methoxy, phenyl, nitrile, cyclopropyl, thienyl or vinyl.
26. A compound according to one of claims 1 to 25, wherein R7 is H1 fluoro, chloro, bromo, methyl or methoxy.
27. A compound according to one of claims 1 to 26, wherein R7 is H.
28. A compound according to one of claims 1 to 27, wherein m is 2, 3, or 4.
29. A compound according to one of claims 1 to 28, wherein m is 3.
30. A compound according to one of claims 1 to 29, wherein R2 is H, halogen or (C-|-C4)alkyl.
31. A compound according to one of claims 1 to 30, wherein R2 is H or (C-|-C2)alkyl
32. A compound according to one of claims 1 to 31 , wherein R2 is H, methyl or ethyl.
33. A compound according to one of claims 1 to 32, wherein n is 1 , 2 or 3.
34. A compound according to one of claims 1 to 33, wherein n is 1 or 2.
35. A compound according to one of claims 1 to 34, wherein n is 1.
36. A compound according to one of claims 1 to 35, wherein RQ and RQ' are independently of each other
H,
(C1-C6)SlKyI, R',
(C-|-C4)alkylene-(C3-C8)cycloalkyl,
(C 1 -C4)alkylene-(C5-C -| njheterocycly I ,
C-|-C4)alkylene-(C6-C10)aryl,
(C1-C6)alkylene-O-(C1-C6)alkyl, (C<|-C4)alkylene-C(O)-(C5-C10)heterocyclyl,
(C-i-C^slKylene-CCOJ-CCβ-CioJsryl,
(C1-C6)SlKyIeRe-C(O)N[(C1-C6)SlKyI]2,
(C1-C6)SlKyIeIIe-C(O)NH-(C1-C6)SlKyI1
(C1-C6)SlKyIeIIe-C(O)O-(C1-C6)SlKyI, C(O)O-(C1 -C6JaIKyI1 C(O)(C1-C6)alkyl,
C(O)R'
C(O)NH-(C-I -C6)alkyl,
C(O)NI(C1 -C6)alkyl]2, or C(O)(C1-C6)alkylene-R\ or RQ and RQ', together with the N-atom to which they are attached, form a (Cs-C1 rj)heterocyclyl group.
37. A compound according to any of claims 1 to 36, wherein RQ and RQ' are independently of each other H,
(C1-C6)aIKyI,
(C5-C-1 o)heterocyclyl, (C3-C8)cycloalkyl, (C6-C1 o)aryl,
(C1-C4)alkylene-(C3-C8)cycloalkyl, (C1-C4)alkylene-(C5-C10)heterocyclyl, (C1-C^aIKyIeIIe-(C6-C10)aryl,
(C1-C6)alkylene-O-(C-| -Ce)alkyl,
(C1-C6)alKylene-C(O)N[(C1-C6)alkyl]2,
(C1-C6)alkylene-C(O)NH-(C1-C6)alkyl,
(C1 -C6)BlKyIeRe-C(O)O-(C1 -C6JaIKyI,
C^O-tC-i-C^alKyl,
C^^^C^alkyl, C(O)(C3-C8)cycloalkyl,
C(O)NH-(C1 -C6)alkyl,
C(O)N[(CrCQ)a\ky\]2,
C(O) (C1-C6)alkylene-(C3-C8)cycloalkyl,
C(O) (C-i-Cβ)alkylene- (Cs-C1 o)heterocyclyl, C(O) (C1-C6)alkylene-(C6-C10)aryl, or RQ and RQ', together with the N-atom to which they are attached form a
(C5-C10)heterocyclyl group.
38. A compound according to any of claims 1 to 37, wherein
RQ is H, (C1-C6)alkyl, (C3-C6)cycloalkyl or (C1-C4)alkylene-^-Ce^ycloalkyl, and
R6' is H,
(C1-C6)alkyl,
(C3-C8)cycloalkyl, (C5-C10)heterocyclyl,
(C5-C10)aryl,
(C1-C4)alkylene-(C3-C8)cycloalkyl,
(C1-C4)alkylene-(C5-C10)heterocyclyl,
(C-i-C^alkylene-tCe-C10)aryl, (C-i-C^alkylene-O-tC-i-C^alkyl,
(C1-C6)alkylene-C^NH^C-i-Ce)alkyl,
(C1-C6)alkylene-C(O)N[(C1-C6)alkyl]2,
(C1-C6)alkylene- C(O) (C1-C6) alkyl,
C(O)(C -i-Ce)alkyl,
C(O)(C-i-C^alkyl,
C(O)(C3-C8)cycloalkyl,
C(O)NH- (C1-C6)alkyl,
C^N[ (C1-C6)alkyl^,
C(O) (C1-C6)alkylene-(C3-C8)cycloalkyl, C(O) (C1-C6)alkylene- (C5-C10)heterocyclyl,
C(O) (C1-C6)alkylene-^Cβ-C10)aryl, or
Rø and RQ', together with the N-atom to which they are attached, form a
(Cs-C10)heterocyclyl group.
39. A compound according to any of claims 1 to 38, wherein R6 is H, (C1-C6)alkyl and
R61 'S H,
(C1-C6)alkyl, (C3-C8)cycloalkyl, (C6-C1 o)aryl, (C5-C1 o)heterocyclyl, (C-i-C4)alkylene-(C3-C8)cycloalkyl, (Ci-C4)alkylene-(C5-C10)heterocyclyl,
(C1-C6)alkylene-(C6-C10)aryl, (Ci-C4)alkylene-O-(C-|-C4)alkyl, CCOJCC^Ce)alkyl,
(Ci-C4)alkylene-C(O)N[(Ci-C4)alkyl]2,
(C1-C6)alkylene-C(O)NH-(C1-C6)alkyl, or R6 and RQ', together with the N-atom to which they are attached, form a (C5-C10)heterocyclyl group.
40. A compound according to any of claims 1 to 39, wherein RQ is H1 (Ci-Ce)alkyl and R6' is H;
(C1-C6JaIlCyI;
(C3-C8)cycloalkyl;
(C1-C4)alkylene-(C3-C8)cycloalkyl;
(C-i^^lkylene-O^C-i-C^alkyl; C(O)(C1 -C4)alkyl;
(Ci-C4)alkylene-C(O)N[(Ci-C4)alkyl]2;
(C1-C4)alkylene-(C5-C10)heterocyclyl wherein heterocyclyl is unsubstituted or substituted one or more times by a group indepedently selected from (C1-C4)alkyl, O(C-|-C4)alkyl, halogen, or phenyl or is substituted once by (C5-C6)heterocyclyl, wherein phenyl or (C5-C6)heterocyclyl is unsubstituted or substituted one to three times by a group indepedently selected from halogen, (Ci-C4)alkyl or O(C-|-C4)alkyl; or
(C-|-C4)alkylene-(C6-C10)aryl wherein aryl is unsubstituted or substituted one or more times by a group independently selected from halogen, (C^-C^alkyl, O-(C-|-C4)alkyl, CN, Sθ2-NH2i SO2-(C1 -C4)alkyl, SO2-N=CH-N[(C1-C4)alkyl]2, NH-CO-(C1 -C4)alkyl, CO-O-(C1 -C4)alkyl, or is substituted once by unsubstituted phenyl, unsubstituted O- phenyl or unsubstituted (C5-Cg)heterocyclyl; or RQ and RQ , together with the N-atom to which they are attached, form a (C5-C6)heterocyclyl group, which is unsubstituted or substituted one to three times by (C1-C4)alkyl or C(O)O(C<|-C4)alkyl; wherein a (C-|-C4)alkyl or (C1-C6)alkyl residue is unsubstituted or substituted one to three times by halogen.
41. A compound according to any of claims 1 to 40, wherein RQ is H, (C1-C6)alkyl and RQ is H, (C1-C6)alkyl or (C3-C8)cycloalkyl.
42. A compound according to any of claims 1 to 41 , wherein RQ is H and RQ' is H, unsubstituted (C1-C6)alkyl or unsubstituted (C3-C8)cycloalkyl.
43. A compound according to any of claims 1 to 42, wherein RQ and R6' are H.
44. A compound according to one of claims 1 to 43, wherein m is 3 and L is attached to the 3-position or to the 4-position of the amino cyclohexane ring.
45. A compound according to one of claims 1 to 44, wherein m is 3 and L is attached to the 4-position of the amino cyclohexane ring.
46. A compound according to one of claims 1 to 45, wherein L is O-methylene, O- ethylene or O.
47. A compound according to one of claims 1 to 46, wherein L is O.
48. A compound according to claim 1 , wherein
R1 is H, (C-i-Cβ)alkyl, (C6-C10)aryl, NH-(C1 -C6)alkyl, NH-(C6-C10)aryl, or N[(C1-C6)alkylfe;
R2 is hydrogen, halogen, or (C1-C6)alkyl;
R3 is H, halogen, (C-i-C^alkylene-R1, O-R" or NHR";
R4 is H, halogen or (C1-C6)alkyl;
R5 is H, (C<|-C6)alkyl, halogen, CN, (C2-C6)alkenyl, (C6-C1 n)aryl, NH-(C6-C10)aryl,
(C1-C6)alkylene-(C6-C10)aryl, (Cs-C1 o)heterocyclyl or
(C1-C6)alkylene-(C5-C10)heterocyclyl;
R6 and R6' are independently of each other H, R', (C1-C8)alkyl, (C-|-C6)alkylene-R',
(C1-C6)alkylene-O-(C1-C6)alkyl, (C1-C6)alkylene-O-R1, (C-i-C^alkylene-CHfR1^, (C1- C6)alkylene-C(O)NH2, (C-i-C^alkylene-C^NH-R1, (C1-C6)alkylene-C(O)N[(Ci-
C4)alkyl]2, (C1-C6)alkylene-C(O)N[R']2, C(O)O-(C1 -C6)alkyl, C(O)(C1 -C6)alkyl,
C(O)(C3-C8)cycloalkyl, C(O)(C5-C10)heterocyclyl, C(O)NH-(C1 -C6)alkyl, C(O)NI(C1-
C6)alkyl]2, C(O)(C1 -C6)alkylene-(C3-C8)cycloalkyl,
C(O)(C1 -C6)alkylene-(C5-C10)heterocyclyl, C(O)(C1 -Ce)alkylene^Cβ-C-i oJaryl, or R6 and R6', together with the N-atom to which they are attached, form a
(C5-C6)heterocyclyl group;
R7 is H, halogen, CN, (C-i-C^alkyl, 0-(C1-C6)alkyl, (C2-C6)alkenyl or R';
Rs is H, halogen or (Ci-Cs)alkyl; m is 2, 3 or 4
n is 1 , 2 or 3, and
L is O, O-methylene or O-ethylene.
49. A compound according to claim 1 , wherein
R1 is H, (C1-C6)alkyl, (C6-C10)aryl, NH-(C1 -C6)alkyl, NH-(C6-C10)aryl, or NI(C1 -C6)alkyl]2;
F*2 is H or (C-|-C4)alkyl;
R3 is H, halogen or NHR", wherein R" is defined as above;
R4 is H, halogen or (C-|-C4)alkyl;
R5 is H, (C-i-Cβ)alkyl, halogen, (C2-C4)alkenyl, (C6-C<io)aryl, (C1-C6)alkylene-(C6- C10)aryl or (Cs-C1 rj)heterocyclyl;
RQ and RQ' are independently of each other H, (C3-C8)cycloalkyl, (C-i-Cg)alkyl, (C1-
Cβ)alkylene-O^C-i-Ce)alkyl, (C-|-C3)alkylene-R'; C(O)(C1 -C6)alkyl, C(O)(C3- C8)cycloalkyl, C(O)(C5-C6)heterocyclyl, C(O)(C1-C6)alkylene-(C3-C8)cycloalkyl, C^^-i-Ce)alkylene^Cs-CeJheterocyclyl or C^^-i-Ce)alkylene^Ce-CToJaryl;
R7 is H, halogen, CN, (C-i-Cβ)alkyl, O(C1-C6)alkyl, (C2-C6)alkenyl or R';
Rg is H, halogen or (C1-C6)alkyl;
m is 2, 3 or 4 n is 1 , 2 or 3; and
L is O.
50. A compound according to claim 1 , wherein
R1 is H, (Ci-C4)alkyl, NH-(C1 -C4)alkyl, Nf(C1 -C4)alkyl]2 or NH-phenyl;
R2 is H, (C-i-C^alkyl; R3 is H, NH-(C5-C6)heteroaryl or NH-phenyl;
R4 is H, halogen or (C1-C4)alkyl;
R5 is H, (C1-C4)alkyl, halogen, (C-|-C4)alkenyl, (C6-C10)aryl, (C-|-C2)alkyl- (Ce-C10)aryl or (Cs-Cβjheteroaryl;
RQ is H1 (C3-C6)cycloalkyl or (C-i-C4)alkyl;
R6 1 is H, (C3-C8)cycloalkyl, (C-i-Cβ)alkyl, (C1-C3)alkylene-R>; C(O)O-(C1-C6)alkyl, C(O)(C1-C6)alkyl, C(O)(C3-C6)cycloalkyl, C(O)(C5-C6)heterocyclyl,
C(O)(C1 -C3)alkylene-(C3-C6)cycloalkyl, C(O)(C1 -C3)alkylene-(C5-C6)heterocyclyl, or C(O)(C1 -C3)alkylene-phenyl;
R7 is H, halogen, CN, (C1-C6)alkyl, O(C<|-C4)alkyl, (C-|-C4)alkenyl, phenyl, cyclopropyl, (Cs-Cρjheteroaryl;
R8 is H, halogen or (C-j-C4)alkyl;
m is 3 n is 1 ; and L is O.
51. Use of at least one compounds of the formula (I) and/or their pharmaceutically acceptable salt as claimed in one of claims 1 to 50 for producing a medicament.
52. Use of at least one compounds of the formula (I) and/or their pharmaceutically acceptable salt as claimed in one of claims 1 to 50 for producing a medicament for the treatment and/or prevention of hypertension, pulmonary hypertension, ocular hypertension, retinopathy, glaucoma, peripheral circulatory disorder, peripheral arterial occlusive disease (PAOD), coronary heart disease, angina pectoris, heart hypertrophy, heart failure, ischemic diseases, ischemic organ failure (end organ damage), fibroid lung, fibroid liver, liver failure, nephropathy, renal failure, fibroid kidney, renal glomerulosclerosis, organ hypertrophy, asthma, chronic obstructive pulmonary disease (COPD), adult respiratory distress syndrome, thrombotic disorders, stroke, cerebral vasospasm, cerebral ischemia, pain, neuronal degeneration, spinal cord injury, Alzheimer's disease, premature birth, erectile dysfunction, endocrine dysfunctions, arteriosclerosis, prostatic hypertrophy, diabetes and complications of diabetes, metabolic syndrome, blood vessel restenosis, atherosclerosis, inflammation, autoimmune diseases, AIDS, osteopathy, infection of digestive tracts with bacteria, sepsis or cancer development and progression.
53. A medicament comprising an effective amount of at least one compound as claimed in any of claims 1 to 50 and/or a pharmacologically acceptable salt thereof, pharmaceutically tolerated excipients and carriers and, where appropriate, further additives and/or other active ingredients.
PCT/EP2007/011167 2006-12-27 2007-12-19 Cycloalkylamine substituted isoquinoline derivatives Ceased WO2008077554A1 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
AU2007338410A AU2007338410B2 (en) 2006-12-27 2007-12-19 Cycloalkylamine substituted isoquinoline derivatives
CA2673920A CA2673920C (en) 2006-12-27 2007-12-19 Cycloalkylamine substituted isoquinoline derivatives
MX2009005964A MX2009005964A (en) 2006-12-27 2007-12-19 Cycloalkylamine substituted isoquinoline derivatives.
EP07856890A EP2125746B1 (en) 2006-12-27 2007-12-19 Cycloalkylamine substituted isoquinoline derivatives
BRPI0721180-5A BRPI0721180A2 (en) 2006-12-27 2007-12-19 Cycloalkylamine-Substituted Isoquinoline Derivatives
JP2009543375A JP5405316B2 (en) 2006-12-27 2007-12-19 Cycloalkylamine substituted isoquinoline derivatives
AT07856890T ATE554072T1 (en) 2006-12-27 2007-12-19 CYCLOALKYLAMINE SUBSTITUTED ISOQUINOLINE DERIVATIVES
CN200780048527XA CN101611012B (en) 2006-12-27 2007-12-19 Cycloalkylamine substituted isoquinoline derivatives
HK10106146.8A HK1140189B (en) 2006-12-27 2007-12-19 Cycloalkylamine substituted isoquinoline derivatives
US12/487,386 US8710228B2 (en) 2006-12-27 2009-06-18 Cycloalkylamine substituted isoquinoline derivatives
IL199539A IL199539A (en) 2006-12-27 2009-06-24 Cycloalkylamine substituted isoquinoline derivatives, uses thereof and medicaments comprising the same
NO20092432A NO20092432L (en) 2006-12-27 2009-06-26 Cycloalkylamine substituted isoquinoline derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06026894 2006-12-27
EP06026894.3 2006-12-27

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/487,386 Continuation US8710228B2 (en) 2006-12-27 2009-06-18 Cycloalkylamine substituted isoquinoline derivatives

Publications (1)

Publication Number Publication Date
WO2008077554A1 true WO2008077554A1 (en) 2008-07-03

Family

ID=38055425

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/011167 Ceased WO2008077554A1 (en) 2006-12-27 2007-12-19 Cycloalkylamine substituted isoquinoline derivatives

Country Status (15)

Country Link
US (1) US8710228B2 (en)
EP (1) EP2125746B1 (en)
JP (1) JP5405316B2 (en)
KR (1) KR20090092303A (en)
CN (1) CN101611012B (en)
AT (1) ATE554072T1 (en)
AU (1) AU2007338410B2 (en)
BR (1) BRPI0721180A2 (en)
CA (1) CA2673920C (en)
IL (1) IL199539A (en)
MX (1) MX2009005964A (en)
MY (1) MY151953A (en)
NO (1) NO20092432L (en)
SV (1) SV2009003317A (en)
WO (1) WO2008077554A1 (en)

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7470787B2 (en) 2005-07-11 2008-12-30 Aerie Pharmaceuticals, Inc. Isoquinoline compounds
WO2009103966A1 (en) * 2008-02-19 2009-08-27 Cancer Research Technology Limited Bicyclylaryl-aryl-amine compounds and their use
US8058045B2 (en) 2007-10-05 2011-11-15 Cancer Research Technology Limited Pyrazin-2-yl-pyridin-2-yl-amine and pyrazin-2-yl-pyrimidin-4-yl-amine compounds and their use
US8357699B2 (en) 2007-01-10 2013-01-22 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
US8394826B2 (en) 2009-05-01 2013-03-12 Aerie Pharmaceuticals, Inc. Dual mechanism inhibitors for the treatment of disease
US8871757B2 (en) 2008-01-17 2014-10-28 Aerie Pharmaceuticals, Inc. 6-and 7-amino isoquinoline compounds and methods for making and using the same
US8951997B2 (en) 2009-06-19 2015-02-10 D. Western Therapeutics Institute, Inc. Substituted isoquinoline derivative
US9040540B2 (en) 2011-11-09 2015-05-26 Cancer Research Technology Limited 5-(pyridin-2-yl-amino)-pyrazine-2-carbonitrile compounds and their therapeutic use
US9096569B2 (en) 2008-07-25 2015-08-04 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
WO2015124877A1 (en) 2014-02-21 2015-08-27 Les Laboratoires Servier Derivatives of 5-benzylisoquinoline for the treatment of cardiovascular diseases
US9415043B2 (en) 2013-03-15 2016-08-16 Aerie Pharmaceuticals, Inc. Combination therapy
US9643927B1 (en) 2015-11-17 2017-05-09 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
US9663503B2 (en) 2012-05-15 2017-05-30 Cancer Research Technology Limited 5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2-pyridyl]amino]pyrazine-2-carbonitrile and therapeutic uses thereof
EP3215142A4 (en) * 2014-11-05 2018-09-05 Flexus Biosciences, Inc. Immunoregulatory agents
US10550087B2 (en) 2015-11-17 2020-02-04 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
US10624882B2 (en) 2006-09-20 2020-04-21 Aerie Pharmaceuticals, Inc. Rho kinase inhibitors
US10858339B2 (en) 2017-03-31 2020-12-08 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
US11389441B2 (en) 2016-08-31 2022-07-19 Aerie Pharmaceuticals, Inc. Ophthalmic compositions
US11427563B2 (en) 2018-09-14 2022-08-30 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
US11566003B2 (en) 2017-03-30 2023-01-31 Genentech, Inc. Isoquinolines as inhibitors of HPK1
US11612606B2 (en) 2018-10-03 2023-03-28 Genentech, Inc. 8-aminoisoquinoline compounds and uses thereof
US12378249B2 (en) 2018-07-24 2025-08-05 Genentech, Inc. Isoquinoline compounds and uses thereof
US12473301B2 (en) 2018-10-02 2025-11-18 Genentech, Inc. Isoquinoline compounds for the treatment of cancer
US12577240B2 (en) 2020-07-11 2026-03-17 Pfizer Inc. Antiviral heteroaryl ketone derivatives
US12606550B2 (en) 2020-04-07 2026-04-21 Crt Pioneer Fund Lp Methods for synthesis of CHK1 inhibitors

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY153756A (en) * 2008-06-24 2015-03-13 Sanofi Aventis Bi-and polycyclic substituted isoquinoline and isoquinoline derivatives as rho kinase inhibitors
CA2728137C (en) * 2008-06-24 2016-10-18 Sanofi-Aventis Substituted isoquinolines and isoquinolinones as rho kinase inhibitors
MY153615A (en) * 2008-06-24 2015-02-27 Sanofi Aventis 6-substituted isoquinolines and isoquinolinones
CN108997222A (en) * 2018-07-23 2018-12-14 山东省农药科学研究院 A kind of synthetic method of the chloro- 5-FU of fluoxastrobin intermediate 4,6- bis-
CN111574413B (en) * 2020-06-08 2022-04-05 杭州尚合生物医药科技有限公司 A kind of preparation method of sulfonyl amidine with 2-aminomethylpyridine and DMF-DMA as amine source
CN115572262B (en) * 2022-10-27 2024-08-27 厦门沃克沃德医药科技有限公司 Isoquinoline derivative and preparation method thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005030791A2 (en) * 2003-09-23 2005-04-07 Merck & Co., Inc. Isoquinolinone potassium channel inhibitors
EP1541559A1 (en) * 2002-07-22 2005-06-15 Asahi Kasei Pharma Corporation 5-substituted isoquinoline derivative
WO2007000240A1 (en) * 2005-06-28 2007-01-04 Sanofi-Aventis Isoquinoline derivatives as inhibitors of rho-kinase
WO2007012422A1 (en) * 2005-07-26 2007-02-01 Sanofi-Aventis Cyclohexylamin isoquinolone derivatives as rho-kinase inhibitors

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2485537B2 (en) 1977-04-13 1986-05-16 Anvar DIPYRIDO (4,3-B) (3,4-F) INDOLES, PROCESS FOR OBTAINING IT, THERAPEUTIC APPLICATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
EP0541559A1 (en) 1990-07-31 1993-05-19 E.I. Du Pont De Nemours And Company Catalytic equilibration of selected halocarbons
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
GB9516709D0 (en) 1995-08-15 1995-10-18 Zeneca Ltd Medicament
ZA9610741B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
BR9711154A (en) 1996-08-12 1999-08-17 Yoshitomi Pharmaceutical Pharmaceutical agent containing rho kinase inhibitor
JPH1087629A (en) 1996-09-18 1998-04-07 Fujisawa Pharmaceut Co Ltd New isoquinoline derivative, and its medicinal use
EP1007525A1 (en) 1997-08-29 2000-06-14 Zeneca Limited Aminometyl oxooxazolidinyl benzene derivatives
TW575567B (en) 1998-10-23 2004-02-11 Akzo Nobel Nv Serine protease inhibitor
GB9912701D0 (en) 1999-06-01 1999-08-04 Smithkline Beecham Plc Novel compounds
US6541456B1 (en) 1999-12-01 2003-04-01 Isis Pharmaceuticals, Inc. Antimicrobial 2-deoxystreptamine compounds
BR0107732A (en) 2000-01-20 2003-03-11 Eisai Ltd Method to prevent or treat a disease
US7217722B2 (en) * 2000-02-01 2007-05-15 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
AU2001239947A1 (en) 2000-02-29 2001-09-12 Curis, Inc. Methods and compositions for regulating adipocytes
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
AR033517A1 (en) 2000-04-08 2003-12-26 Astrazeneca Ab PIPERIDINE DERIVATIVES, PROCESS FOR THE PREPARATION AND USE OF THESE DERIVATIVES IN THE MANUFACTURE OF MEDICINES
GB0013060D0 (en) 2000-05-31 2000-07-19 Astrazeneca Ab Chemical compounds
AU2001296008A1 (en) 2000-10-27 2002-05-06 Takeda Chemical Industries Ltd. Process for preparing substituted aromatic compounds and intermediates therefor
JP2004520347A (en) 2001-01-15 2004-07-08 グラクソ　グループ　リミテッド Arylpiperidine and piperazine derivatives as inducers of LDL-receptor expression
SE0101038D0 (en) 2001-03-23 2001-03-23 Astrazeneca Ab Novel compounds
EP1389194A2 (en) 2001-04-27 2004-02-18 Vertex Pharmaceuticals Incorporated Inhibitors of bace
WO2002100833A1 (en) * 2001-06-12 2002-12-19 Sumitomo Pharmaceuticals Company, Limited Rho KINASE INHIBITORS
GB0117899D0 (en) 2001-07-23 2001-09-12 Astrazeneca Ab Chemical compounds
WO2003024450A1 (en) 2001-09-20 2003-03-27 Eisai Co., Ltd. Methods for treating prion diseases
SE0104340D0 (en) 2001-12-20 2001-12-20 Astrazeneca Ab New compounds
AU2003264427A1 (en) 2002-09-12 2004-04-30 Kirin Beer Kabushiki Kaisha Isoquinoline derivatives having kinasae inhibitory activity and drugs containing the same
WO2004105757A2 (en) 2003-05-29 2004-12-09 Schering Aktiengesellschaft Use of rho-kinase inhibitors in the treatment of aneurysm and cardiac hypertrophy
WO2004113297A2 (en) 2003-06-24 2004-12-29 Neurosearch A/S Aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
US20050067037A1 (en) 2003-09-30 2005-03-31 Conocophillips Company Collapse resistant composite riser
GB0323238D0 (en) 2003-10-03 2003-11-05 Domantis Ltd Synthetic LG binding domains of protein L
US20070060595A1 (en) * 2003-10-10 2007-03-15 Toshio Yoshizawa Novel fused heterocyclic compound and use thereof
US7449477B2 (en) 2003-11-25 2008-11-11 Eli Lilly And Company 7-phenyl-isoquinoline-5-sulfonylamino derivatives as inhibitors of akt (protein kinase B)
JP2005232175A (en) * 2004-01-21 2005-09-02 Asahi Kasei Pharma Kk 5-substituted isoquinoline as medicine
WO2005074535A2 (en) 2004-01-30 2005-08-18 Eisai Co., Ltd. Cholinesterase inhibitors for spinal cord disorders
EP1729761A4 (en) 2004-03-05 2008-09-03 Eisai Co Ltd Cadasil treatment with cholinesterase inhibitors
SE0400850D0 (en) 2004-03-30 2004-03-31 Astrazeneca Ab Novel Compounds
US7517991B2 (en) * 2004-10-12 2009-04-14 Bristol-Myers Squibb Company N-sulfonylpiperidine cannabinoid receptor 1 antagonists
CA2615577C (en) 2005-07-26 2014-09-09 Sanofi-Aventis Piperidinyl-substituted isoquinolone derivatives as rho-kinase inhibitors
TW200745101A (en) 2005-09-30 2007-12-16 Organon Nv 9-Azabicyclo[3.3.1]nonane derivatives
TW200738682A (en) 2005-12-08 2007-10-16 Organon Nv Isoquinoline derivatives
US7618985B2 (en) * 2005-12-08 2009-11-17 N.V. Organon Isoquinoline derivatives
US7893088B2 (en) * 2006-08-18 2011-02-22 N.V. Organon 6-substituted isoquinoline derivatives
MY148902A (en) 2006-12-27 2013-06-14 Sanofi Aventis Substituted isoquinolines and their use as rho-kinase inhibitors
RU2468011C2 (en) 2006-12-27 2012-11-27 Санофи-Авентис Cycloalkylamine-substituted isoquinoline and isoquinolinone derivatives

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1541559A1 (en) * 2002-07-22 2005-06-15 Asahi Kasei Pharma Corporation 5-substituted isoquinoline derivative
WO2005030791A2 (en) * 2003-09-23 2005-04-07 Merck & Co., Inc. Isoquinolinone potassium channel inhibitors
WO2007000240A1 (en) * 2005-06-28 2007-01-04 Sanofi-Aventis Isoquinoline derivatives as inhibitors of rho-kinase
WO2007012422A1 (en) * 2005-07-26 2007-02-01 Sanofi-Aventis Cyclohexylamin isoquinolone derivatives as rho-kinase inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TAMURA ET AL: "Development of specific Rho-kinase inhibitors and their clinical application", BIOCHIMICA ET BIOPHYSICA ACTA (BBA) - PROTEINS & PROTEOMICS, ELSEVIER, vol. 1754, no. 1-2, 30 December 2005 (2005-12-30), pages 245 - 252, XP005214213, ISSN: 1570-9639 *

Cited By (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7470787B2 (en) 2005-07-11 2008-12-30 Aerie Pharmaceuticals, Inc. Isoquinoline compounds
US7671205B2 (en) 2005-07-11 2010-03-02 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
US8034943B2 (en) 2005-07-11 2011-10-11 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
US10624882B2 (en) 2006-09-20 2020-04-21 Aerie Pharmaceuticals, Inc. Rho kinase inhibitors
US9890123B2 (en) 2007-01-10 2018-02-13 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
US8357699B2 (en) 2007-01-10 2013-01-22 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
US10472327B2 (en) 2007-01-10 2019-11-12 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
US8455513B2 (en) 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
US8921392B2 (en) 2007-01-10 2014-12-30 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
US9365518B2 (en) 2007-01-10 2016-06-14 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
US10899714B2 (en) 2007-01-10 2021-01-26 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
US8367658B2 (en) 2007-10-05 2013-02-05 Cancer Research Technology Limited Pyrazin-2-yl-pyridin-2-yl-amine and pyrazin-2-yl-pyrimidin-4-yl-amine compounds and their use
US8058045B2 (en) 2007-10-05 2011-11-15 Cancer Research Technology Limited Pyrazin-2-yl-pyridin-2-yl-amine and pyrazin-2-yl-pyrimidin-4-yl-amine compounds and their use
US8871757B2 (en) 2008-01-17 2014-10-28 Aerie Pharmaceuticals, Inc. 6-and 7-amino isoquinoline compounds and methods for making and using the same
US8530468B2 (en) 2008-02-19 2013-09-10 Cancer Research Technology Limited Bicyclylaryl-aryl-amine compounds and their use
WO2009103966A1 (en) * 2008-02-19 2009-08-27 Cancer Research Technology Limited Bicyclylaryl-aryl-amine compounds and their use
US10882840B2 (en) 2008-07-25 2021-01-05 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
US10532993B2 (en) 2008-07-25 2020-01-14 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
US11021456B2 (en) 2008-07-25 2021-06-01 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
US9512101B2 (en) 2008-07-25 2016-12-06 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
US9096569B2 (en) 2008-07-25 2015-08-04 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
US10112920B2 (en) 2008-07-25 2018-10-30 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
US9884840B2 (en) 2008-07-25 2018-02-06 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
US11618748B2 (en) 2009-05-01 2023-04-04 Aerie Pharmaceuticals, Inc. Dual mechanism inhibitors for the treatment of disease
US10654844B2 (en) 2009-05-01 2020-05-19 Aerie Pharmaceuticals, Inc. Dual mechanism inhibitors for the treatment of disease
US11028081B2 (en) 2009-05-01 2021-06-08 Aerie Pharmaceuticals, Inc. Dual mechanism inhibitors for the treatment of disease
US9951059B2 (en) 2009-05-01 2018-04-24 Aerie Pharmaceuticals, Inc. Dual mechanism inhibitors for the treatment of disease
US8394826B2 (en) 2009-05-01 2013-03-12 Aerie Pharmaceuticals, Inc. Dual mechanism inhibitors for the treatment of disease
US10316029B2 (en) 2009-05-01 2019-06-11 Aerie Pharmaceuticals, Inc. Dual mechanism inhibitors for the treatment of disease
US10174017B2 (en) 2009-05-01 2019-01-08 Aerie Pharmaceuticals, Inc. Dual mechanism inhibitors for the treatment of disease
US8951997B2 (en) 2009-06-19 2015-02-10 D. Western Therapeutics Institute, Inc. Substituted isoquinoline derivative
US9403797B2 (en) 2011-11-09 2016-08-02 Cancer Research Technology Limited 5-(pyridin-2-yl-amino)-pyrazine-2-carbonitrile compounds and their therapeutic use
US9040540B2 (en) 2011-11-09 2015-05-26 Cancer Research Technology Limited 5-(pyridin-2-yl-amino)-pyrazine-2-carbonitrile compounds and their therapeutic use
US9765059B2 (en) 2011-11-09 2017-09-19 Cancer Research Technology Limited 5-(Pyridin-2-yl-amino)-pyrazine-2-carbonitrile compounds and their therapeutic use
US10259806B2 (en) 2012-05-15 2019-04-16 Cancer Research Technology Limited 5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2 pyridyl]amino]pyrazine-2-carbonitrile and therapeutic uses thereof
US9663503B2 (en) 2012-05-15 2017-05-30 Cancer Research Technology Limited 5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2-pyridyl]amino]pyrazine-2-carbonitrile and therapeutic uses thereof
US11787792B2 (en) 2012-05-15 2023-10-17 Cancer Research Technology Limited 5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2 Pyridyl]Amino]Pyrazine-2-carbonitrile and therapeutic uses thereof
US11197853B2 (en) 2013-03-15 2021-12-14 Aerie Pharmaceuticals, Inc. Combination therapy
US11020385B2 (en) 2013-03-15 2021-06-01 Aerie Pharmaceuticals, Inc. Combination therapy
US10588901B2 (en) 2013-03-15 2020-03-17 Aerie Pharmaceuticals, Inc. Combination therapy
US9849122B2 (en) 2013-03-15 2017-12-26 Aerie Pharmaceuticals, Inc. Combination therapy
US11185538B2 (en) 2013-03-15 2021-11-30 Aerie Pharmaceuticals, Inc. Compositions for treating glaucoma or reducing intraocular pressure
US9931336B2 (en) 2013-03-15 2018-04-03 Aerie Pharmaceuticals, Inc. Combination therapy
US9993470B2 (en) 2013-03-15 2018-06-12 Aerie Pharmaceuticals, Inc. Combination therapy
US10568878B2 (en) 2013-03-15 2020-02-25 Aerie Pharmaceuticals, Inc. Combination therapy
US9415043B2 (en) 2013-03-15 2016-08-16 Aerie Pharmaceuticals, Inc. Combination therapy
WO2015124877A1 (en) 2014-02-21 2015-08-27 Les Laboratoires Servier Derivatives of 5-benzylisoquinoline for the treatment of cardiovascular diseases
EP3215142A4 (en) * 2014-11-05 2018-09-05 Flexus Biosciences, Inc. Immunoregulatory agents
US10206893B2 (en) 2014-11-05 2019-02-19 Flexus Biosciences, Inc. Immunoregulatory agents
US9643927B1 (en) 2015-11-17 2017-05-09 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
US10550087B2 (en) 2015-11-17 2020-02-04 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
US11707460B2 (en) 2016-08-31 2023-07-25 Aerie Pharmaceuticals, Inc. Ophthalmic compositions
US11389441B2 (en) 2016-08-31 2022-07-19 Aerie Pharmaceuticals, Inc. Ophthalmic compositions
US11590123B2 (en) 2016-08-31 2023-02-28 Aerie Pharmaceuticals, Inc. Ophthalmic compositions
US11566003B2 (en) 2017-03-30 2023-01-31 Genentech, Inc. Isoquinolines as inhibitors of HPK1
US11312700B2 (en) 2017-03-31 2022-04-26 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
US10858339B2 (en) 2017-03-31 2020-12-08 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
US12018012B2 (en) 2017-03-31 2024-06-25 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
US12378249B2 (en) 2018-07-24 2025-08-05 Genentech, Inc. Isoquinoline compounds and uses thereof
US11427563B2 (en) 2018-09-14 2022-08-30 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
US11891376B2 (en) 2018-09-14 2024-02-06 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
US12473301B2 (en) 2018-10-02 2025-11-18 Genentech, Inc. Isoquinoline compounds for the treatment of cancer
US11612606B2 (en) 2018-10-03 2023-03-28 Genentech, Inc. 8-aminoisoquinoline compounds and uses thereof
US12606550B2 (en) 2020-04-07 2026-04-21 Crt Pioneer Fund Lp Methods for synthesis of CHK1 inhibitors
US12577240B2 (en) 2020-07-11 2026-03-17 Pfizer Inc. Antiviral heteroaryl ketone derivatives
US11541034B2 (en) 2020-09-03 2023-01-03 Pfizer Inc. Nitrile-containing antiviral compounds
US11452711B2 (en) 2020-09-03 2022-09-27 Pfizer Inc. Nitrile-containing antiviral compounds
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds

Also Published As

Publication number Publication date
KR20090092303A (en) 2009-08-31
MX2009005964A (en) 2009-06-15
HK1140189A1 (en) 2010-10-08
AU2007338410B2 (en) 2012-08-16
JP5405316B2 (en) 2014-02-05
AU2007338410A1 (en) 2008-07-03
MY151953A (en) 2014-07-31
EP2125746A1 (en) 2009-12-02
ATE554072T1 (en) 2012-05-15
IL199539A (en) 2014-07-31
SV2009003317A (en) 2010-02-05
US8710228B2 (en) 2014-04-29
US20100081671A1 (en) 2010-04-01
CN101611012B (en) 2012-11-14
CA2673920C (en) 2015-03-24
BRPI0721180A2 (en) 2014-03-18
CN101611012A (en) 2009-12-23
JP2010514719A (en) 2010-05-06
NO20092432L (en) 2009-09-17
CA2673920A1 (en) 2008-07-03
EP2125746B1 (en) 2012-04-18

Similar Documents

Publication Publication Date Title
EP2125746B1 (en) Cycloalkylamine substituted isoquinoline derivatives
AU2007338407B2 (en) Cycloalkylamine substituted isoquinolone derivatives
CA2673919C (en) Cycloalkylamine substituted isoquinolone and isoquinolinone derivatives
EP1910333B1 (en) Piperidinyl-substituted isoquinolone derivatives as rho-kinase inhibitors
EP2102187B1 (en) Substituted isoquinoline and isoquinolinone derivatives as inhibitors of rho-kinase
AU2006274246B2 (en) Cyclohexylamin isoquinolone derivatives as Rho-kinase inhibitors
EP2102164A1 (en) Cycloalkylamine substituted isoquinoline and isoquinolinone derivatives

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780048527.X

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07856890

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: MX/A/2009/005964

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2007856890

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 3728/CHENP/2009

Country of ref document: IN

Ref document number: 1020097013325

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2009543375

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2673920

Country of ref document: CA

Ref document number: 2007338410

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2007338410

Country of ref document: AU

Date of ref document: 20071219

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: PI0721180

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090626